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ABSTRACT 
The main objective of this project is to identify novel genes capable of causing 
monogenic defects in the human immune system by studying paediatric patients with 
severe immunological disorders. While monogenic diseases make up only a small 
fraction of immunological disorders, they provide insight into mechanistic pathways 
that are likely to contribute to common forms of disease when less deleterious variants 
are inherited. Additionally, genetics studies on patients with severe early-onset 
immune pathologies can increase our understanding of the physiology and functioning 
of the human immune system. To clarify the contribution of novel genes in severe 
immunological disorders, the following methodology is used: 1) identification of 
candidate genetic variants through the use of whole-exome sequencing, 2) detailed 
assessment of the peripheral immune system in order to gain insight in disease 
mechanisms and pathways and 3) verification of the role of an identified candidate 
genetic variant in disease pathogenesis by developing functional tests on a case-by-
case basis. This approach was successfully used to identify disease-causing variants in 
three different genes responsible for severe early-onset immune pathology in four 
unrelated families with very different clinical presentations: 
1. A de novo heterozygous gain-of-function mutation in IFIH1 in a 16-year-old girl 
with severe early-onset and refractory systemic lupus erythematosus with 
secondary antiphospholipid syndrome, selective IgA-deficiency and mild lower 
limb spasticity without neuroradiological manifestations. 
2. Recessive homozygous loss-of-function mutations in CECR1 in a 9-year-old boy 
with Castleman's-like disease and in two brothers with combined 
immunodeficiency, lymphoproliferation, autoimmunity and vasculopathy. The 
success of allogeneic hematopoietic stem cell transplantation both in rescuing 
the immunologic phenotype and in preventing further vascular disease in 
ADA2-deficiency was demonstrated. 
3. Recessive compound heterozygous loss-of-function mutations in STAT2 in two 
siblings with severe viral illness. 
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INTRODUCTION 
Disorders of immunity can give rise to a wide spectrum of diseases. This work focuses 
on the identification of disease-causing genetic variants in paediatric patients with 
primary immunodeficiency (PID) and autoimmune/autoinflammatory disease. In the 
introduction, the rationale for studying the underlying genetic causes of these rare 
conditions in these specific populations will be explained. Next, a framework for 
genetic studies in severe early-onset immune pathology will be provided, with an 
overview of the underlying principles and steps that must be followed in order to prove 
that a candidate genetic variant is in fact disease-causing. Finally, an overview will be 
given of the diseases that have been studied in this work. 
1. Rationale behind studying the underlying genetic defect in severe paediatric immune 
pathology 
1.1 Clinical impact of PIDs and autoimmune/autoinflammatory diseases 
PIDs often present and are diagnosed in infancy or childhood, when a failure to mount 
an adequate immune response to invading pathogens results in recurrent and/or 
severe infections [1]. Although PIDs were originally considered to be rare, recent 
studies estimate that up to 1 in 1200 living people worldwide could be affected by a 
form of PID [1], indicating that the prevalence of PID could be similar to that of for 
instance leukaemia [2]. Therefore, PIDs form an important group of diseases in 
paediatric populations. 
In contrast, the majority of patients with autoimmune illnesses develop disease in 
adulthood [3, 4]. These common forms of autoimmune disease affect approximately 
5% of the total world population [3] and are thought to be the consequence of both 
polygenic and environmental factors [5]. Although disease onset in childhood is much 
less common [6], it is often associated with increased disease severity and a worse 
prognosis [3, 7, 8]. Additionally, while common adult-onset (autoimmune) disorders 
are thought to have a complex multifactorial causation, severe early-onset 
autoimmune disease is more likely to be monogenic or oligogenic in origin [5]. 
Similarly, the more recently identified autoinflammatory diseases are rare conditions, 
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also often present in infancy, are likely monogenic and are associated with a high 
morbidity and mortality and decreased quality of life [4, 9, 10]. So despite their low 
prevalence compared to other childhood diseases, early-onset immune diseases are 
clinically important and severely impact the lives of affected individuals and their 
families.  
1.2  Importance of genetic studies for the diagnosis and treatment of PIDs and 
autoimmune/autoinflammatory diseases 
Treatment of PIDs and autoimmune/autoinflammatory diseases is often accompanied 
by serious side-effects and can hold risks on its own [11]. Understanding the genetic 
cause of severe paediatric immune pathologies is critical for the diagnosis and correct 
treatment of these patients, and for the development of new and better targeted 
therapeutics. For example, for years treatment of severe early-onset autoinflammatory 
disease depended on the use of systemic corticosteroids, which was associated with 
severe side-effects such as growth retardation, osteoporosis, metabolic disorders, 
muscle atrophy, delayed wound healing or gastrointestinal ulcers. The discovery of for 
example gain-of-function mutations in the interleukin-1 (IL-1)-regulating gene NLRP3 
(NOD-like receptor (NLR) family, pyrin domain containing 3) in the cryopyrin 
associated periodic syndromes (CAPS), a severely debilitating autoinflammatory 
disease, has led to the successful use of the IL-1 receptor antagonist monoclonal 
antibody (mAb) anakinra and the anti-IL-1β mAb canakinumab to control this disease 
[12]. Even when no specific treatment is available, the identification of the underlying 
genetic defect responsible for their disease is often very important for these patients, as 
it allows them to label their disease and gain understanding of disease pathogenesis 
and prognosis.    
As mentioned before, severe paediatric immune diseases are more likely to have a 
monogenetic cause [5] and therefore make up good candidates for genetic studies. 
Understanding the underlying genetic defect in severe early-onset immune pathology 
may not only be beneficial for patients suffering from these conditions. Although 
monogenic diseases make up only a small fraction of immunological disorders, they 
provide insight into mechanistic pathways that are likely to contribute to common 
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forms of disease when less deleterious variants are inherited [5, 13]. On that account, 
use of new therapeutics that were developed for monogenic diseases can be extended 
to a variety of related immune diseases. For example, discovery of the disease-causing 
mutations in NLRP3 that cause CAPS and subsequent research in the disease 
pathogenesis uncovered the key role of IL-1 in an extended spectrum of 
autoinflammatory conditions. Subsequently, IL-1 blockade has been successfully used 
in other autoinflammatory diseases with a known genetic defect (e.g. mevalonate 
kinase deficiency) as well as in autoinflammatory diseases that are not genetically well 
defined (e.g. systemic juvenile idiopathic arthritis or Still’s disease) [12]. Furthermore, 
the link between metabolic stress and IL-1β-mediated inflammation through activation 
of the NLRP3 inflammasome by accumulation of metabolic substrates such as 
monosodium urate crystals, glucose or cholesterol; provides a rationale for 
therapeutically targeting IL-1 in prevalent diseases such as gout, diabetes mellitus and 
coronary artery disease [12]. Clinical trials based on this hypothesis are being 
conducted at the moment. For now the clinical impact of IL-1 blockade is best 
established in acute gout, where IL-1 blockade leads to a significant relief of pain, 
decreased inflammatory markers and a significant reduction of the number of gout 
flares [12]. 
1.3 Increasing our understanding of physiology through mechanistic studies of patients 
with severe early-onset immune pathology 
Apart from clinical reasons, genetics studies on patients with severe early-onset 
immune pathologies are also important for improving our understanding of the 
physiology and functioning of the human immune system [5, 14]. Studying human 
inborn errors of immunity can reveal crucial pathways underlying both physiological 
and pathological processes. For example, identification of a mutation in MEFV 
(Mediterranean fever), encoding pyrin (S242R), in a disease characterized by 
childhood-onset recurrent episodes of neutrophilic dermatosis and systemic 
inflammation, revealed a guard-like mechanism of pyrin regulation in humans. The 
mutation results in the loss of a 14-3-3 binding motif at phosphorylated S242, Similar, 
loss of both S242 phosphorylation and 14-3-3 binding was observed for bacterial 
effectors that activate the pyrin inflammasome, indicating that the S242R mutation 
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thus recapitulates the effect of pathogen sensing, and triggers inflammasome 
activation and IL-1β production [15]. These studies are complementary to genetic 
studies in animal models (e.g. murine models), that are valuable because they allow 
testing of hypotheses under different experimental conditions but are also subjected to 
certain limitations. A murine phenotype is typically associated with and tested in a 
single genetic, highly inbred background, making the animals more likely to be 
homozygous for modifying genetic factors. Human patients are never 100% 
homozygous, and the identification of a genetic defect in several unrelated individuals 
with a similar disease phenotype but a different genetic background strongly supports 
the causal role of the genetic defect in the examined disease. Another limitation lies in 
the fact that animal models are kept in a tightly controlled environment, which can 
influence the occurrence of a certain phenotype. In contrast, humans are constantly 
exposed to a variety of environmental factors which can provoke the occurrence or 
influence the manifestations of a certain phenotype. Together with interspecies 
variability these limitations can be responsible for observed differences in phenotypes 
between animal models and human patients with similar mutations in the same gene.  
2. Framework for genetic studies in severe early-onset immune pathology 
2.1 Genetics in human immune disease 
Until recent years, analysis of the genetic basis for immune pathology has been a slow 
process of identifying candidate genes based on expression patterns and reverse 
engineering mutations in these genes in mice to determine the impact on immunity 
[16], a process called reverse genetics. By contrast, forward genetics is the process of 
identifying important genes by large-scale genetic analysis of cohorts with strong 
phenotypes. In immunology forward genetics in mice has proven a tremendous boon 
[17]. In human patients with a variety of strong phenotypes forward genetics has been 
used successfully in the search for mutations in familial cohorts of (consanguineous) 
patients or in large groups of unrelated sporadic cases [18]. Genome-wide linkage 
analysis and candidate gene approaches have led to the discovery of over 4000 single-
gene inborn errors [5] (http://www.omim.org/statistics/entry). However, this approach 
has proven more difficult in (immune) pathologies without a distinct well-understood 
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clinical presentation and/or without large consanguineous patient families. Still, severe 
sporadic immune disorders in non-consanguineous families may also be monogenic in 
nature and may be caused by familial single-gene defects or by de novo mutations. The 
development and availability of large scale genetic screening methods such as whole-
exome sequencing has made it possible to further extend the forward genetic approach 
to the entire human population. In Belgium for example 10 million people are 
accessible for immunological screening through medical health services. This 
represents genetic diversity on a scale inconceivable using mouse models, a resource of 
tremendous potential to identify genes involved in immune pathology.  
2.2 Genetic studies in single patients/families or sporadic cases 
Several patients who are followed in the University hospital of Leuven, Belgium, have a 
possible monogenic disease with a very distinctive phenotype that has not been found 
or described in other patients. Experts in statistical genetics have formulated their 
doubts on genetic studies in single patients and emphasize “the critical primacy of 
robust statistical genetic support for the implication of new genes” [19]. They state that 
“multiple confirmations of causality should be obtained in multiple unrelated patients” 
or that “statistical support from multiple cases is strongly encouraged” [19]. Clearly 
being able to confirm certain gene variants in a group of patients with the same clinical 
phenotype provides added confidence that the altered gene is responsible for the 
phenotype. Additionally, it is not possible to firmly conclude full clinical penetrance of 
a certain genotype found in a single, albeit severely affected, patient; given that 
modifying genetic, environmental and stochastic factors may be contributing to the 
phenotype as well.  Nevertheless single-patient reports are not uncommon in the field 
of immunology, where for example 49 out of 232 (21%) examined monogenic PIDs 
were first reported on the basis of a single case [14]. Although extensive experimental 
validation of the causal role of a new genetic defect is required in single-patient studies 
to compensate for the lack of genetic confirmation in unrelated pedigrees, discovery of 
the causal gene in such a single patient could lead the way for its confirmation in other 
patients [14]. 
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Criteria have been proposed by experts in the field for establishing a causal 
relationship between a candidate genotype and the clinical phenotype of a single 
patient [14]:  
1. the candidate genotype must be monogenic, may not occur in healthy 
individuals and must have a frequency less than or equal to the frequency of the 
phenotype 
2. the genetic variant(s) must impair, destroy, or alter the function of the gene 
product 
3. the causal relationship between the candidate genotype and the clinical 
phenotype must be established via a relevant cellular or animal phenotype:  
a. for disorders that affect the function of a cell present in the patient: a 
patient-specific relevant cellular phenotype should be caused by the 
mutant allele and this phenotype should be corrected by a rescue 
experiment 
b. for disorders that affect the development of a cell lacking in the patient: 
development of an animal model that recapitulates both the cellular and 
whole-organism phenotypes may replace the characterization of a 
relevant cellular phenotype 
A detailed overview of these criteria is given on pages 7 - 8. This approach has been 
successfully used to implicate new genes in severe early-onset immune pathology and 
to elucidate disease pathogenesis and pathways involved in the illness, but also to gain 
insight in the functioning of the human immune system overall. For example, 
compound heterozygous loss-of-function mutations in IRF7 (interferon regulatory 
factor 7) were recently found in an otherwise healthy child that suffered from life-
threatening primary influenza infection [20]. Mechanistic studies revealed reduced 
type I and III interferon (IFN) production by leukocytes, plasmacytoid dendritic cells 
(pDCs), dermal fibroblasts and induced pluripotent stem cell (iPSC)-derived 
pulmonary epithelial cells of the patient as well as increased influenza virus replication 
in the latter two cell types. Together with the clinical phenotype these findings suggest 
that IRF7-dependent amplification of type I and III IFNs is required for protection 
against  primary  infection by influenza  virus in  humans [20].  
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Criteria for establishing a causal relationship between a candidate 
genotype and the clinical phenotype of a single patient. 
1. The candidate genotype must be monogenic, may not occur in healthy 
individuals and must have a frequency less than or equal to the frequency 
of the phenotype. 
a. The clinical phenotype must be rare and distinctive and the candidate 
genotype must be monogenic. 
b. Family studies must demonstrate that the candidate genotype of the patient 
is not shared by other family members (complete clinical penetrance, 
Mendelian mode of inheritance). 
c. Population studies, including but not restricted to the same ethnic group, 
must indicate that the candidate genotype does not occur in healthy 
individuals. The frequencies of the candidate variants and genotype are not 
higher than that predicted by the frequency of the clinical phenotype. 
2. The genetic variant(s) must impair, destroy, or alter the function of the 
gene product. 
a. Functional prediction algorithms are helpful but not conclusive. A variation 
that is not conservative and that occurs in a region or at a residue of the 
encoded protein that is highly conserved in evolution provides support for the 
hypothesis that the amino acid is functionally important. 
b. Studies should document whether the variant changes the amount or 
molecular weight of the gene transcript and of the encoded protein. Ideally, 
this should be done in control primary cells or iPSC-derived cell lines, and not 
only in control immortalized cell lines. 
c. The variants must be loss- or gain-of-function for at least one biological 
activity. For variants that result in an amino acid substitution, insertion or 
deletion, in vitro studies should document a functional change that reveals 
the mechanism by which the variant causes disease, e.g. the protein may be 
unstable, it may not bind essential cofactors, or it may not localize 
appropriately. 
3. The causal relationship between the candidate genotype and the clinical 
phenotype must be established via a relevant cellular or animal 
phenotype. 
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a. The candidate gene should be known or shown to be normally expressed in 
cell types relevant to the disease process, e.g. cells affected by the disease 
process, cells which produce factors needed by the affected cells or 
progenitors of the cell lineage affected by the disease. Some genes are broadly 
expressed but have a narrow clinical phenotype. 
b. For disorders that affect the function of a cell (present in the patient), 
experimental studies in vitro must indicate that there is a cellular phenotype 
explained by the candidate genotype, ideally in primary cells. This cellular 
phenotype should reasonably account for the clinical phenotype because the 
cell type is known to be involved in the disease process and the clinical 
phenotype is consistent with it.  
i. The cellular phenotype should be reproduced in independent cell lines: 
Overexpressing the mutant allele in a different system should reproduce 
the cellular phenotype observed in patient primary cells.  For example, 
loss-of-function mutations due to loss-of-expression must be confirmed by 
overexpressing the mutant allele(s) and confirming absent expression, 
negative dominance must be established by co-transfecting the mutant 
and wild-type alleles into cells deficient for the gene product. As 
overexpression can alter the function of a gene, alternatively or 
additionally knockdown or knockout of the wild-type gene, or 
introduction of knock-in mutations in control cells, should reproduce the 
cellular phenotype.  
ii. The cellular phenotype must be rescued by a wild-type allele for loss-of-
function mutations or by knockdown, knockout, or correction of the 
mutant allele for gain-of-function or dominant-negative mutations.  
c. For disorders that affect the development of a cell (lacking in the patient), an 
animal model must indicate in vivo that there are causally related phenotypes 
that mimic the patient’s phenotypes (molecular, cellular, and clinical) and 
that are explained by the candidate genotype. A biological phenotype 
underlying the patient’s clinical phenotype must be replicated in the mutant 
animal. 
Adapted from “Guidelines for genetic studies in single patients: lessons from primary 
Immunodeficiencies” by Casanova, J.L., et al. J Exp Med, 2014. 211(11): p. 2137-49. 
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In another example, a homozygous missense mutation in PRKCD (protein kinase C, 
delta), encoding protein kinase δ (PKCδ), was identified in 3 siblings who presented 
with juvenile-onset systemic lupus erythematosus (SLE) [21]. Mechanistic studies 
demonstrated that reduced activity of PKCδ led to reduced apoptosis of (autoreactive) 
B cells and increased B cell proliferation with increased numbers of immature B cells. 
In PKCδ deficient mice, which exhibit a SLE phenotype, B cell expansion and a 
developmental shift toward immature and naïve B cells was observed as well. These 
findings indicate that PKCδ is crucial in regulating B cell tolerance and preventing self-
reactivity in humans, and that PKCδ deficiency represents a novel genetic defect of 
apoptosis leading to SLE [21]. 
3. Overview of the clinical phenotypes under study 
3.1 Severe early-onset systemic lupus erythematosus, IgA-deficiency and mild lower limb 
spasticity without neuroradiological manifestations 
3.1.1 Systemic lupus erythematosus 
SLE is a prototypic systemic multi-organ autoimmune disease that is characterized by 
the production of autoantibodies against nucleic acids and related nuclear proteins, 
immune complex deposition and systemic vasculitis [22, 23]. Organ systems typically 
affected include skin/mucosae (rash), joints (arthralgia/arthritis), kidneys 
(glomerulonephritis) and/or hematopoetic cells (anemia, leucopenia, 
thrombocytopenia) [7]. Upregulation of IFN responsive genes in patients’ peripheral 
blood cells, the IFN signature, is associated with more severe disease involving the 
kidneys, hematopoetic cells and/or the central nervous system (encephalopathy, 
stroke) [22, 24]. Up to 40% of SLE patients can develop an antiphospholipid 
syndrome, when anti-phospholipid autoantibodies such as anticardiolipine antibodies 
or lupus anticoagulans interfere with coagulation leading to increased clot formation 
or thrombosis [25]. Childhood-onset SLE accounts for 5-10% of all cases, with a 
incidence of about 2.2/100,000 in children aged 3-18 years [7]. In the majority of 
paediatric SLE patients an IFN signature is found [23, 24], and the development of SLE 
in childhood and adolescence is typically associated with a more fulminant disease 
onset and course, more associated damage over time and a relatively high male-to-
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female sex ratio [7]. Childhood-onset disease is associated with an increased mortality 
risk due to infections, cardiovascular, pulmonary or renal disease; and without 
treatment the 5-year mortality rate reaches 95%  [26, 27]. 
SLE is assumed to arise through a complex interplay of environmental and genetic 
factors. Considering the increased disease severity and the shorter exposure time to 
environmental triggers, genetic factors are thought to be relatively more important in 
the pathogenesis of childhood-onset SLE [28]. Patients with monogenic causes of SLE 
often have severe early-onset disease and are thought to comprise ~1% of the adult SLE 
cohort [29]. Known monogenic defects associated with SLE include mutations in 
DNASE1L3 (deoxyribonuclease 1-like 3), DNASE1, PRKCD, TREX1 (three prime repair 
exonuclease 1), TRAP (triiodothyronine receptor auxiliary protein), SAMHD1 (SAM 
domain and HD domain-containing protein 1) and the complement deficiencies [28, 
29]. Through the identification of these genes several mechanisms that contribute to 
the development of SLE have been identified. Defects in apoptosis and clearing of 
nuclear debris leads to production of double-stranded DNA (dsDNA) autoantibodies 
and autoimmunity. For example, recessively inherited loss-of-function mutations in 
TREX1, the main 3’-5’ DNA exonuclease responsible for degrading DNA during 
granzyme A-mediated apoptosis, lead to accumulation of endogenous DNA and 
subsequent IFN-α production [30]. TREX1 deficiency is associated with SLE and 
familial chilblain lupus, but also with Aicardi-Goutières syndrome (AGS), a rare 
neuroimmunologic disorder associated with elevated levels of type I IFN and 
characterized by severe early-onset leucoencephalopathy, brain atrophy and 
intracranial calcifications leading to profound intellectual disability, spasticity and 
dystonia [31, 32]. Other mechanisms include defects in the clearing of apoptotic cell 
bodies and of circulating immune complexes as is seen in the complement deficiencies 
[33], or loss in B cell tolerance as is seen in PKCδ deficiency [21]. Additionally, several 
genetic variants associated with SLE susceptibility have been identified through 
genome-wide association studies (GWAS). Functional studies into the biological 
effects of these variants have implicated several other potential mechanisms and 
pathways in the disease pathogenesis of SLE, such as signalling through nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) and Toll-like receptors (TLRs), 
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adhesion and migration of monocytes and neutrophils, B cell function (activation, 
proliferation, differentiation) and T helper cell (Th) function (Th1, TH17) [29]. 
Conventional treatment of SLE consists of immunosuppressive/immunomodulatory 
drugs such as corticosteroids, hydroxychloroquine, mycophenolate mofetil, 
cyclophosphamide or azathioprine, depending on disease presentation and severity 
[34]. Autologous hematopoietic stem cell transplantation (HSCT) has been used in 
patients with severe SLE refractory to immunosuppression and treatment toxicity, 
however more than 50% of the patients experienced a relapse [35]. Increased insight 
into the pathogenesis of SLE has driven the development of biologic therapies that 
target B cells (e.g. anti-CD20 mAb) or inhibit costimulatory molecules (e.g. anti-
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) mAb) or type I IFNs (e.g. anti-
IFN-α/β receptor (IFNAR) mAb, anifrolumab) [34]. Clinical trials on the use of oral 
Janus kinase (JAK) inhibitors in SLE, to block the IFN signalling cascade downstream 
of IFNAR, are ongoing [36]. 
3.1.2 Selective IgA deficiency and autoimmunity 
Immunoglobuline A (IgA), the most amply produced antibody isotype, serves as a first 
line of defence against inhaled and ingested pathogens at the mucosal surfaces of the 
respiratory, gastrointestinal, and genitourinary tracts [37]. Selective IgA deficiency 
(sIgAD), defined as IgA < 7 mg/dl with normal serum IgG/IgM and normal IgG 
antibody response to vaccination, is considered the most common immunoglobulin 
deficiency. The prevalence of sIgAD varies greatly among populations, from 1/142 in 
Arabian Peninsula to 1/18,500 in Japan [37]. The clinical presentation of sIgAD ranges 
from asymptomatic to recurrent sinopulmonary and gastrointestinal infections. Atopy 
and high IgE levels are also often found in sIgAD patients [38], but a striking finding is 
the presence of autoantibodies in about 40% of sIgAD patients, with or without 
clinical manifestations of autoimmune diseases such as autoimmune hypothyroidism, 
celiac disease, systemic lupus erythematosus or diabetes mellitus [37]. Many 
hypotheses have been put forward to explain the association between sIgAD and 
autoimmunity. Increased exposure to environmental antigens that could possibly 
cross-react with self-antigens could lead to an enhanced immune response and 
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development of autoimmunity, or defective antigen clearance could result in immune 
complex deposition in many organs leading to inflammation [37]. It has also been 
demonstrated that IgA has anti-inflammatory functions. Serum IgA is normally bound 
to its receptor on myeloid cells. While an activating response is obtained when IgA 
binds its antigen, binding of IgA alone to its receptor induces a strong anti-
inflammatory action towards responses induced by other cell-surface receptors on 
phagocytes [37]. This dual function depending on binding of the receptor to 
uncomplexed or antigen-complexed IgA, may contribute to the balance between 
inflammatory and anti-inflammatory processes. Monogenic defects leading to sIgAD 
have not been identified yet, however, genetic variants associated with increased 
susceptibility to both sIgAD and autoimmunity have been identified through GWAS, 
the most important ones being major histocompatibility complex (MHC) haplotype 8.1 
and polymorphisms in CLEC16A (C-type lectin domain family 16) and IFIH1 (interferon 
induced with helicase C domain 1) [39].  
3.1.3 Spastic paraparesis 
Spastic paraparesis is a heterogeneous group of neurological disorders characterized by 
lower limb spasticity and weakness. This condition can be the result of intrauterine 
infections or neonatal asphyxia, and neuroimaging often shows abnormalities such as 
calcifications or periventricular leucomalacia [40]. Although they are much less 
prevalent than cerebral palsy, hereditary disease forms exist in which patients develop 
a progressive loss of corticospinal motor tract function [41]. In these 
neurodegenerative disorders neuroimaging is normal, symptoms occur later in life and 
they usually progress slowly and steadily. When symptoms begin in very early 
childhood, they may be non-progressive and resemble spastic diplegic cerebral palsy. 
The prevalence of hereditary spastic paraparesis (HSP) is estimated to be 1.2 - 
9.6/100,000. More than 50 genetic HSP types have been described, and the associated 
genes are involved in neuronal axon transport, endoplasmic reticulum morphology, 
mitochondrial function, myelin formation, protein folding and endoplasmic reticulum-
stress response, corticospinal tract and other neurodevelopment, fatty acid and 
phospholipid metabolism and endosome membrane trafficking and vesicle formation, 
as described in detail in the review by Fink et al. [41]. Recently, mutations in ADAR1, 
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IFIH1, and RNASEH2B, genes known to be involved in AGS, have been found in 
patients with HSP as well [42]. Neuroimaging was normal or showed nonspecific 
dysmyelination in one patient, and the patients with mutations in ADAR1 and IFIH1 
showed a robust IFN signature in peripheral blood. This association between type I IFN 
and neurological phenotypes such as AGS or HSP suggests that type I IFN may act as a 
neurotoxin during prolonged exposure [42]. 
3.2 Castleman’s disease 
Castleman’s disease is a rare lymphoproliferative disorder characterized by polyclonal 
B cell proliferation. It can be divided into unicentric Castleman’s disease (UCD), when 
a single lymphoid region is involved, and multicentric Castleman’s disease (MCD) in 
which multiple lymphoid regions are involved [43]. In UCD symptoms are mostly local 
due to enlargement of one or more lymph nodes and removal of the lymph node is 
often curative [44]. MCD on the other hand, is often associated with systemic 
symptoms [43] and systemic treatment is necessary [44]. Castleman’s disease is 
characterized by hypersecretion of IL-6 without any significant production of other 
cytokines [45]. The overproduction of IL-6 is assumed to be responsible for systemic 
symptoms such as fever, polyclonal B-cell expansion and 
lymphadenopathy/hepatosplenomegaly, hypergammaglobulinemia and increased 
levels of acute-phase reagents [45, 46]. Before the development of biologicals, therapy 
consisted of corticosteroids, combination chemotherapy and/or 
lenalidomide/thalidomide [44]. Treatment with anti-CD20 mAb (rituximab) has been 
effective in Castleman’s disease, especially in patients with pre-existing autoimmune 
disorders [47]. However, treatment with anti-IL-6 receptor (IL-6R) mAb (tocilizumab) 
has resulted in remarkable clinical improvement, consistent with the major role of IL-6 
in disease pathogenesis [48, 49].  
Castleman’s disease is an orphan disease. Prevalence is estimated to be less than 
1/100,000 [50]. The incidence of UCD is highest in the third and fourth decade of life, 
for MCD the peak of incidence lies in the fourth and fifth decade of life [44, 50]. 
Castleman’s disease is even rarer in children, with only about 100 paediatric cases 
published, and the disease presentation in children is usually that of UCD [43, 50]. 
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Infections with human herpes virus (HHV)-8 are responsible for approximately 50% of 
MCD cases [51], mostly in human immunodeficiency virus (HIV)-positive but also in 
HIV-negative patients, by driving hypercytokinemia secondary to the expression of the 
virus-encoded cytokine, viral IL-6 [52].  Therefore, MCD is often classified as HHV-8-
positive MCD and HHV-8-negative or idiopathic MCD (iMCD). The genetic cause of 
iMCD remains to be elucidated. Functional polymorphisms in the human IL-6R 
leading to increased expression of soluble IL-6R have been found with increased 
frequency in patients with iMCD compared to healthy individuals [53]. This finding 
further illustrates the importance of the IL-6 pathway in disease pathogenesis. iMCD 
can be associated with pre-existing autoimmune disorders such as rheumatoid 
arthritis, Sjögren’s syndrome and SLE [54]. Hypercytokinemia in iMCD is thought to 
be the consequence of either systemic inflammatory disease mechanisms via 
autoantibodies or inflammatory gene mutations, of paraneoplastic syndrome 
mechanisms via ectopic cytokine secretion, and/or a of non-HHV-8 virus [55]. 
3.3 Combined immunodeficiency, lymphoproliferation, autoimmunity and  vasculopathy of 
the central nervous system 
3.3.1 Combined immunodeficiency with autoimmunity and lymphoproliferation 
Combined immunodeficiencies (CIDs) comprise of a heterogeneous group of disorders 
of cellular immunity that are caused by either a deficient number or deficient function 
of T lymphocytes [56]. In contrast with severe combined immunodeficiency (SCID), in 
which profound T cell lymphocytopenia is present, CID patients have a significant 
number of (potentially defective) autologous circulating T cells, although they 
frequently lack naïve T cells [57]. More than 70 different genetic defects responsible 
for T cell dysfunction have been identified [56]. These genetic defects can lead to 
impairment of different types of T cell activity, such as T cell development, antigen 
presentation, activation, costimulation, proliferation/metabolic adaptation, 
quiescence, survival/migration, memory generation/maintenance, (general or 
selective) effector functions, senescence and regulatory functions. CIDs are 
accompanied by a humoral defect as well, either due to intrinsic B cell defects or due 
to the lack of T cell help for antibody production [58]. The nature of the genetic defect 
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might explain differences in clinical presentation of CIDs, however, all of these 
disorders are associated with susceptibility to both bacterial and (severe) viral 
infections, and in some cases fungal and mycobacterial infections as well. Given the 
broad definition of CID, it is difficult to estimate the prevalence of this group of 
disorders. Newborn screening in the United States of America identified SCID in 1 in 
58000 births, however prevalence of non-SCID T cell lymphopenia varied from 1/2100 
to 1/14000 depending on the state although the majority of these cases was not 
associated with T cell dysfunction [59]. The prevalence of common variable 
immunodeficiencies (CVID), an equally heterogeneous group of disorders 
characterized by decreased serum immunoglobulins, poor specific antibody response 
upon vaccination and recurrent bacterial infections, is estimated to range from 
1/25000 to 1/50000 [60]. 
CID is often associated with autoimmunity and lymphoproliferation, since self-
tolerance relies on an intact immune system to suppress autoreactivity and the present 
T cells can expand and attack normal tissue [56]. This seems evident when the genetic 
defect has an effect on regulatory functions of T cells. For example loss-of-function 
mutations in FOXP3 (forkhead box P3), the master transcription factor for the 
development and function of regulatory T cells (Tregs), were identified in patients with 
the ‘immune dysregulation, polyendocrinopathy, enteropathy, X-linked’ (IPEX) 
condition [61]. In the most severe cases patients present with very severe and early-
onset gut disease (probably initiated by excessive inflammation triggered by the gut 
microbiota), food allergies and in a later stage type I diabetes. However, defects in 
other T cell functions can lead to autoimmunity and lymphoproliferation as well. For 
example genetic defects leading to impaired signalling downstream of the T cell 
receptor (TCR) after antigen recognition almost always present with severe 
impairment of T cell immunity but also with autoimmune features. This can be 
explained by changes in TCR signalling strength that can modify the threshold for 
negative selection of self-reactive T cells in the thymus and/or cause impaired 
production of Tregs.  
Depending on the nature and severity of the immune defect, different forms of 
treatment are indicated for CID. In general, patients receive intravenous 
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immunoglobuline (IVIG) replacement therapy in order to maintain protective IgG 
serum levels [58] and most patients also receive infectious prophylaxis [58]. When 
autoimmune/autoinflammatory manifestations are present, addition of 
immunosuppressive treatment is necessary [60]. A wide range of immunosuppressive 
regimens are available but often fail in controlling the disease. Insight in the 
pathogenic mechanisms involved can help in choosing a correct therapeutic approach. 
For example, in autoimmune enteropathy the disease process seems to be mostly 
driven by T cells producing Th1 cytokines such as IL-12 and IFN-γ [62]. Therefore, T 
cell-targeted therapies such as calcineurin inhibitors are often used once steroid 
treatment has failed [60]. For severe T cell deficiencies or in case of treatment failure, 
allogeneic HSCT can be curative and lead to a life-long restoration of a functionally 
normal adaptive immune system [63]. Success of the HSCT in CID depends on the 
availability of a human leukocyte antigen (HLA) compatible healthy donor and the 
effectiveness in controlling pre-existing infections and immune dysregulation [63]. 
Due to the risks associated with (non-HLA-matched) allogeneic HSCT, efforts are 
being made to introduce gene therapy, e.g. correction of the genetic defect in the 
patient’s own hematopoietic stem cell, in the clinical setting [64]. 
3.3.2 Early-onset stroke and vasculopathy/vasculitis of the central nervous system 
Although stroke is often considered to be associated with old age, it can occur in 
children as well. The incidence of stroke in children aged 0-19 years is estimated at 5 
out of 100,000 [65]. The risk of childhood stroke is greatest in the first year of life, and 
peaks during the perinatal period [65]. Risk factors for stroke in children include 
congenital or acquired (e.g. infectious) heart disease, anatomical malformations of 
central nervous system (CNS) blood vessels, CNS infections, head or neck trauma, 
haematological disorders such as sickle cell anaemia or haemophilia, or 
autoimmune/autoinflammatory disorders. In autoimmune/autoinflammatory disease, 
the cause of the stroke can be blood vessel-related, i.e. stroke as a consequence of CNS 
vasculitis or vasculopathy, or due to the development of a coagulation disorder (e.g. 
antiphospholipid syndrome in SLE) [56]. 
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Primary systemic vasculitis, with our without CNS involvement, is a heterogeneous 
group of disorders characterized by blood vessel inflammation [66]. Most of the 
primary vasculitis syndromes are rare in childhood, but are associated with significant 
morbidity and mortality [66]. CNS vasculitis can occur in the context of systemic 
vasculitis with a CNS component, but isolated disease only affecting the CNS exists as 
well, e.g. childhood primary angiitis of the central nervous system (cPACNS). Several 
genetic defects that are associated with CNS vasculitis or vasculopathy have been 
identified. Intracerebral arteriopathy and early-onset stroke is commonly found in 
patients with recessively inherited loss-of-function mutations in SAMHD1, one of the 
disease-causing genes in AGS [67]. Large artery disease is not observed in patients with 
mutations in other AGS-associated genes, perhaps indicating a particular role for 
SAMHD1 in blood vessel integrity. Recently, dominantly inherited loss-of-function 
mutations in TNFAIP3 (tumor necrosis factor, alpha-induced protein 3) leading to A20 
haploinsufficiency were identified in patients with Behçet-like disease, with 1 patient 
suffering from CNS vasculitis as well [68].  
Zhou et al. identified recessively inherited loss-of-function mutations in CECR1 (cat eye 
syndrome chromosome region, candidate 1), encoding adenosine deaminase 2 (ADA2), 
in patients with systemic inflammation, systemic vasculopathy in the form of early-
onset recurrent stroke, livedoid rash or vasculitis, hepatosplenomegaly, 
hypogammaglobulinemia and lymphopenia [69]. Simultaneously, Navon Elkan et al. 
identified recessively inherited loss-of-function mutations in CECR1 in patients with 
systemic polyarteritis nodosa, a necrotizing vasculitis [70]. Patients presented with 
systemic inflammation, livedoid rash, peripheral neuropathy and systemic 
vasculitis/vasculopathy, mostly visceral involvement but several patients presented 
with CNS vasculopathy and early-onset stroke as well. All ADA2-deficient patients had 
reduced levels of ADA2 as well as a reduction in ADA2-specific enzyme activity in the 
blood. Cytokine profiles were normal. Brain biopsies revealed vasculopathy changes 
characterized by compromised endothelial integrity, endothelial cellular activation and 
inflammation. In vitro experiments demonstrated that patient monocytes 
preferentially differentiated into M1 macrophages and induced damage in cocultured 
endothelial-cell layers. Therefore it was hypothesized that possible disease 
18 
 
mechanisms in ADA2 deficiency are proinflammatory macrophage polarization and 
disturbed endothelial integrity.  
3.4 Severe viral illness 
Although many forms of PID are associated with severe, persistent, recurrent, or 
refractory viral illness, isolated susceptibility to viral infections is considered to be 
rarer [71]. While in the past susceptibility to severe viral diseases was thought to be the 
consequence of deficient lymphocyte or innate immune cell responses, especially CD8+ 
T cell or natural killer (NK) cell responses [56, 71], several defects in innate pathogen 
recognition receptors [72] and signalling molecules [20] have been identified that can 
lead to either pathogen-specific susceptibility or predisposition to severe disease 
associated with multiple viruses [71]. It is difficult to estimate the prevalence of 
disorders due to isolated susceptibility to viral infections. Life-threatening disease is 
often wrongfully contributed to bacterial disease, and viral infection can be more 
difficult to document as pathogen-specific tests by polymerase chain reaction (PCR) 
are mostly used for diagnosis in current practice. For specific disease entities such as 
herpes simplex encephalitis (HSE), a well-defined and well-documented disease caused 
by a pathogen-specific susceptibility to herpes simplex virus (HSV)-1, an estimated 
prevalence of about 1/10,000 has been established and mutations in six genes of the 
TLR3 signalling pathway have been identified in children with HSE [73]. 
Many of the genetic defects in innate immunity identified in patients with isolated 
viral susceptibility, are associated with a failure in the induction of, signalling of or 
response to type I IFN. For example, both defects in the TLR3 signalling pathway in 
HSE and genetic defects in IRF7 in a patient suffering from life-threatening influenza 
infections lead to a failure to induce type I IFN [20, 73]. Increased susceptibility to 
measles can be associated with either signal transducer and activator of transcription 2 
(STAT2) deficiency or IFNAR deficiency, both leading to a failure to respond to this 
group of cytokines [74, 75]. Additionally, susceptibility to viral infection has been 
observed in mice with genetic defects in the IFN signalling pathway, for example 
deficiency of Ifnar1 [76] or Stat1 [77]. Furthermore, most viruses have developed 
strategies to evade the IFN response and lose pathogenicity when their IFN antagonists 
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are knocked out [78]. All these findings demonstrate the importance of the type I IFN 
response in innate antiviral defence.  
Prevention forms an important part of the management of PID patients with or 
without isolated increased susceptibility to viral illness. Non-live vaccines can 
significantly reduce the number of viral infections in PID patients, for example in the 
IRF7-deficient patients annual influenza vaccination as sole secondary prevention was 
sufficient to prevent further disease [20]. The administration of live-attenuated 
vaccines is contraindicated in PID patients, especially in those patients with an 
increased susceptibility to these pathogens [79]. Vaccination of the family and 
surroundings as well as sufficient population vaccination coverage is necessary to 
provide herd immunity to those patients. Patients can receive prophylactic IVIG 
treatment, in the hope of preventing severe and recurrent viral illness [80]. 
Additionally, environmental exposure to viral pathogens should be avoided when 
possible. However, once a severe viral illness has developed, treatment is challenging. 
Several antiviral drugs are available that do not destroy the pathogen but intervene in 
viral replication and can therefore assist in controlling the disease, for example 
acyclovir, a nucleoside-analog (9-(2-hydroxyethoxymethyl) guanine) that specifically 
inhibits replication in herpes viridae [81]. For specific pathogens monoclonal 
antibodies have been developed that help clear the infection, for example palivizumab, 
a monoclonal antibody against respiratory syncytial virus (RSV) [82]. Otherwise, 
treatment remains limited to intensive supportive care. 
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OBJECTIVES 
The main objective of this project is to identify novel genes capable of causing 
monogenic defects in the human immune system by studying paediatric patients with 
severe immunological disorders. The project received approval by the ethical 
committee of the University Hospital of Leuven, Belgium (study reference number: 
S52653). By collecting both genetic and immunological data from patients with 
distinct clinical manifestations belonging to the whole spectrum of immune 
dysregulated conditions (both hypo & hyper immune states) but without a genetic 
diagnosis, strong associations between clinical phenotype, immune phenotype and 
genotype are searched for. 
To clarify the contribution of novel genes in severe immunological disorders, the 
following sub-objectives are formulated:  
1. to identify candidate genetic variants responsible for severe early-onset 
immunological disorders in humans 
2. to investigate alterations in the peripheral immune system of patients with 
these disorders in order to gain insight in pathways involved in disease 
pathogenesis 
3. to verify the role of a candidate genetic variant in disease pathogenesis and 
prove it is causal 
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METHODOLOGY 
1. Genetic analysis: identification of a candidate genetic variant 
1.1 Sequencing techniques 
The development of ‘next generation sequencing’ (NGS) techniques such as whole-
exome sequencing (WES) and whole-genome sequencing (WGS) have revolutionized 
genetic studies by allowing detailed exome- or genome-wide screening for disease-
causing variants [83-85]. In WES the protein-coding regions of the genome are 
sequenced [83]. Although these regions make up approximately 1% of the human 
genome, it is estimated that 85% of the disease-causing mutations are located in 
coding regions  of the genome [86], rendering WES a distinct option in the search for 
disease-causing variants. Disadvantages of WES compared to WGS include incomplete 
coverage of the target region, difficulties in detecting copy number variants (CNV) as 
well as large insertions and deletions, and of course the inability to detect variants in 
promoter sequences, intronic regulatory sequences or other regulatory sequences such 
as long non-coding RNAs or microRNAs. The major advantages of WES over WGS are 
the lower cost, the shorter sequencing time and the smaller, more manageable data set 
for faster and easier analysis [87].  
Based on the arguments stated above as well on the availability of the technique in our 
research institution, WES was chosen to screen the entire human exome and the 
adjacent intronic regions containing splice sites for possible disease-causing genetic 
variants. Given the severe clinical phenotypes in our patient cohort, we hypothesized 
that there is a high chance that the causative mutations are located in the coding 
regions of the genome and that this strategy would therefore be successful. It is 
important to mention however, that due to its rapidly decreasing costs and the 
development of faster sequencing methods, WGS is becoming an increasingly 
attractive alternative for WES [88]. Although it remains difficult to interpret variants 
in intronic or intergenic regions, WGS is a superior technique for the detection of 
CNVs and it provides increased coverage of the target region in comparison with WES. 
Furthermore, recent studies have demonstrated that WGS is more efficient in calling 
high-quality coding single nucleotide variants (SNV) as well [88], suggesting that WGS 
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might be a more powerful technique than WES for detecting potential disease-causing 
mutations in the targeted exome. 
1.2 Selection of a candidate genetic variant 
The technical aspects of target enrichment and massive parallel sequencing in WES 
have been described in detail before [83]. Briefly, genomic DNA is fragmented and an 
fragmentation 
preparation of exome library 
capture amplification 
sequencing 
generation of sequence reads 
...GGCAGCGGACAGCGGCACGCACATTTGACCTGTCCCGCAGACA...  
...GACAGCGGCACGCACATTTGACCTGTCCCGCAGACAA... 
alignment to reference genome 
CATTCGAATGGCAGCGGACAGCGGCACGCACATTTCACCTGTCCCGCAGACAAC 
...GGCAGCGGACAGCGGCACGCACATTTGACCTGTCCCGCAGACA...  
...GACAGCGGCACGCACATTTGACCTGTCCCGCAGACAA... 
variant calling 
CATTCGAATGGCAGCGGACAGCGGCACGCACATTTCACCTGTCCCGCAGACAAC 
...GGCAGCGGACAGCGGCACGCACATTTGACCTGTCCCGCAGACA...  
...GACAGCGGCACGCACATTTGACCTGTCCCGCAGACAA... 
Homozygous  C > G 
genomic DNA 
annotation and functional characterization 
Codon 240: TCA > TGA 
p.S240X 
 G 
Figure 1: Steps for generating whole-exome sequencing data. 
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exome sequence library is prepared by capturing the target region (exome) and 
amplifying it by PCR. After sequencing of the sample, the fragment reads are aligned to 
the reference genome, single nucleotide variants and insertions/deletions are 
identified and the variants are annotated. Figure 1 shows a schematic overview of the 
basic steps for generating WES data. A detailed description of the technical aspects of 
the technique is mentioned in the methods section of each publication in this 
manuscript. The selection of candidate genetic variants is an important part of this 
work and therefore the principles and current practices for achieving this are discussed 
in more detail. An overview of the necessary steps for selecting a candidate genetic 
variant can be found in Figure 2. 
1.2.1 Selection of rare variants 
WES can generate up to 20,000 genetic variants per individual compared to the 
reference genome [89]. When selecting candidate disease-causing genetic variants in 
patients suffering from rare diseases, it is important to focus on rare genotypes as well. 
Therefore, genotype and allele frequencies are important factors, and filtering out 
common polymorphisms is the first step in narrowing down the number of genetic 
variants in an individual. This can be achieved by searching for the variant in multiple 
online databases such as 1000Genomes [90], NHLBI ESP6500 [91], HapMap [92], 
dbSNP [93] or ExAc [94]. These public databases contain the frequencies of genetic 
variations of a large number of individuals of various ethnicities that were obtained 
using NGS techniques. It is important to mention that public databases can contain 
disease-causing variants as well. Therefore, excluding all variants that are found in 
these databases might be too strict, especially in the case of rare disorders with a 
suspected recessive inheritance which can be caused by a rare variant that can be 
found in control heterozygotes as well. Genotype frequency is more relevant than allele 
frequency, and depending on the suspected mode of inheritance and the expected 
frequency of the phenotype, variants with a low frequency in public databases (e.g. 
control allele frequency < 0,5% or 1%) should be included in the analysis as well. 
Furthermore, an in-house database that contains data from ethnically matched DNA 
samples analysed using the same technology is a powerful tool for excluding common 
polymorphisms specific for the examined population and has been used in this study.  
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20,000 
variants 
absent or rare (allele frequency < 1%) in public databases 
(1000Genomes, HapMap, ESP6500, ExAc) 
common variants 
familial study: de novo heterozygous, homozygous or 
compound heterozygous variants 
coding 
nonsynonymous, nonsense, splice site, in-frame/out-
of-frame insertions/deletions, stop loss 
non-coding 
synonymous 
UTR, intronic 
absent or rare in in-house database 
gene information: known disease association, 
expressed in relevant tissue(s), purifying selection 
functional prediction algorithms 
genetic confirmation:  
 segregation of the phenotype in the pedigree 
 Sanger sequencing 
Figure 2: Filtering steps of exomic variants for the identification of candidate 
genetic variants Mendelian disease mutations or rare variants with large effects.  
25 
 
1.2.2 Family studies 
Even after filtering out common polymorphisms, 500-1000 rare variants can still be 
found in one individual [89]. In the context of a rare, possibly Mendelian disorder in a 
single patient or family, WES is preferentially performed on a trio consisting of the 
patient and both parents.  Based on the observed pattern of inheritance in the family, 
analysis of the exome data of all three individuals is performed to identify rare de novo 
heterozygous or rare inherited homozygous or compound heterozygous genetic 
variants. Previous familial studies have shown that one trio contains on average 12 rare 
genotypes: one de novo genotype (absent in control population), one hemizygous 
genotype (control allele frequency < 1%, never observed in male controls and never 
homozygous in female controls), three homozygous and seven compound 
heterozygous genotypes (control allele frequencies < 1%) [95]. Even when using less 
stringent criteria, the familial study approach will lead to a manageable list of 
candidate variants. When examining extremely consanguineous families with a large 
number of homozygous variants, additional WES of healthy siblings offers the most 
added information, since this data can be used to exclude homozygous variants that 
are present in the healthy siblings and are therefore most likely not disease-causing. 
1.2.3 Prioritizing candidate genetic variants 
Next, the remaining candidate genetic variants must be prioritized and the most 
plausible one selected for further mechanistic studies. A variant can be selected or 
filtered out based on available information of the mutated gene, and/or based on the 
predicted impact of the variant on gene function.  
Several arguments based on available gene information can be made for selecting a 
candidate disease-causing gene: 
1. The protein encoded by the gene belongs to a pathway already implicated in 
patients with a similar phenotype. Databases and software such as ‘The human 
gene connectome server’ (HGCS) that allow researchers to prioritize a list of 
genes by their biological proximity to defined core genes (i.e. genes that are 
known to be associated with the phenotype) and to predict novel gene 
pathways, are freely available [96]. 
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2. Gene transcripts are expressed in tissue affected by the phenotype or in tissues 
that could influence or contribute to the phenotype. Public databases 
containing information on gene expression in a wide array of human or murine 
cell lines, cell types, tissues and organs are available and easy accessible [97, 
98]. 
3. Genes containing multiple deleterious mutations in the general population are 
unlikely to be responsible for a rare, severe phenotype with complete 
penetrance. A database and software for the calculation of the nonsynonymous 
mutational load in each protein-coding gene in the general population (i.e. the 
gene damage index) are freely available [99]. In contrast, variants in genes 
under tight purifying selection are more likely causative of rare, severe early-
onset diseases. Statistical methods for detecting the different types of selection 
have been developed and for most human genes the extent of purifying 
selection is now known [100]. 
The predicted impact of the variant on gene function can also be used to (further) 
prioritize candidate genetic variants. Nonsense mutations, in-frame and out-of-frame 
insertions and deletions, and mutations of the stop codon (stop loss) are likely to be 
deleterious. The impact of missense mutations can vary greatly and their pathogenicity 
can be predicted using functional prediction algorithms such as SIFT [101] and 
Polyphen-2 [102] that are based on a combination of biochemical and evolutionary 
data. The CADD algorithm scores the deleteriousness of both SNVs and 
insertions/deletions by weighing and integrating multiple annotations/scores of the 
variants [103]. Splice site variants that disrupt the consensus dinucleotide splice sites 
(+/-1 and +/-2) are also likely to be pathogenic. For variants located further away from 
the intron/exon boundary prediction algorithms exist as well, e.g. Human splicing 
finder 3.0 [104], NetGene2 [105] or NNSplice [106]. In contrast, UTR variants and 
intronic variants far beyond acceptor and donor sites at intron/exon boundaries are 
difficult to interpret in single patients, although they can interfere with splicing and 
other regulatory processes as well. Synonymous variants are usually considered far less 
likely to be pathogenic and are often filtered out, however, they can be disease-causing 
as well through several mechanisms: 
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1. Alternative splicing: A synonymous variant can lead to the creation of a new 
splice site. A mild form of cystic fibrosis caused by alternative splicing due to a 
synonymous c.2811G>T variant (p.Gly893Gly) in CFTR (cystic fibrosis 
transmembrane conductance regulator) has been described [107]. It seems 
imaginable that some synonymous variants might have some subtle effect on 
splicing without actually creating or destroying a splice site as well. 
2. Alterations in gene expression through altered interaction with 
microRNAs: A synonymous c.313C>T variant (p.Leu105Leu) in IRGM 
(immunity-related GTPase M), encoding a regulator of autophagy, leads to an 
increased risk of developing Crohn’s disease due to reduced binding with miR-
196 [108]. Specifically, miR-196 binds well to the C allele, thus downregulating 
IRGM, but not to the T allele.  The T allele therefore leads to higher disease risk 
because overexpression of IRGM reduces the cell's ability to autophagize 
invading bacteria. 
3. Altered secondary mRNA structure: Synonymous variants can impact the 
efficiency of translation and thus the amount of protein produced. A 
synonymous c.474A>C variant (p.Val158Val) in COMT (catechol-O-
methyltransferase), encoding a protein implied in catecholamine inactivation, 
leads to increased stability of the secondary mRNA structure and therefore 
reduced amounts of translated protein, reduced enzymatic activity and 
increased pain sensitivity in individuals carrying this variant [109]. By 
influencing the speed at which translation proceeds along the mRNA and since 
proteins begin to fold while they are still being translated, synonymous 
variants can lead to totally different protein folding as well.    
Other mechanisms might exist through which synonymous variants can be harmful. In 
Drosophila melanogaster 22% of synonymous sites evolve under very strong selective 
constraint and are highly conserved [110]. Genes enriched in strongly constrained 
synonymous sites are often involved in key developmental pathways [110]. The 
observed purifying selection acting on synonymous sites is likely not limited to 
Drosophila, and an important role of synonymous variants in human genetic disease 
should be considered. However, due to the difficulty in interpreting synonymous 
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variants and the expert opinion that the majority of synonymous variants found in a 
genome are less likely to be responsible for severe, early-onset immune diseases, they 
were excluded from analysis in a first step. 
1.2.4 Genetic confirmation of the candidate genetic variant(s) 
Once a candidate genetic variant/genotype is identified, it is first confirmed by Sanger 
sequencing. False positive findings due to technical aspects of WES (e.g. incorrect 
nucleotide incorporation during target enrichment, assembly misalignment) are 
possible and therefore a variant has to be confirmed by use of an alternative 
sequencing technique [83]. In a next step, segregation of the variant/genotype with the 
phenotype in the pedigree is investigated. For single patient cases complete penetrance 
is a necessary requirement [14]. Discovery of the same genotype of a single patient in 
an unaffected individual of the family should be a reason for excluding the candidate 
genetic variant(s), until unrelated individuals with a similar phenotype and variants in 
the same gene are found. 
2. Immunophenotyping: screening for alterations in the peripheral immune system 
Advanced analysis of the peripheral immune system of patients and healthy 
individuals is performed, in order to identify alterations in the patient immune system 
compared to that of healthy age-matched individuals. The hypothesis is that the 
observed alterations in the peripheral immune system, i.e. the patient’s immune 
phenotype, can provide insight in disease mechanisms and pathways involved in 
disease pathogenesis. For example, the observed shift towards immature B cells in 
PKCδ-deficient patients who suffer from SLE together with a similar observation in 
PKCδ-deficient mice demonstrates the importance of PKCδ for mature naïve B cell 
differentiation and for the regulation of B cell tolerance [21]. The obtained information 
on alterations in the patient immune system can also be useful in the selection of 
candidate genetic variants, when for example one gene out of a list of candidate 
genetic variants is expressed in an immune cell type that is (severely) affected in the 
patient(s).  
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However, careful interpretation of the observed alterations is necessary, since other 
factors, both genetic and environmental, can influence the function of the peripheral 
immune system and the appearance of an immune phenotype as well. Genetic 
regulation of the immune phenotype by relatively common genetic variants identified 
by GWAS has been demonstrated previously, when 23 independent variants at 13 loci 
where found to be associated with changes in the percentage of certain immune cell 
subsets [111]. For example, variants downstream of the HLA-DRA gene, previously 
identified as risk alleles for ulcerative colitis [112], systemic sclerosis [113], Parkinson´s 
disease [114], and Hodgkin´s lymphoma [115], are associated with decreased levels of 
memory CD8+ T cells that do not express the costimulatory molecule CD28 
(CD45+CD28-CD8+ cells) [111]. Additionally, environmental stressors such as 
pathogens, toxins and/or medication can affect an individual’s immune phenotype as 
well.  
While gender typically has negligible effects on the immune phenotype, important 
age-related changes in proportions and function of different immune cell subsets have 
been demonstrated previously.  The influence of old age, i.e. the decline in immune 
function in the elderly, has been studied extensively. For example, profound changes in 
T cell function and subsets such as a reduction in naive CD8+ T cells are observed in 
elder individuals and are thought to be responsible for the reduced vaccination success 
in this population [116, 117]. Although age-related changes in the immune phenotype 
from infancy to young-adulthood have been investigated less, studies in different 
ethnic populations demonstrate similar findings: a decline in percentages of naïve 
CD4+ and CD8+ T cells  and naïve B cells with age accompanied by an increase of 
memory CD4+ and CD8+ T cells and memory B cells indicating active development of 
the immune system, greater innate immune responses to TLR agonists in young 
children while regulatory responses (e.g. percentages of FoxP3+ Tregs) decrease with 
age, an increase in T cell percentages and decrease in B cell percentages with age,… 
[118-120]. These findings underline the importance of using age-matched healthy 
individuals as controls when examining the peripheral immune system [121]. 
When examining the peripheral immune system, both cellular (e.g. lymphocytes, 
monocytes) and humoral (e.g. immunoglobulines, autoantibodies, cytokines) immune 
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components can be studied. The immunological profiling in this work falls along three 
basic categories: (1) analysis of blood plasma, (2) ex vivo leukocyte analysis and (3) in 
vitro analysis of stimulated leukocytes. By studying both cellular and humoral immune 
components of patients with severe early-onset immune pathology, both adaptive and 
innate immune system abnormalities are investigated in these disorders. Measurement 
of humoral immune components such as autoantibodies, antibody isotype levels and 
serum acute-phase reactants in patient plasma and/or serum is performed by the 
laboratory of the University hospital of Leuven. When necessary, cytokines can be 
measured in patient plasma and/or serum by Elisa, an assay that is still considered to 
be the gold standard for the detection and quantitative measurement of a specific 
substance in a liquid sample.  
A human immunophenotyping platform using multicolour flow cytometry was 
previously developed in the Autoimmune Genetics Laboratory at KU Leuven, and is 
used to screen for immune cell alterations (i.e. changes in relative percentages of 
immune cell subsets) in the examined patients compared to healthy age-matched 
controls. Given the large variability and heterogeneity in the human immune system, 
even in a healthy population, accurate measurement of variations in the human 
immune system requires the use of standardized assays [122]. Figure 3 represent the 
workflow of the immunophenotyping platform. Flow cytometry is a powerful tool for 
analysing the function and the phenotype of immune cells, as it allows for the 
characterization of many subsets of cells in a complex mixture such as blood. Flow 
cytometry can be used to assess the expression of both cell-surface proteins and 
intracellular (phospho)proteins as well as other functional readouts [123, 124]. Through 
use of this technique relative percentages of subsets of peripheral blood mononuclear 
cells (PBMCs) are assessed, i.e. B and T lymphocytes, NK cells, NKT cells and dendritic 
cells (DCs). Within the B and T lymphocyte compartment, several developmental 
stages of B and T cells (e.g. naïve vs antigen-experienced) as well as Th subsets are 
quantified.  Table 2 contains an overview of the immunological profiling with the 
markers used to define the different cell populations.  
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Figure 3: Workflow of the immunophenotyping platform. PBMCs, peripheral 
blood mononuclear cells. Adapted from “Standardizing immunophenotyping for 
the Human Immunology Project” by Maecker H.T., et al. Nat Rev Immunol. 2012 
Feb 17;12(3):191-200. 
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Table 2: Advanced analysis of the peripheral immune system 
Blood plasma analysis 
UZ Leuven laboratory autoantibodies (ANA, ANCA, …) 
serum proteins (CRP, ferritin, …) 
antibody isotype levels 
Cytokine profiles measured by Elisa IL-6, IL-10, TNF-α, IFN-α, IFN-γ, IL-17A, … 
Direct ex vivo analysis of PBMCs using flow cytometry 
Quantification of PBMC subsets NK cells (CD4-CD8-CD3-CD19-CD14-CD56+) 
NKT cells (CD4-CD8-CD3+CD19-CD14-D56+) 
myeloid dendritic cells (CD19-CD3-CD14-CD56-
CD11c+HLA-DR+) 
plasmacytoid dendritic cells (CD19-CD3-CD14-
CD56-CD11c-CD123+HLA-DR+) 
Quantification of T cell subsets recent thymic immigrants (CD4+ or CD8+ 
CD45RA+CD31+) 
regulatory T cells (CD4+CD25hiIL7RAloFoxp3+) 
double negative T cells (CD4-CD8-CD3+CD56-) 
follicular T cells (CD4+CXCR5+CD45RO+) 
γδ T cells (CD3+γδ+) 
naive T cell (CD4+ or CD8+ CD45RA+) 
antigen-experienced T cells (CD4+ or CD8+ 
CD45RA-) 
Quantification of B cell subsets naive B cells (CD19+CD27-IgM+) 
IgM memory B cells (CD19+CD27+IgM+) 
switched memory B cells (CD19+CD27+IgM-) 
IgE+ B cells (CD19+IgE+) 
plasmablasts (CD19+CD24-CD38hi)  
transitional B cells (CD19+CD24hiCD38hi) 
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In vitro analysis of stimulated PBMCs 
TH1/TH2/TH17/Tfh quantification 5 hour PMA and ionomycin restimulation in 
Golgi-stop followed by intracellular cytokine 
staining for IFN-γ, IL-4, IL-2 and IL-17 
ANA, antinuclear antibodies; ANCA, antineutrophil cytoplasmic antibodies; CRP, C-reactive 
protein; IL, interleukin; TNF-α, tumor necrosis factor alpha; IFN-α, interferon-alpha; IFN-γ, 
interferon-gamma; PBMCs, peripheral blood mononuclear cells; NK cells, natural killer cells; 
NKT cells, natural killer T cells; PMA, phorbol myristate acetate. 
3. Verification of the role of a candidate genetic variant in disease pathogenesis and 
proof of causality 
When a candidate genetic variant or a list of candidate variants is available, functional 
tests are developed on a case by case basis in order to prove that a variant is disease-
causing. For each examined case, specific tests are described in detail in the 
corresponding chapters. The underlying principles and steps necessary for addressing 
these scientific aspects are described here and are based on the paper ‘guidelines for 
the genetic studies of single patients’ by JL Casanova et al. 1) which states that, after 
identification of the candidate genetic variant(s), functional and mechanistic studies 
must (1) demonstrate that the genetic variant(s) impair, destroy, or alter the function 
of the gene product, and (2) establish a causal relationship between the candidate 
genotype and the clinical phenotype via a relevant cellular or animal phenotype [14].  
3.1 The genetic variant(s) must impair, destroy or alter the function of the gene product 
In a first step, the impact of the variant(s) on gene expression is tested. A possible 
limitation here could be that the gene is only expressed in difficultly obtainable cell 
types, or only during specific developmental stages. In the study of immunological 
diseases however, many of the relevant cell types are easy accessible by a simple blood 
sample. Changes in the amount or molecular weight of the gene transcript can be 
assessed. For protein-coding genes, protein expression can be examined on patient 
primary cells, or on recipient cells transfected with N- or C-terminal tagged protein if 
there is no antibody to the protein of interest available. Reduced or absent gene 
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expression is often the first experimental evidence that the variant(s) could be disease-
causing.  
In a second step, in vitro studies must demonstrate that the variants are loss- or gain-
of-function for at least one biological activity. Loss of protein expression of course 
correlates with loss-of-function of the protein, however this can lead to (increased) 
activation of a pathway if the protein has an inhibitory function. For expressed 
proteins, in vitro studies should reveal a functional change and the corresponding 
mechanism by which the variant causes disease. Examples of such mechanisms could 
be failure of the protein to localize to certain cell compartments, failure to bind 
cofactors or target proteins, or aberrant constitutive activity of the protein. In general, 
functional studies are more difficult to conduct than expression studies because they 
require knowledge on the function of the examined gene and availability of specific 
tools. For example, examining chances in location or distribution of the protein within 
the patient cells can be done by immunofluorescence microscopy, however this 
requires a specific antibody.  
Ideally, all biochemical studies of a candidate mutant allele should be performed in 
comparison with rare or common mutant alleles found in individuals without the 
phenotype under study that serve as negative controls. 
3.2 The causal relationship between the candidate genotype and the clinical phenotype 
must be established via a relevant cellular or animal phenotype 
A first step consists of the identification of an in vitro cellular phenotype for the 
patient: relevant, ideally primary patient cells should demonstrate a functional 
abnormality that is caused by the candidate genetic variant(s). This cellular phenotype 
should be able to explain the clinical phenotype of the patient, for example because the 
cell type is affected by or is known to be involved in the disease process. As mentioned 
earlier, a wide range of immune cell types are easily accessible by blood sample. 
Dermal fibroblasts are another primary cell type that is relatively easy to obtain by skin 
biopsy. The development of iPSCs-technology has enabled the study of other non-
hematopoietic cell types that might be affected by disease as well, such as neurons 
[125], hepatocytes [126], cardiomyocytes [127], or respiratory epithelial cells [128]. In 
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immune pathology, this approach was used to demonstrate impaired intrinsic 
immunity and enhanced HSV-1 growth in patient-specific, iPSC-derived TLR3-deficient 
neurons and oligodendrocytes [129]. 
When such an in vitro cellular phenotype is available, establishing the causal 
relationship between genotype and phenotype can be done in various ways depending 
on the nature of the genotype: 
1. A rescue experiment that counteracts the effect of the genetic variant(s) must 
correct the cellular phenotype. For loss-of-function variants, introduction of the 
wild-type gene should correct the cellular phenotype, unless the mutation is 
dominant-negative. If the mutant allele is dominant by haploinsufficiency, it 
can be rescued by overexpression of the wild-type gene as well. For gain-of-
function or dominant-negative mutations, knockdown, knockout, or correction 
of the mutant allele should correct the cellular phenotype. 
2. Introduction of the genetic variant(s) in independent cell lines should reproduce 
or mimic the cellular phenotype. Overexpressing the mutant allele in a different 
system should reproduce the cellular phenotype observed in patient primary 
cells.  For example, loss-of-function mutations due to loss-of-expression must 
be confirmed by overexpressing the mutant allele(s) and confirming absent 
expression, and negative dominance must be established by co-transfecting the 
mutant and wild-type alleles into cells deficient for the gene product. As 
overexpression can alter the function of a gene, alternatively or additionally 
knockdown or knockout of the wild-type gene, or introduction of knock-in 
mutations in control cells, should reproduce the cellular phenotype. 
3. If no relevant cellular phenotype can be found, the disease-causing effect of a 
genotype can be proved by an animal model, under the condition that it 
recapitulates the whole-organism phenotype of the patient in vivo. This means 
that the phenotype of the mutant animal must mimic the molecular, cellular 
and clinical phenotype of the patient. Mice are the most commonly used animal 
models for studying human immune disease [130]. Although the percentage of 
human genes without any homolog currently detectable in the mouse genome 
has been estimated to be less than 1% [131], there is always the possibility that 
36 
 
no mouse homolog of the gene of interest exists and that a different animal 
model must be used. Different techniques for manipulating the genome of 
animal models such as targeted mutagenesis or transgenesis have been 
developed [132], however, since animal models are not used in this work, they 
will not be further discussed. 
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RESULTS 
By using the earlier stated approach, disease-causing variants were identified in two 
genes that were not known to be involved in severe early-onset immune pathology at 
the time of discovery, namely in IFIH1 and CECR1. A de novo gain-of-function mutation 
in IFIH1 was found in a 16-year-old girl with severe early-onset and refractory systemic 
lupus erythematosus, selective IgA-deficiency and mild lower limb spasticity without 
neuroradiological manifestations. These results were published in Arthritis & 
Rheumatology. Recessive loss-of-function mutations in CECR1 were found in a 9-year-
old boy with Castleman’s-like disease and in two siblings with combined 
immunodeficiency, lymphoproliferation, autoimmunity and vasculopathy. These 
results were published as two separate comments on the original articles by Zhou et al. 
and Navon Elkan et al. in New England Journal of Medicine. Subsequently, a detailed 
description of the results of the treatment of one sibling with allogenic HSCT was 
published in the Journal of Allergy and Clinical Immunology. While the corresponding 
comment in New England Journal of Medicine was not referenced in the latter article, 
the reviewers of the Journal of Allergy and Clinical Immunology were made aware of 
its existence and content, and consented to the inclusion of these results in a more 
detailed paper.  Additionally, compound heterozygous mutations in STAT2 were found 
in two siblings who suffered from severe viral illness. STAT2 deficiency was previously 
described in a consanguineous family [75] and in two siblings suffering from febrile 
illness following live measles vaccine and of whom one went on to develop opsoclonus-
myoclonus syndrome [133]. Identification of STAT2 deficiency in this third unrelated 
family strengthens this data. These results were submitted and are currently in review 
in the Journal of Allergy and Clinical Immunology. Each of the following chapters will 
be dedicated to one gene.  
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ABSTRACT 
Objective. To identify the underlying genetic defect in a 16-year-old girl with severe 
early-onset and refractory systemic lupus erythematosus (SLE), IgA deficiency, and 
mild lower limb spasticity without neuroradiologic manifestations. 
Methods. Whole-exome sequencing and extensive immunologic analysis were 
performed on samples from the index patient. 
Results. We identified a de novo p.R779H IFIH1 gain-of-function mutation in a patient 
with severe early-onset SLE, selective IgA deficiency, and mild lower limb spasticity. 
The same mutation in IFIH1 was recently identified in patients with Aicardi-Goutières 
syndrome, a rare neuroimmunologic disorder associated with elevated levels of type I 
interferon (IFN). IFN induced with helicase C domain 1 (IFIH1) functions as an 
intracellular innate immune receptor that senses viral nucleic acids and leads to the 
induction of type I IFN and proinflammatory cytokines. Despite systemic 
immunosuppressive treatment, disease activity persisted in the patient and was 
associated with elevated serum levels of IFNα and up-regulation of IFIH1 itself. 
Conclusion. This finding adds a new genetic causation for Mendelian lupus and 
greatly extends the disease spectrum associated with mutations in IFIH1 (ranging from 
inflammatory encephalopathy to prototypic systemic autoimmune disease). This 
marked phenotypic heterogeneity, despite an identical mutation, demonstrates the 
importance of modifying factors in type I IFN–dependent pathologies caused by 
mutations in IFIH1. 
 
Keywords: systemic lupus erythematosus, IgA-deficiency, IFIH1 
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Interferon induced with helicase C domain 1 (IFIH1), a member of the retinoic acid–
inducible gene 1 (RIG-I)–like family of cytoplasmic RNA receptors, senses double-
stranded RNA and mediates an anti-viral response by activating type I interferon 
signaling [1]. Recently, gain-of-function mutations in IFIH1 were identified in patients 
with Aicardi-Goutières syndrome (AGS) [2], a rare neuroimmunologic disorder 
associated with elevated levels of type I interferon (IFN) and characterized by 
leucoencephalopathy, brain atrophy and intracranial calcifications leading to profound 
intellectual disability, spasticity and dystonia [3].  The same IFIH1 mutation was also 
identified in a patient with spastic paraplegia with normal results on neuroimaging and 
normal cognitive function [4]. 
Systemic lupus erythematosus (SLE) is a systemic multi-organ autoimmune disease 
that is associated with elevated levels of type I interferon [5]. Patients with monogenic 
causes of SLE are thought to comprise ~1% of the adult SLE cohort, with greater 
prevalence among patients with severe early-onset disease [6]. Known genetic defects 
associated with SLE include mutations in DNASE1L3, DNASE1, PRKCD, TREX1 and 
SAMHD1 [6].  Mutations in TREX1 and SAMHD1 are also found in AGS, demonstrating 
genetic associations between AGS and SLE [6]. In genome-wide association studies 
(GWAS) common polymorphisms in IFIH1 have been identified as risk factors for SLE 
[7], type I diabetes mellitus [8] and selective IgA-deficiency [9].  
PATIENT AND METHODS 
The study was approved by the Ethics Committee of UZ Leuven, Belgium, and written 
informed consent was obtained from the parents of the patient and the age- matched 
healthy individuals. The study was performed in accordance with the modified version 
of the Declaration of Helsinki. 
Clinical features of the index patient. The patient, a 16-year-old girl of European 
Belgian ancestry, initially presented with frequent respiratory infections before the age 
of 1 year. Immunologic testing revealed selective IgA deficiency. By the age of 2.5 years 
she developed lower limb spasticity, without cognitive or developmental impairment. 
Magnetic resonance imaging (MRI) of the brain and spine showed no abnormalities. At  
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Table 1: Blood analysis results in a SLE patient with a gain-of-function mutation in 
IFIH1. 
 Age 
8 years 15.3 years 16.2 years 16.8 years 
WBC count, x 109 U/L (4.5 – 13.5) 5.8 5.01 7.44 7.86 
Neutrophil count, , x 109 U/L (2.0 – 8.0) 3.6 2.8 6.4 6.0 
Lymphocyte count, x 109 U/L (1.5 – 6.5) 1.4 1.7 0.9 1.1 
Hemoglobin, g/dL (12 - 16) 10.6 11.9 11.7 9.9 
Thrombocyte count, x 109 U/L (150 - 450) 108 243 297 294 
Erythrocyte sedimentation rate, mm/h 74 29 11 8 
C-reactive protein, mg/L NA <0.3 <0.3 <0.3 
C3, g/L (0.79 - 1.52) 0.87 0.60 0.93 0.81 
C3d, % (≤ 2.4) 4.6 12.2 3.0 2.3 
C4, g/L (0.16 - 0.38) 0.1 NA 0.11 0.13 
IgG, g/L (5.58 - 12.54) 16.9 18.9 10.3 9.36 
IgA, g/L (0.13 - 1.08) <0.07 NA NA NA 
IgM, g/L (0.34 - 1.42) 1.44 NA NA NA 
ANA titer † >1/640 1/320 1/640 1/160 
dsDNA (Farr), IU/mL >100 >100 35.8 17.4 
pANCA titer 1/640 NA NA NA 
Anti-cardiolipin IgM, MPL U/ml (< 20) 78 NA NA NA 
Anti-cardiolipin IgG, GPL U/mL (< 20) 8.0 26.7 4.4 NA 
Lupus anticoagulans Strongly 
positive 
Strongly 
positive 
Strongly 
positive 
NA 
Anti-thyroglobuline Abs, kU/L (≤ 200)  272 NA NA NA 
Anti-thyroid peroxidase Abs, kU/L (≤ 100) 853 NA NA NA 
SLE: systemic lupus erythematosus; WBC: white blood cell; NA: not available; ANA: 
antinuclear antibody; pANCA: perinuclear antineutrophil cytoplasmic antibody, Abs: 
antibodies. † By Farr immunoassay. 
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8 years old, the patient was diagnosed as having SLE with secondary antiphospholipid 
syndrome. Clinically, her disease manifested as arthritis, livedo rash, necrotizing 
cutaneous vasculitis, and deep venous thrombosis. Blood analysis demonstrated a 
marked inflammatory response, complement activation, and an abnormal 
autoantibody profile, including highly increased levels of anti–double-stranded DNA, 
anticardiolipin, and antithyroid antibodies (Table 1). Single photon–emission 
computed tomography, computed tomography, and MRI of the brain showed no 
abnormalities. Despite systemic immunosuppressive treatment, persistently increased 
levels of circulating autoantibodies and complement activation remained, and 
attempts at decreasing immunosuppressive medication were associated with disease 
flares. Spasticity remained confined to the lower limbs, cognitive functioning remained 
excellent, and results of all neuroradiologic examinations remained normal. 
Whole-exome sequencing. We performed whole-exome sequencing on genomic 
DNA from the patient and the patient’s unaffected mother. Genomic DNA samples 
were prepared from heparinized peripheral blood using a QIAamp DNA Blood Midi kit 
(Qiagen). Exome sequence libraries were prepared using a SeqCap EZ Human Exome 
Library version 3.0 kit (Roche NimbleGen). Paired-end sequencing was performed on 
an Illumina HiSeq2000 (Genomics Core Facility). Burrows-Wheeler Aligner software 
was used to align the sequence reads to Human Reference Genome Build hg19. GATK 
Unified Genotyper was used to identify single nucleotide variants and 
insertions/deletions. ANNOVAR software was used for annotation. 
Sanger method of sequencing. The region of interest in exon 12 of IFIH1 was 
sequenced using the primers 5’-CTTTCTTCCTCTGGAGTCACCCATC-3’ and 5’-
CAGACCTTCTTCTGCCACTGTGG-3’. Sanger sequencing was performed on an ABI 
3730xl Genetic Analyzer (Applied Biosystems) at the LGC Genomics Facility in Berlin, 
Germany. Sequencing data were analyzed using CLC Main Workbench 6.9.1 (CLC Bio). 
Flow cytometry. Peripheral blood mononuclear cells (PBMCs) were isolated from the 
heparinized blood of subjects using a lymphocyte separation medium (MP 
Biomedicals) and frozen in 10% DMSO (Sigma). Thawed cells were stained with 
antibodies against CD11c (3.9), CD3 (SK7), CD4 (RPA-T4), CD8a (RPA-T8), CD19 
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(HIB19), CD45RA (HI100), CD56 (MEM188), HLA–DR (LN3), IFNg (4S.B3), 
interleukin-17 (IL-17) (eBio64DEC17), IL-2 (MQ1-17H12), CD31 (WM-59), CCR7 (3D12), 
CD27 (O323), IgE (IgE21), CD24 (eBioSN3, SN3 A5-2 H10), CD38 (HIT2), g=d T cell 
receptor (B1.1), CD56 (MEM188), CD14 (61D3), CD123 (6H6), and IL-4 (8D4-8) (all 
from eBioscience), FoxP3 (206D) and IgM (MHM-88) (both from BioLegend), and 
CXCR5 (IgG23) (R&D Systems). For cytokine staining, T cells were stimulated ex vivo 
for 5 hours in 50 ng/ml phorbol 12-myristate 13-acetate (PMA) and 500 ng/ml 
ionomycin (both from Sigma) in the presence of GolgiStop (BD Biosciences) before 
staining. Prior to intracellular staining, cells were surface stained as described, fixed, 
and permeabilized using a fixation/permeabilization buffer (eBioscience) for FoxP3 
staining or using Cytofix/Cytoperm (BD Biosciences) for other intracellular staining. 
All data were acquired on a BDFACSCanto II and analyzed with FlowJo (Tree Star). 
Real-time quantitative polymerase chain reaction (RT-qPCR). Total RNA was 
isolated from PBMCs using an RNeasy Mini kit (Qiagen). Complementary DNA 
(cDNA) was synthesized by reverse transcription using a SuperScript III First-Strand 
Synthesis System (Life Technologies). The cDNA was analyzed by real-time 
quantitative PCR. An appropriate amount of the cDNA was mixed with Fast SYBR 
Green Master Mix (Applied Biosystems) supplemented with gene-specific primers: for 
IFIH1, 5’-CATATGCGCTTTCCCAGTG-3’ (forward) and 5’-
TGAGCATACTCCTCTGGTTTCA-3’ (reverse); for β-actin, 5’-
CTGGGACGACATGGAGAAAA-3’ (forward) and 5’-AAGGAAGGCTGGAAGAGTGC-3’ 
(reverse); for GAPDH, 5’-AGAAGGCTGGG GCTCATTTG-3’ (forward) and 5’-
GCATCAGCAGAGGGGGCAGA-3’ (reverse); and for HPRT, 5’-
GTAGCCCTCTGTGTGCTCAAGG-3’ (forward) and 5’-
GGCTTATATCCAACACTTCGTGGGG-3’ (reverse). Real-time quantitative PCR analysis 
was performed on a StepOnePlus realtime PCR system (ABI). The thermal cycling 
protocol was 1 cycle of 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 
seconds and 60°C for 1 minute. The resultant PCR products were analyzed with ABI 
7500 software (Applied Biosystems). Gene expression was analyzed with the 2–ΔΔCt 
method [10], and all quantifications were normalized to the average of the level of β-
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actin, GAPDH, and HPRT. Experiments were performed in triplicate and repeated 
twice. 
RESULTS 
Alterations in the peripheral immune system. Extensive profiling of the patient’s 
peripheral immune cells was performed at age 15 years, when the patient’s disease was 
clinically stable and treatment was limited to mycophenolate mofetil. Of the major 
mononuclear leukocyte cell types surveyed, natural killer cell percentages were 
decreased (data not shown), percentages of T cells were reduced (especially among 
CD4+ T cells), and CD19+ B cell percentages were increased compared to healthy age-
matched individuals (Figure 1A). Within the CD19+ B lymphocyte population, 
plasmablast levels were elevated and an excess of CD27+ memory B cells (the majority 
of which were IgM+IgD+) was found (Figure 1B), whereas the percentage of switched 
memory B cells was reduced. Within the CD4+ T lymphocyte population, the 
percentage of naive cells and antigen-experienced cells in the patient was comparable 
to that in healthy individuals, and cytokine production after stimulation with 
PMA/ionomycin appeared normal (Figures 1C and D). CD4+ follicular helper T (Tfh) 
cell numbers were relatively increased (Figure 1D). The percentage of Treg cells 
(CD4+FoxP3+ T cells) was also increased (Figure 1D); however, few of these cells were 
CD25high (data not shown). Within the CD8+ T lymphocyte population, we found an 
expansion of antigen-experienced cells (Figure 1C); however, cytokine production after 
stimulation with PMA/ionomycin was normal (data not shown).  
Identification of a de novo mutation in IFIH1 and IFIH1 expression in PBMCs. 
Whole-exome sequencing was performed on genomic DNA from the patient and the 
patient’s unaffected mother. After filtering out common polymorphisms, we identified 
a heterozygous c.G2336A mutation in IFIH1, leading to a p.R779H missense mutation. 
The mutation in the patient and the de novo status were confirmed by Sanger 
sequencing of DNA from the patient, both parents, and the patient’s sister (Figure 2A). 
The same p.R779H missense mutation in IFIH1 was recently described by Rice et al in 2 
individuals. Only after extended treatment with high-dose corticosteroids (which was 
started because of a severely debilitating disease flare) did we see a reduction in serum 
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Figure 1. Immunologic profile of peripheral blood mononuclear cells from a 
systemic lupus erythematosus patient with a gain-of-function mutation in 
IFIH1 (solid circles) as compared to healthy age-matched controls (open 
circles). Percentages of the major leukocyte subsets (A), CD19+ B lymphocyte 
subsets (B), CD4+ and CD8+ T lymphocyte subsets (C), and T helper cell 
lineages (D) were determined. Bars show the mean ± SD in the healthy 
controls. Ag: antigen; IL-2: interleukin-2; Tfh: follicular helper T cell. 
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levels of IFNα (Figure 2B). Subsequently, autoantibody titers were also reduced and 
complement activation was no longer present (Table 1), consistent with an IFNα-
mediated mechanism of disease. As IFIH-1 is up-regulated by type I IFN (8), IFIH1 
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Figure 2. Confirmation of a de novo mutation in IFIH1, serum interferon-α 
(IFNα) levels, and IFIH1 expression in peripheral blood mononuclear cells 
(PBMCs) from a systemic lupus erythematosus patient with a gain-of-function 
mutation in IFIH1. A, Sanger sequencing of the region of interest in exon 12 of 
IFIH1 in samples from the patient and her unaffected family members (top). 
The pedigree of the affected patient (solid symbol) and her parents and sibling 
shows the IFIH1 genotype (wild-type [WT; nonmutated] or p.R779H mutation) 
(bottom). B, Serum IFNα levels in the patient at various ages. Shaded bar 
indicates the period during which the patient was treated with corticosteroids. 
C, Relative IFIH1 gene expression in PBMCs from the patient at 3 time points 
(solid circles) as compared to healthy age-matched controls (n = 6; open 
circles). Bars show the mean ± SD in the healthy controls. 
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expression in the patient’s PBMCs was tested and found to be 10-fold up-regulated 
(Figure 2C). When serum levels of IFNα were reduced, the overexpression of IFIH1 was 
reduced as well. These findings suggest that excessive activation of IFIH-1 is generated 
both from the gain-of-function mutation and also from the presence of a positive 
feedback loop around IFIH-1, leading to persistent production of IFNα and subsequent 
immune dysregulation. 
DISCUSSION 
We identified a de novo IFIH1 mutation in a patient with elevated serum levels of IFNα, 
severe early-onset SLE, selective IgA deficiency, and mild lower limb spasticity without 
neuroradiologic manifestations. Strikingly, despite the common molecular etiology, 
the clinical presentation of this patient varied widely from that of other IFIH1 gain-of-
function patients (2,4). Although several cases in the cohort described by Rice et al 
manifested some immunologic abnormalities, the primary clinical manifestation was 
AGS. Conversely, the index patient described herein had no clinical features of AGS, 
with a clinical presentation dominated by early-onset SLE, IgA deficiency, and spastic 
paraplegia. In the study by Rice et al, 1 of the 2 AGS patients with the same p.R779H 
missense mutation developed chilblains at age 6 years and the other presented with 
generalized urticaria and mildly positive antinuclear antibodies at age 12 years (2). 
Strikingly, the father and paternal grandmother of the first patient carried the 
mutation but were asymptomatic. This indicates that the clinical phenotype associated 
with IFIH1 mutations is diverse and includes an asymptomatic phenotype, isolated 
spastic paraplegia, severe inflammatory encephalopathy, and prototypic systemic 
autoimmune disease. This marked phenotypic heterogeneity demonstrates the 
importance of genetic, environmental, or stochastic modifying factors in type I 
interferonopathies caused by mutations in IFIH1. 
In addition to the SLE manifestation, the patient described herein presented with 
selective IgA deficiency. We did not formally demonstrate whether selective IgA 
deficiency in the patient is due to the mutation in IFIH1; however, the association 
between selective IgA deficiency and SLE, as well as the finding of a common IFIH1 
polymorphism conferring risk in both diseases (7,9), indicates a shared genetic 
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predisposition between selective IgA deficiency and SLE through IFIH1. An intriguing 
possibility is that selective IgA deficiency may be the modifying factor that drove the 
interferonopathy toward the SLE phenotype in this patient. Selective IgA deficiency 
leads to a defective host defense against viral infections and an abnormal presentation 
of viral antigens. The possibility of exogenous viral-derived RNA playing a role in the 
pathogenesis of interferonopathies has been proposed as a possible explanation for the 
observed clinical non-penetrance (2). As serum IgA is thought to protect against 
autoimmunity by helping control inflammation, low levels of IgA or absent IgA may 
favor the development of autoimmunity and autoantibody production (11). It is 
therefore possible that selective IgA deficiency directed the interferonopathy in this 
patient toward the SLE phenotype. Further clinical investigation of patients with IFIH1 
mutations is necessary to determine the relative frequency of SLE and AGS, and 
whether selective IgA deficiency is disproportionally associated with one of the 
potential outcomes related to type I interferonopathies. 
Immunologic assessment identified disturbances consistent with SLE, with increased 
levels of CD19+ B cells, CD27+ plasma cells, and a bias toward CD27+ IgM+IgD+ 
memory B cells. This immunologic signature has previously been described in patients 
with active SLE (12) and is indicative of a capacity for T cell–independent antibody 
production (13,14). Potentially contributing to a B cell–driven etiology was a relative 
increase in Tfh cell numbers and an increase in the CD4+CD25-FoxP3+ T cell 
population (a proposed dysfunctional Treg cell population) (15). This cell population 
can suppress T cell proliferation, but not IFNγ production, in vitro (15), so despite their 
increased proportion, the selective functional defect in these Treg cells might 
contribute to a failure to control autoimmune dysregulation. As these changes have 
been identified in other SLE patients (12,15,16), these results suggest that persistently 
elevated serum IFNα levels distort the immune system into an autoantibody-prone 
configuration. This mechanistic interpretation is consistent with our clinical 
observation of persistent inflammation and autoimmune activation despite 
immunosuppressive treatment. Serum levels of IFNα and, subsequently, 
autoantibodies were found to be reduced only after several months of treatment with 
high-dose corticosteroids. While this treatment has been effective, the IFNα-driven 
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nature of the disease process suggests that more targeted inhibition of IFIH-1 or IFNα 
would produce the same outcome with fewer side effects. 
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SUMMARY 
Adenosine deaminase 2 deficiency can present with immunodeficiency dominated by 
auto-immune cytopenia and lymphoproliferation. Hematopoietic stem cell 
transplantation restores adenosine deaminase 2 enzyme activity and represents a 
potentially curative treatment.  
 
Keywords: adenosine deaminase 2 deficiency - immunodeficiency - hematopoietic 
stem cell transplantation  
 
Abbreviations: 
ADA   adenosine deaminase  
CECR1   cat eye syndrome chromosome region, candidate 1 
CID   combined immunodeficiency 
CMV   cytomegalovirus 
CT   computerized tomography 
EBV   Epstein-Barr virus 
GvHD   graft versus host disease 
HHV   human herpes virus 
HSCT   hematopoietic stem cell transplantation 
HSV   herpes simpex virus 
IVIG   intravenous immunoglobulin 
MRI   magnetic resonance imaging 
PBMC   peripheral blood mononuclear cells  
PHA   phytohemagglutinin 
PID   primary immunodeficiency 
RSV   respiratory syncytial virus 
VOD   veno-occlusive disease 
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To the Editor: 
Recently, recessively inherited loss-of-function mutations in CECR1 (cat eye syndrome 
chromosome region, candidate 1), which encodes adenosine deaminase 2 (ADA2), 
were identified in patients with a complex immunologic and vascular phenotype [1,2]. 
Possible mechanisms for this disorder are proinflammatory polarization and disturbed 
endothelial integrity [1,2]. Zhou et al. reported that aggressive systemic 
immunosuppressive treatment was not effective in controlling inflammation but 
hypothesized that hematopoietic stem cell transplantation (HSCT) might be curative 
given that bone marrow–derived monocytes and macrophages are the main source of 
secreted ADA2 [1]. Here we report on 2 related patients with homozygous p.Arg169Gln 
missense mutations in ADA2 located within the putative receptor-binding domain [3]. 
Our observations in these siblings demonstrate the clinical heterogeneity associated 
with ADA2 deficiency and show that HSCT can be an effective therapy. In the index 
patient the clinical course was dominated by autoimmunity and lymphoproliferation 
with a combined immunodeficiency–like phenotype, which prompted HSCT from a 
healthy sibling. Despite early complications, transplantation was successful both in 
rescuing the immunologic phenotype and in preventing vascular disease; at 5 years 
after HSCT, the patient remains off treatment. 
The index patient (P1) was the second child of a father of Moroccan descent and a 
white mother. He was first admitted at age 6 months for complicated human 
respiratory syncytial virus infection. At this time, hypogammaglobulinemia was noted 
(see Table E1 in this article’s Online Repository at www.jacionline.org). At age 12 
months, P1 presented with fever, lymphadenitis, generalized lymphadenopathy, and 
hepatosplenomegaly. Staphylococcus aureus was cultured from the lymph nodes, and 
fever resolved within 24 hours of starting amoxicillin–clavulanic acid treatment. 
Pancytopenia, hypogammaglobulinemia, and the absence of specific antibodies were 
found (see Table E1). Results of blood PCRs for Epstein–Barr virus (EBV), 
cytomegalovirus (CMV), human herpesvirus (HHV) 6, HHV-8, and adenovirus were 
negative. However, adenovirus and norovirus were detected in the stool. Computed 
tomographic scans confirmed generalized lymphoproliferation with mediastinal and 
intra-abdominal lymphadenopathy and splenomegaly. Lymphoma was suspected, but 
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the results of lymph node biopsy and bone marrow examination were normal. 
Macrophage activation syndrome as the cause of the pancytopenia and 
lymphoproliferation was excluded based on serum markers (including soluble IL-2 
receptor) and the absence of hemophagocytosis on bone marrow examination. A 
primary immune deficiency (PID) with predominant lymphoproliferation and 
autoimmunity was suspected, and known genetic causes were excluded. Prednisone (2 
mg/kg) led to resolution of the thrombocytopenia and splenomegaly. However, 
attempts to taper led to a relapse of thrombocytopenia. Despite the addition of 
mycophenolate mofetil, sirolimus, tacrolimus, cyclosporine, and mercaptopurine, the 
cytopenia and lymphoproliferation persisted. 
Because of growth failure secondary to chronic corticosteroid treatment, HSCT was 
considered at the age of 3 years. The patient’s HLA-identical healthy elder brother was 
chosen as the donor. After conditioning with oral busulfan and cyclophosphamide, 7.5 
X 106 CD34+ bone marrow–derived hematopoieticstem cells per kilogram were 
infused. Anti–graft-versus-host disease (GvHD) prophylaxis consisted of cyclosporine, 
whereas steroids were slowly tapered. Antiviral prophylaxis consisting of acyclovir and 
intravenous immunoglobulin (IVIG) administration and antifungal prophylaxis with 
fluconazole was added. The transplantation was complicated by late engraftment of 
neutrophils (day 26 <1.5 X 109/L) and persistent severe thrombocytopenia (<10 X 109/L) 
refractory to transfusion, although at day 28, whole blood chimerism was greater than 
95%. At day 36, magnetic resonance imaging (MRI) of the brain, which was performed 
because of severe sudden-onset headache, identified a pineal gland hemorrhage (see 
Fig E1, A, in this article’s Online Repository at www.jacionline.org). The thrombocyte 
level was 2 X 109/L but increased to greater than 50 X 109/L at day 40 after 2 infusions 
of rituximab. Veno-occlusive disease (VOD) was diagnosed according to the Seattle 
criteria at day 60 and was accompanied by a relapse of thrombocytopenia. VOD 
responded well to fluid restriction. Platelet levels of greater than 100 X 109/L were 
reached at day 111. Adenovirus reactivation was found at day 40, with accompanying 
intestinal GvHD grade III, which responded to corticosteroids. Cyclosporine was 
stopped at day 150. IVIG was discontinued at day 180. Immunoreconstitution at day 
360 was excellent, including normal antibody levels, normal numbers of B- and T-
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lymphocytes, and normal T-cell proliferation in response to PHA. Moreover, response 
to polysaccharide vaccine was normal (data not shown). Five years after 
transplantation, P1 is clinically well and off all medication. No more 
lymphoproliferation has occurred, and the most recent MRI of the brain 5 years after 
HSCT did not show any signs of acute or chronic small infarcts.  
Two years after transplantation of P1, his younger brother (P2) presented at age 5 
months with profound Coombs (2) anemia (hemoglobin, 2 g/dL), which was attributed 
to PCR-verified HHV-6–associated erythroblastopenia. At this time, immunologic 
analysis of P2 was normal. Several episodes of PCR-verified facial herpes simplex virus 
infection followed. At age 23 months, P2 was admitted with abdominal pain and ileus 
refractory to conservative treatment. He had generalized lymphadenopathy and 
hepatosplenomegaly, as well as hypogammaglobulinemia and intermittent 
lymphopenia and neutropenia (see Table E1). Results of blood polyomavirus PCR were 
positive. Bone marrow examination was normal. Partial enterectomy was performed; 
biopsy showed an atypical ulcerative bowel disease devoid of plasma cells (see Fig E1, 
B), as can be seen in patients with common variable immunodeficiency [4]. No CMV, 
EBV, herpes simplex virus, HHV-6, polyomavirus, or adenovirus could be detected in 
the biopsy specimen, and no signs of vasculitis could be observed in the entire surgical 
specimen. Obstruction persisted despite aggressive systemic immunosuppressive 
treatment and was only relieved after treatment with sirolimus. At this time, IVIG was 
started, and sirolimus was slowly tapered without clinical relapse. Subsequently, P2 did 
not receive any immunosuppressive treatment for a period of 13 months but was solely 
treated with IVIG. At 3.5 years of age, P2 had neurologic manifestations in the form of 
2 episodes of acute loss of balance in the absence of fever or signs of systemic 
inflammation on blood analysis, Repeated MRI of the brain did not reveal any lesions 
compatible with ischemic or hemorrhagic stroke. A transient ischemic attack (TIA) 
was suspected, and treatment with sirolimus was restarted.  
Whole-exome sequencing was performed on the untreated patient (P2), the parents, 
and the healthy sibling (for details, see the Methods section in this article’s Online 
Repository at www.jacionline.org). We hypothesized a recessive model of inheritance. 
After filtering out common polymorphisms, we identified a homozygous c.G506A 
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variant in CECR1, resulting in a p.Arg169Gln missense mutation in ADA2. Sanger 
sequencing on DNA obtained from the cheek swab of the patient who underwent 
transplantation confirmed that he was also homozygous for this variant. Both parents 
were carriers, whereas the sibling donor was homozygous for the wild-type form of 
CECR1 (see Fig E2 in this article’s Online Repository at www.jacionline.org). ADA2 
enzyme activity in plasma (Table I) was essentially absent in P2, the patient who did 
not undergo transplantation, whereas in post-HSCT plasma from P1, ADA2 activity was 
comparable with that of his healthy donor and in the range for healthy control 
subjects. Both parents have intermediate plasma ADA2 activity. Of note, neither 
adenosine nor deoxyadenosine levels were increased (<0.4 mmol/L) in plasma of P2 
(these levels have not been measured in previous patients). Both P1 and P2 had normal 
ADA1 activity in dried blood spots, and deoxyadenosine nucleotides were 
undetectable. 
Table 1: Plasma ADA2 activity in the affected pedigree 
Sample Age (years) Plasma ADA2 activity (mU/mL) 
* 
Patient 1 post-HSCT 8  22.07 
Patient 2 3  0.11 
Healthy sibling (= HSCT donor) 10  19.14 
Father 43  7.20 
Mother 40  2.91 
* Reference values for plasma ADA2 activity (mU/mL), mean ± SD (min-max) 
 ADA2 Deficient (n = 4) 1.0 ± 0.4 (0.6 – 1.4) 
ADA2 Carriers (n = 4) 4.9 ± 0.3 (4.6 – 5.3) 
Control subjects (n = 5 + pooled human plasma) 14.0 ± 6.1 (4.8 – 21.3) 
 
Although it has been speculated that the clinical consequences of ADA2 deficiency 
might be due to increased extracellular adenosine, our findings suggest this is not the 
case and that ADA2 actually has a minimal role compared with ADA1 in adenosine 
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metabolism in vivo, which is consistent with the very different substrate affinities of 
the 2 ADA enzymes (see the Methods section in this article’s Online Repository).  
Because of the observed immunodeficiency, we performed extensive profiling of 
peripheral immune cells of P2 (for details, see the Methods section in this article’s 
Online Repository). Of the major mononuclear leukocyte cell types surveyed, CD4+ T 
cell numbers were increased and CD8+ T cell numbers were reduced in P2 compared 
with those in healthy age-matched control subjects. B cell, natural killer cell, and 
dendritic cell numbers were within 1 SD of the mean of the healthy control subjects 
(Fig 1, A). Within the T lymphocyte population, we found defective T cell activation, 
with increased naive and low effector and memory subsets (Fig 1, B and D). Within the 
Th cell population, numbers of regulatory T cells were increased, whereas Th1, Th2, 
and follicular helper CD4+ T cell numbers were low (Fig 1, C). T cell proliferation in 
response to Candida species, tetanus, and PHA was normal (data not shown). Within 
the B lymphocyte population, naive B cell numbers were increased at the expense of 
memory and plasmablasts (Fig 1, E), which is suggestive of a defect in B lymphocyte 
differentiation or T cell provision of help. Limited immunoprofiling performed before 
HSCT showed similar findings in P1 (see Table E2 in this article’s Online Repository at 
www.jacionline.org). 
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Figure 1. Serum IL-6 levels and immunoprofiling in ADA2-deficient patients. A, 
Major blood leukocyte subsets. B, CD4+ T lymphocyte subsets. C, Th cell 
lineages. D, CD8+ T lymphocyte subsets. E, B cell subsets. P2’s values are shown 
as filled circles, and values of healthy age-matched control subjects are 
indicated by open circles. Means and SDs (error bars) shown exclude values for 
the patient. F, IL-6 levels in sera of P1 and P2. The vertical line indicates the 
moment of HSCT followed by pineal stroke in P1. The gray shading indicates the 
periods in which P2 was treated with sirolimus. DC, Dendritic cell; mDC, 
myeloid dendritic cell; NK, natural killer cell; NKT, natural killer T cell; pDC, 
plasmacytoid dendritic cell; RTE, recent thymic emigrant; TCM, central 
memory T cell; TEM, effector memory T cell; TEMRA, CD45RA-expressing 
effector memory T cell; Tfh, follicular T cell; Th17, IL-17–expressing helper T 
cell; Treg, regulatory T cell. 
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Because of the presence of severe inflammation in P1, serum IL-6 levels were measured 
from initial evaluation to last follow-up (Fig 1, F). IL-6 levels were persistently high 
before HSCT and before engraftment, but after HSCT IL-6 levels slowly decreased and 
were undetectable at 3 years post-HSCT. In P2 serum IL-6 levels were extremely 
increased, despite the absence of clinical signs of inflammation, with levels peaking at 
the time of bowel obstruction and at the time of the suspected TIAs. IL-6 was 
undetectable in the healthy sibling and in healthy control subjects. Moreover, TNF-α 
was not detectable in the serum of P1 and P2 at the time of the highest IL-6 levels. The 
immune profile of the other family members was normal (data not shown).Together, 
these data demonstrate a profound defect in T cell–dependent antibody-mediated 
responses and a failure to regulate normal inflammatory cytokine production in ADA2-
deficient patients, adding to the previously identified function of ADA2 in in vitro 
stimulation of Th cells [5].  
PIDs with autoimmunity and lymphoproliferation dominated the clinical image in our 
patients. The index patient P1 presented with persistent autoimmune pancytopenia 
and lymphoproliferation, whereas P2 had an episode of lymphoproliferation, bowel 
involvement, and 2 possible TIAs. Both patients only had fever during infectious 
episodes, and unlike previously reported patients, neither showed skin involvement or 
clear signs of vasculitis. P1 had a stroke as an apparent early complication of HSCT in 
the context of prolonged and severe thrombocytopenia. Only 3 years after initial 
presentation, P2 presented with 2 potential TIAs, although transient labyrinthitis 
caused by a viral infection could not be excluded. Therefore in retrospect vasculitis and 
inflammation might have been present at a subclinical level in both patients, but 
vasculopathy and inflammation did not dominate the clinical presentation, as is the 
case in the patients reported by Zhou et al. [1] and Elkan et al. [2]. Interestingly, serum 
IL-6 levels were increased in both patients in the absence of clinical and (routine) 
biochemical signs of inflammation. This suggests that ADA2 deficiency might lead to a 
subclinical state of inflammation. This phenotypic discrepancy cannot be explained 
entirely by CECR1 genotype because the p.Arg169Gln mutation was previously 
observed in hemizygous and homozygous form [1,2]. The ADA2-deficient patients 
previously described had decreased serum immunoglobulin levels and enhanced B cell 
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apoptosis in vitro [1]. By contrast, our patients had abnormalities suggesting an in vivo 
defect in T cell activation and proliferation, corresponding to their increased 
susceptibility to viral infections and combined immunodeficiency–like phenotype. 
Taken together, these observations suggest that ADA2 deficiency has a more varied 
clinical phenotype than initially reported and that the diagnosis should be considered 
in cases of undiagnosed PID characterized by lymphoproliferation and autoimmunity, 
even in the absence of overt vasculopathy or inflammation. 
As reported by Zhou et al. we found that treatment with a variety of 
immunosuppressive medications resulted in poor disease control in P1 [1]. However, 
both at the time of bowel obstruction and at the time of potential TIA, P2 seemed to 
respond well to sirolimus treatment. Sirolimus reduces M1 macrophage differentiation 
and IL-6 production [6]. Because ADA2 deficiency drives macrophages toward a more 
proinflammatory M1 profile [1], we present sirolimus as a potential therapeutic option 
to at least temporarily control inflammatory complications in ADA2-deficient patients. 
TNF-α was undetectable in the serum of our patients. However, this finding does not 
at all exclude a role for this cytokine in disease pathogenesis. Indeed, etanercept led to 
a significant response in all patients reported by Elkan et al.[1] and should therefore be 
considered as a potential treatment. 
In the index patient P1 we successfully performed an allogeneic HSCT. At 5 years after 
HSCT, consecutive clinical and biochemical investigations in P1 have shown no signs of 
immunologic disorder and no additional strokes. This result supports the potential of 
HSCT as a long-term treatment strategy for ADA2 deficiency. However, caution is 
warranted because the HSCT procedure in P1 was characterized by severe early 
complications. Indeed, ADA2-deficient patients might present as high-risk candidates 
for HSCT. First, the inflammatory response associated with conditioning is 
superimposed on the inflammatory state intrinsic to ADA2 deficiency, which might 
negatively affect engraftment. Second, the compromised endothelial integrity observed 
in patients with ADA2 deficiency could predispose to development of VOD, a 
potentially fatal complication of HSCT. This combination of inflammation and 
endothelial injury might further increase the risk of stroke in the pre-engraftment and 
early post-engraftment phases [7] as observed in P1. It is reasonable to hypothesize that 
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ADA2-deficient patients might benefit from VOD prophylaxis with defibrotide, as well 
as from pretreatment with anti–IL-6 mAbs, rituximab, or both. Moreover, treatment 
with etanercept peri-HSCT could be considered in the context of ADA2 deficiency, 
especially given its usefulness in preventing and treating acute GvHD. However, given 
the underlying immunodeficiency, the risk of infection needs to be carefully balanced 
when using anti–IL-6 and anti–TNF-a mAbs. 
Allogeneic HSCT restored normal plasma ADA2 activity in P1, which is consistent with 
bone marrow–derived monocytes and macrophages being the main sources of secreted 
ADA2. Whether ADA2 plays a role in other tissues and the effect of this on long-term 
prognosis remains unclear. A recent report on HSCT in a patient with ADA2 deficiency 
with a 9-year follow-up is promising and supports our findings [8]. However, it is 
plausible that the benefit from HSCT to our patient is entirely due to restoration of 
normal plasma ADA2 levels. If true, future treatment with exogenous ADA2 might 
provide an alternative therapy for ADA2 deficiency in patients in whom allogeneic 
HSCT is contraindicated. 
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Online Repository 
METHODS 
The study was performed in accordance with the modified version of the Declaration 
of Helsinki. The study was approved by the Ethics Committee of UZ Leuven. Written 
informed consent was obtained before DNA isolation from blood of all family members 
and from cheek epithelium of the transplanted patient. 
Functional assays 
PBMCs were isolated from heparinized blood of patients, family members, and control 
subjects and analyzed by using flow cytometry, as previously described [E1]. Serum IL-
6 levels were measured by means of ELISA, according to the manufacturer’s 
instructions (BD Bioscience, San Jose, Calif). 
Whole-exome sequencing. We performed whole-exome sequencing on the 
untreated patient and on the unaffected parents and sibling. Genomic DNA samples 
for whole-exome sequencing were prepared from heparinized peripheral blood by 
using the QIAamp DNA Blood Midi Kit (QIAGEN, Hilden, Germany). Exome sequence 
libraries were prepared with a SeqCap EZ Human Exome Library v3.0 kit (Roche 
NimbleGen, Madison, Wis). Paired-end sequencing was performed on the Illumina 
HiSeq2000 (Genomics Core Facility, University of Leuven, Leuven, Belgium). BWA 
software was used to align the sequence reads to the Human Reference Genome Build 
hg19. The GATK Unified Genotyper was used to identify single nucleotide variants and 
insertions/deletions. ANNOVAR was used for annotation. 
Sanger sequencing. A somatic DNA sample of the patient undergoing transplantation 
was obtained from a cheek swab by using the GenElute Mammalian Genomic DNA 
Miniprep Kit (Sigma-Aldrich, St Louis, Mo). The region of interest in exon 2 of CECR1 
was sequenced with the primers 5’-GTTTGTACCAAGGGAGACACCTACC-3’ and 5’-
CTGGCTGGTGAGGAATGTCAC-3’. Sanger sequencing was performed on an ABI 3730 
XL Genetic Analyzer (Applied Biosystems, Foster City, Calif) at the LGC Genomics 
Facility in Berlin, Germany. Sequencing data were analyzed by using DNADynamo 
(Blue Tractor Software, Llanfairfechan, United Kingdom). 
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Flow cytometry. PBMCs were isolated from heparinized blood of patients and control 
subjects by using lymphocyte separation medium (MP Biomedicals, Solon, Ohio) and 
frozen in 10% dimethyl sulfoxide (Sigma). Thawed cells were stained with antibodies 
(from eBioscience [San Diego, Calif], unless stated otherwise) against CD11c (3.9), CD3 
(SK7), CD4 (RPA-T4), CD8a (RPA-T8), CD19 (HIB19), CD45RA (HI100), CD56 
(MEM188), HLA-DR (LN3), forkhead box protein 3 (FOXP3; 206D; BioLegend, San 
Diego, Calif), IFN-g (4S.B3 IL-17, eBio64DEC17), IL-2 (MQ1-17H12), CXCR5 (IgG23; 
R&D Systems,Minneapolis,Minn), CD31 (WM-59), CCR7 (3D12), IgM (MHM-88, 
BioLegend), CD27 (O323), IgE (IgE21), CD24 (eBioSN3, SN3 A5-2 H10), CD38 (HIT2), 
gd T-cell receptor (B1.1), CD56 (MEM188), CD14 (61D3), CD123 (6H6), and IL-4 (8D4-
8). For cytokine staining, T cells were stimulated ex vivo for 5 hours in 50 ng/mL 
phorbol 12-myristate 13-acetate (Sigma) and 500 ng/mL ionomycin (Sigma) in the 
presence of GolgiStop (BD Biosciences) before staining. Before intracellular staining, 
cells were first surface stained as described, fixed, and permeabilized with 
fixation/permeabilization buffer (eBioscience) for forkhead box protein 3 staining or 
Cytofix/Cytoperm (BD) for other intracellular stainings. All data were acquired on BD 
FACSCanto II and analyzed with FlowJo (Tree Star, Ashland, Ore). 
ELISA for measurement of IL-6 levels in serum. An in-house validated ELISA was 
used based on a commercially available antibody pair (BD Biosciences). 
Measurements of ADA1 and ADA2 activity in plasma. ADA2 activity in plasma was 
measured by using the HPLC method described by Zhou et al.[E2] ADA1 activity and 
concentrations of total adenosine and deoxyadenosine nucleotides in extracts of dried 
blood spots were measured, as previously described [E3,E4]. The concentrations of 
adenosine and deoxyadenosine in plasma were determined by means of HPLC analysis 
of a neutralized perchloric acid extract of plasma. In brief, 200 mL of plasma was 
acidified with 40 mL of 5 N perchloric acid and centrifuged, and the supernatant was 
neutralized with 3 N KOH and 1 M KHCO3. After centrifugation, 100 mL of the 
supernatant was analyzed on a C18 mBondapak column (Waters Corporation, Milford, 
Mass) by using 0.05 mol/L NH4H2PO4, 8% methanol, and 1% acetonitrile (pH 5.2; 
flow rate, 0.5 mL/min) as the mobile phase and monitoring absorbance at 260 and 280 
nm with a diode array detector. The lower limit of quantitation for adenosine and 
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deoxyadenosine in this assay was 0.8 mmol/L; the lower limit of detection was taken as 
half the lower limit of quantitation or 0.4 mmol/L. 
RESULTS 
X-linked lymphoproliferative disease type I and II, Wiskott-Aldrich syndrome, 
autoimmune lymphoproliferative syndrome, ADA1 deficiency, purine nucleoside 
phosphorylase deficiency, and immune dysregulation–polyendocrinopathy–
enteropathy–Xlinked syndrome were excluded by means of functional and genetic 
analyses. 
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FIGURES 
 
A B 
Figure E1: Vasculopathology and immunopathology in patients with 
ADA2-deficiency. A, Sagittal T1-weighted MRI of P1 showing pineal gland 
hemorrhage (arrow). B, Hematoxylin and eosin staining of jejunal 
ulceration in P2 showing chronic ulcer with predominant eosinophils 
(arrows), some neutrophils and lymphocytes and very few plasma cells. 
Plasma cells as stained by CD138 staining are indicated by arrows in the 
inlet. 
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Figure E2: Familial 
inheritance of CECR1 
mutation. The region of 
interest in exon 2 of CECR1 
was sequenced by means of 
Sanger sequencing. A-E, 
Sequence reads for the 
father (Fig E2, A), mother 
(Fig E2, B), healthy sibling 
(HSCT donor; Fig E2, C), 
patient 1 after HSCT 
(chimerism accounts for 
presence of a minor G peak; 
Fig E2, D), and patient 2 (Fig 
E2, E). F, Family tree of the 
affected pedigree, indicating 
affected patients and CECR1 
genotype. 
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Table E1: Clinical presentation, laboratory values, and therapeutic history of ADA2-
deficient patients 
. Patient 1 Patient 2 
Clinical phenotype   
Clinical presentation hypogammaglobulin
emia, pancytopenia, 
lymphoproliferation 
hypogammaglobulinemia, 
(intermittent) lymphopenia 
and neutropenia, 
lymphoproliferation 
Viral infections confirmed by PCR RSV,adenovirus, 
norovirus 
HHV-6, HSV, polyomavirus 
Stroke hemorrhage in pineal 
gland 
none 
Laboratory values (obtained at initial clinical presentation) 
White blood cell count (kU/µL) 2.02 9.08 
Neutrophil count (kU/µL) 0.3 6.4 
Lymphocyte count (kU/µL) 1.0 1.7 
Hemoglobin (g/dL) 8.8 9.7 
Thrombocytes (kU/µL) 25 300 
ALT (5-38 U/L) 44 15 
AST (0-41 U/L) 64 6 
IgG (3.02 - 9.85 g/L) <1.00 2.77 
IgA (0.13 - 1.08 g/L) <0.07 0.11 
IgM (0.26 - 1.60 g/L) 0.09 0.27 
IgE (0-91 IU/mL) <2 30 
IgD (<10 U/mL) 0 0 
ANA negative not determined 
ANCA negative not determined 
Thrombocyte autoantibodies anti-gpIIB-IIIa Ab 
present 
not determined 
Erythrocyte autoantibodies anti-MNS1 Ab not determined 
Lymphocyte count (kU/µl) (at 
moment of immunophenotyping) 
0.39 3.0 
Therapeutic history   
Immunosuppressive medication CS, sirolimus, MMF, 
tacrolimus, 
ciclosporin, 
mercaptopurin 
CS, azathioprine, sirolimus 
Immunoglobulin substitution yes (before HSCT) yes 
Allogenic HSCT yes no 
ALT, Alanine aminotransferase; ANA, antinuclear antibody; ANCA, antineutrophil 
cytoplasmic antibody; AST, aspartate aminotransferase; HSV, herpes simplex virus; 
RSV, respiratory syncytial virus; CS, corticosteroids; MMF, mycophenolate mofetil. 
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Table E2: Relative frequencies of peripheral blood leukocyte populations in P1 before 
HSCT compared with those in healthy age-matched control subjects 
Subset 
Defining surface 
markers 
Patient 
(%) 
Healthy volunteers 
(%) Range (min-max) 
T cells CD3+ 80.6 52.9-65.2 
CD4+ T cells CD4+ CD8- 63.8 29.4-65.2 
  → Treg CD25+Foxp3+ 10.0 - 
CD8+ T cells  CD4- CD8+ 0.83 17.6-23.2 
B cells CD19+ 5.56 11.8-30.4 
  → transitional CD38highCD24high 0.2  
  → naive CD27-IgD+ 97.8  
  → immature CD27+IgD+ 0.1  
  → switched memory  CD27+IgD- 0.3  
CD3+, CD4+, and CD8+ T cells and CD19+ B cells are shown as percentages of total 
lymphocytes. Regulatory T (Treg) cells are shown as percentages of CD4+ T cells. B cell 
subsets are shown as percentages of CD19+ B cells. Foxp3, Forkhead box protein 3. 
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To the Editor: 
The studies by Zhou et al. and Navon Elkan et al. identified novel mutations in CECR1, 
encoding ADA2, as the cause of a syndrome including systemic vasculopathy and 
inflammation. We independently identified a homozygous p.Gly47Arg mutation in 
CECR1 in a Jewish boy with a phenotype similar to that seen in Castleman's disease and 
found treatment with anti–interleukin-6 receptor antibody (tocilizumab) to be 
curative. The boy presented at 5 years of age with recurrent fevers, splenomegaly, 
generalized lymphadenopathies, increasing levels of acute-phase reactants, anemia, 
thrombocytosis, and polyclonal hyperimmunoglobulinemia. Whole-body imaging with 
18F-fluorodeoxyglucose–positron-emission tomography–computed tomography (FDG-
PET-CT) showed multiple lymph nodes with FDG avidity and increased splenic uptake. 
Tests for human herpesvirus 8 (HHV-8) were negative. Serum levels of interleukin-6 
were highly elevated (180.5 pg per milliliter), and immunohistochemical analysis of a 
specimen obtained on lymph-node biopsy confirmed strong expression of interleukin-
6. Treatment with tocilizumab resulted in a rapid, complete, and persistent 
suppression of clinical features and laboratory abnormalities. 
In mice, loss-of-function adenosine deaminase has been reported to stimulate 
interleukin-6 induction through activation of the adenosine A2B receptor [1], 
suggesting a link between the loss of enzymatic ADA2 function and the increase in 
levels of interleukin-6 in this patient. Our results indicate that mutant ADA2 is a cause 
of interleukin-6–mediated lymphoproliferation and systemic inflammation and should 
be investigated as a cause of Castleman's disease. 
REFERENCE 
Dai Y, Zhang W, Wen J, Zhang Y, Kellems RE, Xia Y. A2B adenosine receptor-mediated 
induction of IL-6 promotes CKD. J Am Soc Nephrol 2011;22:890-901. 
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ADDITIONAL DATA 
Table 2: Plasma ADA2 activity in the affected pedigree of a patient with Castleman’s-
like disease 
Sample Age (years) Plasma ADA2 activity (mU/mL) 
* 
Patient  8 0.18 
Father 62 3.75 
Mother 44 3.65 
* Reference values for plasma ADA2 activity (mU/mL), mean ± SD (min-max) 
 ADA2 Deficient (n = 4) 1.0 ± 0.4 (0.6 – 1.4) 
ADA2 Carriers (n = 4) 4.9 ± 0.3 (4.6 – 5.3) 
Control subjects (n = 5 + pooled human plasma) 14.0 ± 6.1 (4.8 – 21.3) 
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To the Editor: 
Zhou et al. and Navon Elkan et al. identified novel mutations in CECR1 as the cause of 
a syndrome that includes vasculopathy, inflammation, and immunodeficiency. The 
authors suggest that hematopoietic stem-cell transplantation (HSCT) should be 
explored as a possible treatment for this new primary immunodeficiency. We have 
independently identified two brothers with homozygous p.Arg169Gln mutations in 
CECR1 and found HSCT to be curative. One boy presented at 13 months of age and the 
other at 5 months of age. 
The older patient presented with combined immunodeficiency, cytopenia, and 
lymphoproliferation. He underwent immunosuppressive therapy and immunoglobulin 
substitution, but disease control was insufficient. He then underwent allogeneic HSCT 
at 3 years of age. A hemorrhagic stroke of the pineal gland developed 36 days after 
HSCT. During the next 5 years, this patient had complete resolution of the 
immunologic phenotype and no further occurrences of stroke. The younger patient 
presented with a similar phenotype but had a better response to immunosuppression 
and immunoglobulin substitution. 
Plasma ADA2 activity was in the normal range in the HSCT recipient, but was absent 
in his brother (Hershfield M: personal communication). These results independently 
verify the CECR1 mutation as a cause of novel primary immunodeficiency and further 
support the suitability of HSCT for the treatment of this condition. 
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SUMMARY 
STAT2-deficiency is associated with a profound failure of type I interferon signalling 
leading to a defect in antiviral immunity and potentially fatal viral illness.  
 
Key words: STAT2-deficiency, type I interferon, viral illness 
 
Abbreviations: 
CSF     cerebral spinal fluid 
EBV     Epstein–Barr virus 
EMSA     electrophoretic mobility shift assay 
F2A     FDMV 2A peptide 
FDMV    foot-and-mouth disease virus 
GAF     gamma-interferon activation factor 
GAS     gamma-interferon activation site 
HPIV3    human parainfluenza virus type 3 
HSV     herpes simplex virus 
IFN     interferon 
IFNAR    IFN-α/β receptor 
IgE     immunoglobulin E 
IgG     immunoglobulin G 
IRF9     interferon regulatory factor 9 
ISG     IFN-stimulated genes 
ISG15     IFN-stimulated gene 15  
ISGF3     interferon-stimulated gene factor 3 
ISRE     IFN-stimulated response element 
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IVIG     intravenous immunoglobulin 
JAK     Janus kinase 
MeV     measles virus  
MMR     measles-mumps-rubella 
MSCV     murine stem cell virus 
MX1     MX Dynamin-Like GTPase 1 
NK cell    natural killer cell 
OAS1     2'-5'-oligoadenylate synthetase 1 
PBMC     peripheral blood mononuclear cells 
PME     primary measles encephalitis 
RSV     respiratory syncytial virus 
RT-qPCR    real-time quantitative polymerase chain reaction 
SSPE     subacute sclerosing panencephalitis 
STAT2    transducer and activator of transcription 2 
SV40     Simian virus 40 
TLR     Toll-like receptor 
TYK2     tyrosine kinase 2 
VSV     vesicular stomatitis virus 
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To the editor: 
STAT2 deficiency has been proposed as the cause of unusually severe viral illness in 
infancy. The only reported cases of STAT2 deficiency consist of an extended family in 
which two siblings developed disseminated vaccine-strain measles following routine 
immunization, of whom the infant sibling died from a probable viral infection [1]. 
Strikingly, there was incomplete clinical penetrance in this kindred, giving rise to 
questions regarding the completeness of the STAT2 defect. Two other siblings with 
STAT2 deficiency were also reported to suffer from febrile illness following live measles 
vaccine; one went on to develop opsoclonus-myoclonus syndrome [2]. STAT2 
deficiency was associated with a profound failure of type I interferon (IFN) signalling, 
which is thought to be responsible for the observed defect in antiviral immunity.  
The IFN response is one of the most important innate antiviral defences. Three types 
of IFNs have been identified: IFN-α/β (type I), IFN-γ (type II) and IFN-λ (type III) [3]. 
These cytokines are secreted following pathogen exposure, by most cell types (types I 
and III) or by activated T and NK lymphocytes, in the context of an immune response 
(type II IFN). Binding of IFNs to their receptor on their target cells leads to activation 
of the Janus kinase signal transducer and activator of transcription (JAK-STAT) 
signalling pathways and subsequently induces expression of hundreds of diverse IFN-
stimulated genes (ISGs), the products of which may have direct or indirect antiviral 
activity. In the canonical type I IFN signalling pathway (Figure 1), binding of IFN-α/β 
to the type I IFN receptor IFNAR activates the receptor-associated JAK1 and tyrosine 
kinase 2 (TYK2), who then phosphorylate and activate STAT1 and STAT2. 
Phosphorylated STAT1 and STAT2 associate with interferon regulatory factor 9 (IRF9) 
to form the heterotrimeric transcription factor interferon-stimulated gene factor 3 
(ISGF3) that binds to IFN-stimulated response elements (ISREs) in the promotor 
region of IFN-α/β–stimulated genes. Although type III IFNs bind to a distinct receptor, 
activation of the same signalling pathway occurs resulting in a similar transcriptional 
profile as type I IFNs [4]. In contrast, binding of type II IFN to the IFN-γ receptor 
activates JAK1 and JAK2, leading to phosphorylation of STAT1 but not STAT2 [3]. 
Phosphorylated STAT1 homodimerizes and forms the gamma-interferon activation 
factor (GAF), a transcription factor that binds to gamma-interferon activation site 
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(GAS) in the regulatory regions of IFN-γ–induced genes. Type I IFN can also weakly 
activate GAF due to the phosphorylation of STAT1. While ISGF3 induces the expression 
of classical antiviral genes, GAF induces the expression of pro-inflammatory genes [3]. 
Additionally, several IRFs can induce certain ISGs as well, either after direct activation 
by viral infection or following IFN induction [5]. Most cell types can respond to type I 
IFN (IFN-β and multiple IFN-α subclasses) and IFN-γ, whereas type III IFN (IFN-λ1, -λ2 
and - λ3) mostly targets hepatocytes and mucosal epithelial cells, hereby providing 
protection against the frequent viral attacks that are typical for barrier tissues [4].  
 
Here we report on two siblings with compound heterozygous mutations in STAT2 who 
suffer from severe viral illness and of whom one sibling succumbed at the age of 7 
years from an infection with an unidentified agent. 
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Figure 1: The canonical type I and type II interferon pathway.  
92 
 
RESULTS 
Clinical and genetic features of the patients 
Patient 1 (P1) was the second child of unrelated parents of Belgian European descent. 
The first 3 years of his life were characterized by frequent and severe viral infections 
often requiring hospital admission. At age 18 months he developed high fever 1 week 
after administration of the MMR-vaccine, with a morbilliform rash, conjunctivitis, 
lymphadenopathies and arthritis. He recovered with supportive care. Basic 
immunological screening was normal. Physical and mental development were normal 
apart from an increased tendency for dental caries. From the age of 4 years he had a 
relatively infection-free period, but at age 7 years he succumbed to an infection with an 
unidentified agent. Clinically he suffered from a mild febrile illness, but after 48h his 
condition suddenly deteriorated and he died of multiple organ failure in the context of 
diffuse intravascular coagulopathy. All cultures remained negative and no causal 
pathogen could be identified. 
His younger sister P2 also suffered from frequent and severe viral infections in her first 
years of life, including severe and recurrent Varicella zoster infections, recurrent and 
disseminated Coxsackie infections, enteroviral meningitis and persistent cutaneous 
Human papillomavirus and Mollusca contagiosa. Infectious episodes were 
accompanied by moderate thrombopenia, lymphopenia, leucopenia and serological 
signs of immune dysregulation (including elevated IgG and IgE levels). Between 
infectious bouts, immunological screening could not demonstrate abnormalities in 
adaptive or innate immunity, with normal numbers of leucocyte subsets, normal 
lymphocyte proliferation tests, normal immunoglobulin levels and vaccine responses 
and normal activation of Toll-like receptor (TLR) pathways (Table E1). Physical and 
mental development were normal except for the same increased susceptibility to 
dental caries as P1. At age 18 months she developed disseminated measles following 
routine immunization, complicated by hepatitis and pneumonitis. At this time, she 
received a high dose of intravenous immunoglobulin (IVIG) (1 gram IVIG per kg body 
weight) due to her poor condition and the emergence of coagulopathy, after which she 
recovered and became afebrile within 24 hours. At age 2.5 years P2 suffered from a 
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severe primary infection with Epstein–Barr virus (EBV), associated with massive 
immune dysregulation that again responded well to high dose IVIG treatment. 
Macrophage activation syndrome was excluded based on international criteria. Over 
the next 3 years repeated measurements by PCR showed persistent EBV presence in 
both blood and cerebral spinal fluid (CSF), despite the presence of anti-EBV IgG (Table 
E2). From the age of 5 years the frequency and severity of viral infections decreased, 
but P2 still suffered from chronic lung disease with productive cough requiring chronic 
antibiotic treatment with azithromycine, inhalation steroids and daily respiratory 
physiotherapy. At age 9 years P2 still experiences several mild viral infections per year, 
mostly upper respiratory infections. She is off all medication.  
Whole-exome sequencing was performed on P2, the parents and the younger healthy 
sibling (For detailed methods, see OR). After filtering out common polymorphisms, we 
found that P2 had compound heterozygous c.G1576A and c.C1528T variants in STAT2, 
resulting in a p.Gly522Arg missense mutation and a premature stop codon at amino 
acid 506 (p.Arg506X). Sanger sequencing on DNA obtained from a frozen bone 
marrow sample of the deceased brother P1 confirmed that he carried both variants as 
well. The p.Gly522Arg mutation was inherited from the mother, the premature stop 
codon p.Arg506X from the father. The healthy younger brother was homozygous for 
the wild type form of STAT2 (Figure 2A); no DNA was available from the older healthy 
brother. 
Assessment of the STAT2 defect 
STAT1 and STAT2 expression and activation were examined in fibroblast and 
peripheral blood mononuclear cells (PBMC) of P2, the parents and the younger 
healthy brother as well as two unrelated controls (refer to the OR for Methods). 
Immunoblotting for STAT2 and phosphorylated STAT2 after stimulation with IFN-α 
(type I interferon) demonstrated absence of expression of both full length and 
truncated protein in P2, and reduced expression and phosphorylation in both parents 
compatible with their carrier status (Figure 2B). By contrast, STAT1 expression and 
phosphorylation after stimulation with IFN-γ (type II interferon) was normal (Figure 
2C). 
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Figure 2: Familial inheritance of STAT2 mutations and expression of 
STAT1, STAT2, phosphorylated STAT1 and phosphorylated STAT2. A) 
Family tree of the affected pedigree, indicating affected patients and STAT2 
genotype. B and C) Peripheral blood mononuclear cells (PBMC) and fibroblasts 
of all family members and 2 unrelated healthy controls were treated with IFN-α 
or IFN-γ at 103 Units per ml for 30 min or left untreated. STAT1 and STAT2 
expression was verified on cytoplasmic protein extract of PBMC and expression 
of phosphorylated STAT1 and phosphorylated STAT2 was verified on nuclear 
protein extract of fibroblasts by Western Blot, expression of PAN14.3.3 and hn 
RPI respectively was assessed as loading control.  WT, wild-type; IFN, interferon; 
STAT, signal transducer and activator of transcription; hn RPI, heterogeneous 
nuclear ribonucleoproteins I. 
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To further assess whether the STAT2 defect is complete or partial, upregulation of the 
IFN-stimulated genes (ISGs) MX1, ISG15 and OAS1 in response to IFN-α and IFN-γ was 
measured by RT-qPCR in primary fibroblasts of P2, her parents and her healthy sibling 
and in Simian virus 40 (SV40)-transformed fibroblasts of all family members and the 
STAT1-deficient individual (refer to the OR for Methods). While primary fibroblasts of 
all family members exhibited a similar response to IFN-γ and the fibroblasts of the 
parents and healthy sibling showed marked upregulation of the ISGs in response to 
IFN-α, fibroblasts of P2 failed to upregulate MX1, ISG15 and OAS1 in response to IFN-α 
(data not shown). In contrast, RT-qPCR on SV40-transformed fibroblasts of several 
Figure 3: Relative expression of Mx1, 
ISG15 and OAS1 in SV40-transformed 
fibroblasts. SV40-transformed fibroblasts 
of all family members and a STAT1-deficient 
patient were treated with IFN-α or IFN-γ at 
10
3
 Units per ml for 6 hours or left 
untreated. Expression of Mx1, ISG15 and 
OAS1 was measured by RT-qPCR and 
normalized to the average of ACTB and 
GUSB. P-values were calculated by regular 
two-way ANOVA with Tukey multiple 
comparisons tests to correct for multiple 
comparisons.  
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family members demonstrated several abnormalities in the response to IFN-α and IFN-
γ. Most strikingly, ISG upregulation was already present in SV40-transformed 
fibroblasts of the mother in untreated conditions, whereas ISG expression was very low 
in SV40-transformed fibroblasts of the father in untreated condition. SV40-fibroblasts 
of the father did upregulate ISGs in response to IFN-α but not significantly in response 
to IFN-γ, whereas SV40-fibroblasts of P2 failed to significantly upregulate MX1, ISG15 
and OAS1 in response to IFN-α and IFN-γ (Figure 3). It has been demonstrated before 
that ectopic expression of SV40 large T antigen following immortalisation results in 
the induction of ISGs in human fibroblasts and confers an antiviral state [6], and these 
findings seem to confirm this.  
Additionally, electrophoretic mobility shift assay (EMSA) was performed on SV40-
transformed fibroblasts extracts of all family members (refer to the OR for Methods), 
to test for binding of the ISGF3-complex and GAF-complex to the ISRE-elements and 
GAS-elements respectively that are present in the promotor regions of ISGs, after 
stimulation with IFN-α and IFN-γ. P2’s SV40-fibroblasts showed impaired activation of 
the ISGF3-complex in response to IFN-α, but normal activation of the GAS-complex in 
response to IFN-γ (data not shown). Supershift assays of the ISRE- and GAS-binding 
proteins were performed on SV40-fibroblasts extracts of P2 and her healthy sibling 
after stimulation with IFN-α and IFN-γ, using antibodies against STAT1, STAT2 and 
STAT3. In P2 and her healthy sibling, the GAS-binding proteins produced in response 
to IFN-γ contained STAT1 (GAF-complex). In the healthy sibling, ISRE-binding 
proteins in response to IFN-α contained both STAT1 and STAT2 (ISGF3-complex), 
however in P2, no STAT2 protein was detected upon stimulation with IFN-α (data not 
shown). 
Finally, to confirm that the STAT2 defect is complete, STAT2 cDNA containing either 
the c.G1576A or the c.C1528T variant, resulting in the p.Gly522Arg mutation or the 
premature stop codon p.Arg506X, was overexpressed in a STAT2-deficient cell line 
(U6A) and STAT2 expression was measured by Western Blot (refer to the OR for 
Methods). While STAT2 expression was absent following overexpression of the mutant 
allele carrying the p.Arg506X mutation, indicating that the c.C1528T variant drives 
nonsense-mediated decay, normal STAT2 expression was found following 
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overexpression of the mutant allele carrying the p.Gly522Arg mutation (Figure 4). The 
c.G1576A variant occurs in the late exonic position, and Human splicing finder 3.0 
[104] predicts that it alters/destroys the wild-type donor site which will probably affect 
splicing. It is therefore likely that the c.G1576A variant is a coding splice site variant, 
and that aberrant splicing is responsible for the loss of expression of the STAT2 allele 
carrying this variant. Analysis of STAT2 transcripts in PBMCs, primary fibroblasts and 
EVB-transformed B cells of P2 and her mother revealed multiple splicing variants (data 
not shown). Previous immunoblotting for STAT2 and phosphorylated STAT2 after 
stimulation with IFN-α demonstrated absence of expression of both full length and 
truncated protein in P2. Immunoblotting showed reduced expression and 
phosphorylation in both parents compatible with their carrier status, and absence of 
truncated or different-length STAT2 protein as well. Given that the antibody used for 
detecting STAT2 is directed against an epitope located at the N-terminus (amino acids 
1-178), and that this nucleotide regions is present in the identified STAT2 transcripts, it 
is highly probable that an aberrant or truncated STAT2 protein would have been 
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Figure 4: Overexpression of different STAT2 variants in a STAT2-deficient 
cell line (U6A). U6A cells were transfected with plasmids containing either 
wild-type STAT2, c.G1576A STAT2, c.C1528T STAT2, both c.G1576A STAT2 and 
c.C1528T STAT2 or plasmid without STAT2 insert. 72 hours after transfection 
cells were treated with either IFN-α or IFN-γ at 10
3
 Units per ml for 30 min or 
left untreated. Expression of STAT1, STAT2, phosphorylated STAT1 and 
phosphorylated STAT2 was verified on whole cell lysates by Western Blot.   
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detected by Western Blot if it was translated in PBMCs or primary fibroblasts of P2 and 
her mother. Together with the findings of failure to upregulate ISGs and the impaired 
activation of the ISGF3-complex in response to IFN-α, we conclude that the examined 
cell types of P2 are in fact STAT2-null.   
Increased susceptibility of patient’s primary fibroblasts to in vitro viral infections 
Next, we tested P2’s susceptibility to viral infections in vitro by measuring cell death in 
fibroblast cultures of all family members infected with a panel of negative-strand RNA 
viruses (Measles virus (MeV), Vesicular stomatitis virus (VSV), Human parainfluenza 
virus type 3 (HPIV3) and Respiratory syncytial virus (RSV))  (refer to the OR for 
Methods).    We   observed   increased  cell  death  in  P2  compared  to  healthy  family 
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Figure 5: Increased susceptibility of patient fibroblasts to in vitro infection 
with negative-strand RNA viruses. A) Fibroblasts of all family members were 
infected with Measles virus (MeV), Vesicular stomatitis virus (VSV), Human 
parainfluenza virus type 3 (HPIV3) and Respiratory syncytial virus (RSV). Cell 
death over time was measured with Celltox Green Cytotoxicity Assay. B) 
Fibroblasts of all family members were pre-treated with IFN-α and IFN-γ at 103 
U/ml for 24h and subsequently infected with MeV. Cell death over time was 
measured with Celltox Green Cytotoxicity Assay. C) Fibroblasts of patient 2 and 
her healthy sibling were pre-treated with IFN-α and IFN-γ at 103 U/ml for 24h 
and subsequently infected with MeV. Cells were fixed at day 7 post-infection and 
visualized by H&E staining. D, E and F) Fibroblasts of all family members were 
pre-treated with IFN-α and IFN-γ at 103 U/ml for 24h and subsequently infected 
with HPIV3, VSV and RSV respectively. Cell death over time was measured with 
Celltox Green Cytotoxicity Assay. P-values were calculated for comparison of 
slopes generated by linear regression. ****, p < 0,0001; ***, 0,0001 < p < 0,001; 
**, 0,001 < p < 0,01; *, 0,01 < P < 0,05; ns, not significant. 
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members after infection with MeV, VSV and HPIV3, but not RSV (Figure 5A). 
Pretreatment with exogenous IFN-α and IFN-γ protected the fibroblasts of healthy 
family members from in vitro infection with MeV, VSV and HPIV3 while for P2 
pretreatment with IFN-γ was protective but IFN-α had no effect (Figure 5B, 5C, 5D and 
5E). These results are compatible with disease caused by unresponsiveness to IFN-α, 
without altering the capacity to signal via STAT1 in response to IFN-γ. Pretreatment 
with exogenous IFN-γ improved cell survival in all family members during in vitro RSV 
infection, but pre-treatment with IFN-α only had a partial effect in all family members 
except the father. Strikingly, a partial effect of IFN-α pretreatment was observed in 
patient fibroblasts as well. Additionally, no significant difference was detected in the 
response to IFN-α of patient fibroblasts compared to fibroblasts of her other family 
members (Figure 5F). 
To unambiguously establish a causal relationship between the STAT2 mutations and 
the cellular/clinical defect in P2, a rescue of the cellular anomaly (viral susceptibility 
and unresponsiveness to IFN-α) was performed by introduction of wild-type STAT2 
cDNA in SV40-transformed fibroblasts of P2. Two strategies were followed to achieve 
stable expression of wild-type STAT2: 1) development of a Murine stem cell virus 
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Figure 6: STAT2 expression in SV40-transformed fibroblasts of patient 
2 and her healthy sibling after transduction with lentivirus and 
retrovirus. After transduction STAT2 expression was verified on whole cell 
lysate of SV40-transformed fibroblasts by Western Blot. NT, non-
transduced; mock,,retroviral vector without STAT2 insert.  
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(MSCV) retroviral vector encoding wild-type STAT2 (refer to the OR for Methods), and 
2) purchase of a lentiviral vector encoding wild-type STAT2 (Amsbio). Transduction 
was performed on SV40-transformed fibroblasts given the higher transduction 
efficiency in this cell type compared to primary fibroblasts. Transduction with the 
lentivirus resulted in very low STAT2 expression in P2’s SV40-transformed fibroblasts. 
In contrast, transduction with the retrovirus led to high expression of wild-type STAT2 
in SV40-transformed fibroblasts of P2 (Figure 6). 
While repeating the viral experiments on SV40-transformed fibroblasts of all family 
members and a STAT1-deficient patient and on the STAT2-deficient cell line U6A, a 
different response of SV40-transformed fibroblasts of the family members to in vitro 
viral infection was detected compared to the response of their primary fibroblasts 
(registered by daily monitoring and observation by bright-light microscope). Most 
strikingly, very little cell death was observed in SV40-transformed fibroblasts of the 
mother infected with VSV, MeV and RSV: the cells appeared to have become resistant 
to viral infection and the course of cell death mimicked that of cells pretreated with 
IFN-α or IFN-γ. In contrast, without pretreatment the SV40-transformed fibroblasts of 
the father seemed to be almost as susceptible to these viruses as the SV40-fibroblasts 
of the patient. These findings correlated with the ISG upregulation observed by RT-
qPCR in SV40-transformed fibroblasts of the mother and very low ISG expression in 
SV40-transformed fibroblasts of the father in untreated condition. Additionally, the 
STAT2-deficient cell line U6A did not support the conditions of the viral assay, namely 
the low percentage of fetal bovine serum and prolonged culture, high levels of cell 
death were observed in the first two days of the experiment in all experimental 
conditions. Therefore, it was concluded that SV40-transformed fibroblasts were not 
ideal for the viral assays and that STAT2-deficient cell line U6A could not be used as a 
control, but that the viral assays and the rescue experiment should be performed on 
primary fibroblasts.  
In order to achieve stable and efficient expression of wild-type STAT2 in primary 
fibroblasts, a lentiviral vector suitable for transduction of primary fibroblasts and 
encoding both wild-type STAT2 and GFP linked by the 2A peptide from the foot-and-
mouth disease virus (FDMV) (F2A) or only GFP (mock vector) will be developed. 
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Primary fibroblasts of all family members will be transduced so that they can serve as 
controls for P2’s fibroblasts. Primary fibroblast cultures with stable expression of wild-
type STAT2 will be generated by sorting of efficiently transduced fibroblasts co-
expressing wild-type STAT2 and GFP, and by culturing the cells under selective 
pressure. These experiments and the finalisation of this project are ongoing. 
DISCUSSION 
STAT2-deficiency has been proposed as the cause of unusually severe viral illness in 
infancy [1]. Here we report on a third, unrelated family with STAT2 deficiency in two 
siblings who suffered from frequent and severe viral infections. Deficiency in these 
patients appears complete, at least in the few tested cell types, based on protein 
expression, absent STAT2 phosphorylation, absent binding of ISGF3 to ISRE, and 
absence of induction of ISGs following IFN-α stimulation. Physical and mental 
development of both siblings was normal, except for a tendency for dental caries and 
erosion in both siblings and to a lesser extent in their parents. Enamel defects, 
although more severe, have been described in STAT3 deficiency and STAT1 gain-of-
function mutations [7,8], however it is unclear at this moment whether this dental 
defect can be attributed to STAT2 deficiency.  
Increased susceptibility to vaccine-strain measles with complicated measles infection 
following routine immunization has been documented in both families, and may be a 
warning sign for STAT2 deficiency. This susceptibility highlights the importance of 
type I IFN signalling in the initial immune response against measles infections [9]. 1-3 
patients per 1000 measles cases develop primary measles encephalitis (PME), and 4-11 
patients per 100,000 measles cases develop subacute sclerosing panencephalitis 
(SSPE), which is caused by persistent infection of the brain by an aberrant measles 
virus [9]. Whether STAT2 deficiency or mildly damaging genetic variants in STAT2 
underlie cases of PME and/or SSPE remains to be elucidated.  
Hambleton et al. reported that in the first described family the majority of childhood 
viral illnesses were remarkably mild (for example, unremarkable Varicella zoster 
infection and Herpes simplex virus (HSV) primo-infection). Although some childhood 
viral illnesses such as RSV bronchiolitis had a relatively uneventful course in P2, she 
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did, however, suffer from severe Varicella and Enterovirus infections requiring multiple 
hospital admissions. The recurrent viral respiratory infections led to chronic 
inflammatory post-viral lung disease in P2. She also suffered from persistent warts and 
Mollusca contagiosa. In contrast to the STAT2-deficient patients described by 
Hambleton et al., P2 had a severe course of primary EBV infection with delayed EBV 
suppression in peripheral blood and CSF, in line with the important role of type I IFN 
signalling in the initial immune response against EBV [10]. Together, the clinical 
presentation in this third family seems to be more severe than the one described by 
Hambleton et al. Similar findings have been reported in other innate immune 
disorders such as TLR3-deficiency, where HSV-1 primo-infection manifestations can 
range from asymptomatic to life-threatening encephalitis [11]. STAT2 deficiency may 
display incomplete penetrance for several viral infections, except perhaps for infection 
caused by the live attenuated measles vaccine. 
Hambleton et al. reported a decrease in frequency and severity of viral infections with 
increasing age [1], similar to the clinical evolution in innate immune disorders affecting 
TLR signalling pathways, where individuals who survive beyond childhood largely 
outgrow their susceptibility to invasive bacterial infections [12]. They hypothesized 
that this effect is due to the development of adaptive immunity. We observed a similar 
effect in P1 and P2, however, after a relatively infection-free period, P1 suddenly died at 
age 7 years of an infection with an unidentified pathogen. This demonstrates that 
STAT2-deficient patients may still be at risk for overwhelming viral illness at a later 
age, when confronted with a virus to which they are particularly susceptible. 
The impaired response to IFN-α and the severe and potentially life-threatening viral 
diseases in STAT2-deficient patients are reminiscent of the phenotype of patients with 
autosomal recessive STAT1 deficiency, who additionally suffer from severe infections 
with weakly virulent mycobacteria and other intracellular bacteria [13]. Their viral 
phenotype however seems more severe and broader than that of STAT2 deficiency. 
Hambleton et al. interpreted the apparently normal resistance of STAT2-deficient 
patients to several viruses as evidence that type I IFN signalling might be redundant in 
humans. Consistent with the more severe phenotype of STAT1-deficient patients, we 
favor the alternative hypothesis that there are STAT2-independent cellular responses 
104 
 
to type I IFNs. Similar, albeit less severe, presentation has been observed in patients 
with autosomal recessive partial STAT1 deficiency [14]. Comprehensive analysis of 
STAT1-deficient cells strongly suggests that the corresponding patients’ viral 
susceptibility is due to an impaired IFN-α/β response, whereas their susceptibility to 
intracellular bacteria is due to defective IFN-γ signalling [15].  
Finally, we observed a good response to high doses of IVIG in P2 during infectious 
episodes associated with severe immune dysregulation. This response may in part be 
due to the anti-inflammatory effect of high doses of IVIG [16], however, it is possible 
that passive immunization may also play a role in controlling the ongoing viral 
infections. Therefore it could be argued that IgG replacement therapy might be 
beneficial for STAT2-deficient patients during childhood, until their adaptive immune 
system has sufficiently developed, as shown in patients with TIR deficiency [11]. 
However, the history of P1 has demonstrated that patients may still be at risk for 
overwhelming viral illness beyond early childhood. Based on our limited experience, 
we recommend monthly IVIG substitution to prevent infections, and high dose IVIG 
treatment in the course of severe (viral) infectious episodes with signs of emerging 
coagulopathy and/or immune dysregulation. 
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METHODS 
The study was performed in accordance with the modified version of the Helsinki 
declaration. The study was approved by the Ethics Committee of UZ Leuven. Written 
informed consent was obtained prior to DNA isolation from blood of all family 
members and from bone marrow of the deceased patient.   
Genetic analysis 
Whole-exome sequencing. We performed whole-exome sequencing on the surviving 
patient and on the unaffected parents and younger sibling. Genomic DNA samples for 
whole-exome sequencing were prepared from heparinized peripheral blood using the 
QIAamp DNA Blood Midi Kit (QIAGEN, Hilden, Germany). Exome sequence libraries 
were prepared using a SeqCap EZ Human Exome Library v3.0 kit (Roche NimbleGen, 
Madison, Wisconsin, USA). Paired-end sequencing was performed on the Illumina 
HiSeq2000 (Genomics Core Facility, University of Leuven, Belgium). BWA software 
was used to align the sequence reads to the Human Reference Genome Build hg19. 
GATK Unified Genotyper was used to identify single nucleotide variants and 
insertions/deletions. ANNOVAR was used for annotation. 
Sanger sequencing. A DNA sample of the transplanted patient was obtained from a 
bone marrow sample using the GenElute Mammalian Genomic DNA Miniprep Kit 
(Sigma-Aldrich, St-Louis, USA). The regions of interest in exon 17 of STAT2 were 
sequenced using the primers 5’- GTTCTGCCCTGTGGGACAGATAG -3’ and 5’- 
CTCAATTGCCTGGGCTTCAGTTC -3’. Sanger sequencing was performed on an ABI 
3730 XL Genetic Analyzer (Applied Biosystems) at the LGC Genomics Facility in 
Berlin, Germany. Sequencing data were analyzed using CLC Main Workbench 6.9.1 
(CLC Bio, Denmark). 
Functional assays 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood of 
the patient, family members and two unrelated controls using lymphocyte separation 
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medium (LSM, MP Biomedicals) and cultured at 2x 106 cells per ml in RPMI medium 
with 10% FBS and supplemental penicillin and streptomycin. Dermal fibroblasts were 
obtained from skin biopsies of the patient, family members and two unrelated controls 
and cultured in DMEM medium with 10% FBS and supplemental penicillin and 
streptomycin. 
Western blot analysis. Dermal fibroblast cultures  and PBMC of the patient, family 
members and two unrelated adult controls were stimulated with IFN-α 1000 U/mL 
(ThermoFisher Scientific, Waltham, MA) or IFN-γ 1000 U/mL (R&D systems, 
Mineapolis, MN) for 30 minutes, or left unstimulated. Cytoplasmic and nuclear 
extracts were prepared using a nuclear extraction kit (Active Motif Corp, Carlsbad, CA) 
according to the manufacturer's instructions. Cytoplasmic protein lysates (20 μg per 
sample) were subjected to SDS-PAGE separation on 4-12% Bis-Tris Plus gels (Life 
Technologies, Carlsbad, CA), transferred to a polyvinylidene difluoride membrane (GE 
Healthcare, Buckinghamshire, United Kingdom) and immunoblotted with primary 
antibodies against STAT1 p84/p91 (M-22, sc-592; Santa Cruz Biotechnology, Dallas, 
TX), STAT2  (22/Stat2, 610187; BD Biosciences, San Jose, CA) and loading control PAN 
14-3-3 (K-19, sc-629; Santa Cruz Biotechnology, Dallas, TX). Nuclear protein lysates 
were treated in a similar way but were immunoblotted with primary antibodies against 
phospho-STAT1 (Tyr701, sc-7988; Santa Cruz Biotechnology, Dallas, TX), phospho-
STAT2 (Tyr689, AF2890; R&D Systems, Mineapolis, MN) and loading control 
heterogeneous nuclear ribonucleoprotein I (3H7, sc-73391; Santa Cruz Biotechnology, 
Dallas, TX). Primary antibodies were detected with horseradish peroxidase–conjugated 
secondary antibody (sc-2317 and sc-2005, Santa Cruz Biotechnology, Dallas, TX). All 
Western blot images were captured and quantified with a ChemiDoc MP imager and 
Image Lab software (Bio-Rad Laboratories, Hercules, CA) after adding Pierce ECL 
Western blotting substrate (Thermo Scientific, Waltham, MA). STAT1 and STAT2 
expression was normalized to the respective value for PAN 14-3-3 expression, 
phosphorylated STAT1 and phosphorylated STAT2 expression was normalized to the 
respective value for heterogeneous nuclear ribonucleoprotein I expression. 
Viral Assays. Dermal fibroblasts of the patient and the family members were seeded in 
96-well plates at 2x 104 cells per well in 200 µL DMEM medium with 2% FBS and 
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supplemental penicillin and streptomycin, and were stimulated with IFN-α 1000 U/mL 
(Thermo Scientific, Waltham, MA) or IFN-γ 1000 U/mL (R&D systems, Mineapolis, 
MN) for 24 hours, or left unstimulated. Cells were infected with measles virus (strain 
Edmonston-Zagreb, MOI 0.03), vesicular stomatitis virus (strain Indiana, MOI 0.005), 
human parainfluenza virus type 3 (strain C243, MOI 0.05) or with respiratory syncytial 
virus (strain Long, MOI 0.003). Cell death post infection was measured for 72h using 
CellTox™ Green Cytotoxicity Assay (Promega, Madison, WI) according to the 
manufacturer's instructions. Measurements were started at 144 hours post infection for 
measles virus, 6 hours post infection for vesicular stomatitis virus and 72 hours post 
infection for human parainfluenza virus type 3 and respiratory syncytial virus. 
Experiments were performed in technical replicates and were repeated three times. A 
representative experiment was shown in Figure 2.  
Statistical analysis of viral assays. Linear regression was performed: for each virus, 
individual and treatment condition, the slope of cell death in function of time was 
calculated. For each virus, the slope calculated for healthy individuals without IFN 
pretreatment was compared to that of the patient in this condition, or within each 
individual the slopes calculated for IFN pretreatment were compared with the slope 
calculated for the untreated condition. 
Real-time quantitative polymerase chain reaction (RT-qPCR). Total RNA was 
isolated from SV40-transformed fibroblasts and primary fibroblasts with TrizolReagent 
(Invitrogen) by following the manufacturer’s instructions. Complementary DNA 
(cDNA) was synthesized by reverse transcription using the SuperScript Vilo cDNA 
synthesis kit (Life Technologies). The cDNA was analyzed by real-time quantitative 
PCR. An appropriate amount of the cDNA was mixed with TaqMan Gene Expression 
Master Mix (Life Technologies) supplemented with gene-specific Taqman probes: for 
MX1 (Hs00895608-m1, Life technologies), for OAS1, (Hs00973635-m1, Life 
technologies), for ISG15 (Hs00192713-m1, Life technologies), for ACTB, (Hs01060665-
g1, Life technologies), and for GUSB (Hs00939627-m1, Life technologies). Real-time 
quantitative PCR analysis was performed on a StepOnePlus realtime PCR system (ABI). 
The resultant PCR products were analysed with ABI 7500 software (Applied 
Biosystems). Gene expression was analysed with the 2–ΔΔCt method [10], and all 
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quantifications were normalized to the average of the level of ACTB and GUSB. 
Experiments were performed in triplicate and repeated twice on primary fibroblasts. 
Statistical analysis was performed by regular two-way Anova and Tukey multiple 
comparisons tests are used to correct for multiple comparisons. 
Electrophoretic mobility shift assay (EMSA). EMSA was performed as described 
before by Stéphanie Boisson-Dupuis[134]. SV40-transformed fibroblasts were 
stimulated with 105 IU IFN-γ per ml or 105 IU IFN-α per ml for 30 minutes. 10 μg of 
nuclear extracts were used for assessment of GAS-binding proteins, and 20 μg of 
nuclear extracts for ISRE-binding proteins. For supershift assays, antibodies against 
STAT1 (sc345X), STAT2 (sc476X), STAT3 (sc7179X) and p48/IRF9 (sc496X) (Santa 
Cruz) were used, and rabbit IgG (Sigma) as an isotypic control. 
Overexpression experiments. Full-length ORF of wild-type STAT2 was amplified 
using PrimeSTAR GXL DNA Polymerase (Takara-Bio) (forward primer: 5’-
AAAAAACTCGAGATGGCGCAGTGGGAAAT GCTG-3’, reverse primer: 5’-
AAAAAAGAATTCCTAGAAGTCAGAAGGCAT-3’) and cloned into the pMCSV puro 
plasmid backbone (Clontech) between the XhoI/EcoRI restriction sites under a 
constitutively active LTR-promotor. To generate the p.Gly522Arg and p.Arg506X 
mutations in STAT2, site-directed mutagenesis was undertaken using the Q5 Site-
Directed Mutagenesis Kit (New England Biolabs) (forward primer p.Gly522Arg: 5’-
TCAATTACAAaGCTTCCGGAAG-3’, reverse primer p.Gly522Arg: 5’-
GGAGGATTCCTGTCAATG-3’, forward primer p.Arg506X: 5’-
CTATGTTGGCtGAGGCCTCAA-3’, reverse primer p.Arg506X: 5’-
GAGGAGAACTGCCAACTG-3’). 106 STAT2-deficient cells (U6A) were transfected with 
5 μg of plasmid DNA containing either wild-type STAT2, p.Gly522Arg STAT2, 
p.Arg506X STAT2 or a mock vector, using lipofectamine 3000 (Thermo Fischer 
Scientific). 72 hours after transfection cells were stimulated with IFN-α 103 IU/ml and 
IFN-γ 103 IU/ml for 30 minutes, subsequently harvested and protein extracts were 
prepared and immunoblotted for STAT2 and phosphorylated STAT2 as previously 
described. 
110 
 
Transduction of SV40-fibroblasts with wild-type STAT2. Full-length ORF of wild-
type STAT2 was cloned into the pMCSV puro plasmid backbone (Clontech) as 
previously described. This pMSCV puro plasmid contains a puromycin resistance gene 
as a selectable marker. Retroviruses were produced and viral stocks were concentrated 
using Retro-X concentrator (Clontech) according to the manufacturer’s instructions. 
SV40-fibroblasts of the patient were transduced using Polybrene (8µg/ml) and an 
inoculation spin (1,200 x g for 60 min at 32°C). After 48 hours transduced cells were 
selected for puromycin resistance (0.25 µg/ml) and left to proliferate under selective 
pressure (puromycin 0.125 µg/ml). STAT2 expression was verified by Western blot as 
previously described. Viral experiments were repeated on the transduced cells as 
previously described, after puromycin treatment was stopped for 7 days. 
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TABLES 
Table E1: Lymphocyte subsets and Ig measurements in patient 2. 
Leucocyte subset or Ig 2 years 5 years 10 years 
Neutrophils (kU/µL) 6,4 (1,5 – 8,5) 2,6 (1,5 – 8,5) 4,7 (1,8 – 8,0) 
Lymphocytes (kU/µL) 4,3 (2,7 – 11,9) 2,9 (1,7 – 6,9) 2,5 (1,5 – 6,5) 
T cells (kU/µL) 2,2 (1,4 – 8,0) 1,7 (0,9 – 4,5) 1,4 (0,7 – 4,2) 
CD4+ T cells (kU/µL) 1,4 (0,9 – 5,5) 0,89 (0,5 – 2,4) 0,82 (0,5 – 2,4) 
CD8+ T cells (kU/µL) 0,74 (0,4 – 2,3) 0,64 (0,3 – 1,6) 0,51 (0,3 – 1,6)  
NK cells (kU/µL) 0,15 (0,1  – 1,4) 0,68 (0,1 – 1,0) 0,59 (0,1 – 1,0)  
B cells (kU/µL) 1,05 (0,6 – 3,1) 0,51 (0,2 – 2,1) 0,65 (0,2 – 2,1) 
Switched memory B cells NA 13.4 % 13.5% 
IgG (g/L) 16.2 (3.02 – 9.85) 11.7 (4.78 – 11.29) 11.8 (5.30 – 13.06) 
IgA (g/L) 0.78 (0.13 – 1.08) 0.89 (0.35 – 1.90) 1.06 (0.60 – 2.70) 
IgM (g/L) 1.32 (0.26 – 1.60) 0.54 (0.34 – 1.34) 0.49 (0.43 – 1.73) 
IgE (kU/L) 47 (<91) 1177 (<224) 1127 (<331) 
Measles Ab protective protective NA 
Poliomyelitis Ab protective NA NA 
EBNA absent protective NA 
Hepatitis B Ab protective absent NA 
NK cells, natural killer cells; EBNA, Epstein-Barr virus nuclear antigen; NA, not 
available. 
 
Table E2: EBV measurement by PCR in patient 2. 
Age (years) 2,5  3 4 4,5 5,5 10 
EBV (log copies/ml) 4.73 2.99 4.25 3.07 4.33 (blood) 
2.71 (CSF) 
undetectable 
EBV, Epstein-Barr virus; CSF, cerebrospinal fluid; PCR, polymerase chain reaction. 
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DISCUSSION 
1. A de novo heterozygous IFIH1 mutation in a 16-year-old girl with severe early-onset 
and refractory systemic lupus erythematosus, IgA-deficiency and mild lower limb 
spasticity without neuroradiological manifestations 
1.1 Modifying factors in diseases associated with IFIH1 gain-of-function mutations 
Gain-of-function mutations in IFIH1 have been identified in a spectrum of disorders 
associated with elevated levels of type I IFN, such as AGS [135], HSP [42] and 
Singleton-Merten syndrome (SMS), a rare autosomal-dominant disorder characterized 
by early and extreme aortic and valvular calcification, dental anomalies (early-onset 
periodontitis and root resorption), osteopenia, and acro-osteolysis [136]. The term 
‘type I interferonopathies’ has been used to describe this novel group of inborn errors 
of immunity associated with upregulation of type I IFN [137]. Genetic defects in genes 
known to be involved in type I interferonopathies are often associated with a wide 
range of clinical manifestations. This is clearly the case for mutations in IFIH1, but is 
for example also described in TREX1 deficiency which can be associated with AGS and 
SLE, but also with familial chilblain lupus and with retinal vasculopathy with cerebral 
leukodystrophy [138]. Interestingly, IFIH1 gain-of-function mutations are also found in 
healthy family members of patients. However, all patients as well as asymptomatic 
family members carrying the IFIH1 mutation had a profound IFN signature [135]. 
Therefore it seems possible that IFIH1 gain-of-function mutations can function as a 
major predisposing factor for the development of type I interferonopathies, but that 
they are insufficient to drive disease on their own and that other genetic, 
environmental, or stochastic modifying factors leading to for example a break in 
tolerance play a role in disease development.  
The possibility of sIgAD acting as a modifying factor in the development of SLE in the 
patient described in this work has been discussed in detail in the publication. This 
effect could be partially environmental (increased exposure to viral antigens) and 
partially genetic (loss of the protective/inhibitory role of IgA against autoimmunity). 
Identifying other genetic modifying factors by for example GWAS or by assessing the 
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burden of known SLE or sIgAD risk alleles identified by GWAS, is not possible in a 
single patient. It would be interesting though to perform this type of genetic analysis 
on a cohort of individuals with IFIH1 gain-of-function mutations, to gain insight into 
the interplay between a Mendelian mutation and common risk variants in IFIH1-
associated type I interferonopathies. However this would require a sufficiently large 
group of patients to provide the necessary power to answer this question.  
1.2 Treatment of type I interferonopathies 
Immunophenotyping of the patient described in this work led to the identification of 
an immunological signature, i.e. both cellular and humoral disturbances, that was 
previously found in patients with active SLE. The finding of persistent disease activity 
linked to high serum levels of IFN-α as well as the identification of the genetic defect 
and cellular pathways responsible, suggests the IFN-driven nature of the disease and 
provides a rationale for trying targeted inhibition of IFIH1 or the type I IFN-pathway to 
control disease in this patient. Targeted inhibition of the type I IFN-pathway may be 
beneficial for all individuals with (IFIH1-associated) type I interferonopathies, not only 
for controlling the immunological disease manifestations but perhaps also for 
preventing further disease progression, for example further neurological deterioration 
in AGS. Examining the clinical course in AGS has shown that a therapeutic window of 
opportunity exists, and that assessment of type I interferon activity might serve as a 
useful biomarker [139]. However, the assumption here would be that type I IFN is the 
(sole or most important) driver of neurological deterioration in AGS, which remains a 
hypothesis at this time. 
As mentioned briefly in the article, IFIH1 senses long double-stranded RNA (dsRNA) 
and mediates an anti-viral response by activating type I interferon signalling [140]. 
After binding with (viral) dsRNA, IFIH1 interacts with the adaptor molecule 
mitochondrial antiviral signalling protein (MAVS) which leads to the production of 
type I IFN through recruitment of IRF3 and production of pro-inflammatory cytokines 
through activation of NF-κB. Subsequently type I IFN acts on cells expressing IFNAR 
by activating the JAK-STAT pathway downstream of IFNAR and inducing the 
expression of hundreds of IFN-stimulated genes (ISGs) (Figure 4). The resulting gene 
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products have a broad effect on multiple cell types: 1) they initiate an intracellular 
antiviral program in all cells expressing IFNAR to limit viral replication and further 
spreading of infectious agents, 2) they enhance antigen presentation and the 
production of cytokines and chemokines by innate immune cells and 3) they activate 
adaptive immunity, for example by augmenting antibody production by B cells [141]. 
Clinical trials with several molecules that target IFN-α or its receptor, or the signalling 
Figure 4: IFIH1-mediated type I IFN signaling and potential treatment 
strategies. dsRNA, double-stranded RNA; IFIH1, interferon induced with 
helicase C domain 1; IRF3, interferon regulatory factor 3; JAK, Janus kinase; 
MAVS, mitochondrial antivirus signaling protein; NF-κB, nuclear factor kappa B; 
STAT, signal transducer and activator of transcription; ISGF3, interferon-
stimulated gene factor 3. 
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cascade downstream of IFNAR (JAK-inhibitors), are either underway or have 
demonstrated their (lack of) effectiveness.  
Several biologicals that target IFN-α, e.g. sifalimumab or rontalizumab, have been 
developed and tested in phase II clinical trials [142, 143]. Although these drugs had 
acceptable safety profiles and treatment led to a dose-dependent reduction of the IFN 
signature in peripheral blood of SLE patients, the clinical effect was disappointing, 
with no significant reduction in disease activity compared to placebo in patients with 
moderate to severely active extrarenal SLE. Hence, it is possible that direct targeting of 
IFN-α might not be successful in controlling SLE. An alternative approach would be to 
block IFNAR, which is expected to block the activity of all type I IFN types, including 
IFN-β. Therefore, efficacy but also toxicity might be higher compared to biologicals 
directly targeting IFN-α. A phase II trial of anifrolumab, a monoclonal antibody against 
subunit 1 of IFNAR that inhibits the activity of all type I IFNs, demonstrated a 
significant reduction of disease activity compared to placebo in adult patients with 
moderate to severe SLE [144]. Occurrence of severe adverse events was similar in 
placebo or anifrolumab treated patients apart from a dose-dependent increase in 
Herpes zoster as well as (mostly unconfirmed) influenza infections. Subsequently, an 
anifrolumab phase III program was started [145]. Overall, IFNAR blockade could be a 
promising strategy for the treatment of moderate to severe SLE, and could be 
beneficial for IFIH1-associated type I interferonopathies.  
A third possibility would be to block the signalling cascade downstream of IFNAR by 
using JAK-inhibitors. At the moment no evidence is available on the effectiveness of 
JAK-inhibitors in patients with SLE, but improvement of autoimmunity and nephritis 
was observed in lupus prone mice treated with tofacitinib, a JAK1/3-inhibitor already 
used for treatment of rheumatoid arthritis [146]. Also, treatment with ruxolitinib, a 
JAK1/2 inhibitor, lead to significant clinical improvement in three patients with 
aleopecia areata [147], and in a patient with JAK2 V617F-positive post–polycythemia 
vera myelofibrosis and dermatomyositis [148]. A phase I trial testing the safety of 
tofacitinib in SLE is currently being undertaken. Additionally, treatment with the 
JAK1/2-inhibitor baricitinib is also being tried [149] in other type I interferonopathies 
such as chronic atypical neutrophilic dermatosis with lipodystrophy and elevated 
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temperature (CANDLE) [150] or stimulator of interferon genes (STING)-associated 
vasculopathy with onset in infancy (SAVI) [151]. The disease mechanism in SAVI, an 
autoinflammatory disorder due to gain-of-function mutations in STING, is similar to 
that of IFIH1-associated type I interferonopathies. In SAVI constitutively activated 
STING leads to increased production of IFN-β which binds to IFNAR, activates the 
JAK-STAT pathway and leads to the induction of ISGs. In vitro studies have already 
demonstrated a reduction of the constitutive up-regulation of phosphorylated STAT1 
in SAVI patients’ lymphocytes by JAK inhibitors [151] and a preliminary study showed 
significant clinical improvement of two SAVI patients treated with ruxolitinib [152]. If 
treatment of SAVI with JAK-inhibitors proves to be successful in larger trials, this 
could also be the case in patients with IFIH1-associated type I interferonopathies. 
2. Recessively inherited homozygous CECR1 mutations in a 9-year-old boy with 
Castleman’s-like disease and in two siblings with combined immunodeficiency, 
lymphoproliferation, autoimmunity and vasculopathy 
2.1 Clinical and immunophenotypical heterogeneity in ADA2 deficiency 
Recessively inherited loss-of-function mutations in CECR1, leading to ADA2 deficiency, 
were identified in a patient with Castleman’s-like disease and in two siblings with CID, 
lymphoproliferation, autoimmunity and vasculopathy. During the work-up of these 
single family cases, two other research groups identified disease-causing mutations in 
CECR1 in two cohorts of patients. In one cohort patients presented with polyarteritis 
nodosa (PAN) [70], whereas in the other cohort they presented with systemic 
inflammation, systemic vasculopathy in the form of early-onset recurrent stroke, 
livedoid rash or vasculitis, hepatosplenomegaly, hypogammaglobulinemia and 
lymphopenia [69]. Additionally, mutations in CECR1 were also identified in a family 
with Sneddon's syndrome, an autoinflammatory disorder characterized by intermittent 
fevers, livedoid rash and leg ulcerations [153]. Several affected family members 
developed early-adulthood stroke as well. These findings demonstrate the important 
clinical heterogeneity in ADA2 deficiency.  
All patient cases published so far presented with some sort of systemic inflammation. 
In both CID siblings however the inflammation appeared to be subclinical, without 
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recurrent fevers or increased acute-phase reactants. Only through the use of assays not 
available in standard clinical practice such as serum IL-6 measurement by Elisa, did 
the important systemic inflammation become apparent in these patients. Another 
important feature of ADA2 deficiency, the vasculitis/vasculopathy and inflammatory 
skin lesions do not always seem to be overtly present either, at least not early in the 
disease presentation. The patient with Castleman’s disease and the transplanted sibling 
examined in this work never developed livedoid rash or inflammatory skin lesions, 
however the younger sibling recently developed a livedoid rash at the age of 5 years. 
Over a follow-up period of seven years up until now the patient with Castleman’s-like 
disease has not developed any signs of vasculopathy.  At the time of discovery of the 
genetic defect vasculopathy was not an overt manifestation in the CID siblings either, 
however subclinical vasculitis was probably already present. The older brother 
developed a haemorrhagic stroke during the course of the HSCT, which was thought to 
be a consequence of a HSCT induction-related cytokine storm and the severe 
thrombocytopenia at that time. His younger brother however has developed two 
ischemic strokes over the past year (after publication in Journal of Allergy and Clinical 
Immunology 2014), as well as a relapse in inflammatory bowel disease. Later disease or 
stroke onset has been described in other patients as well [70, 153], so careful follow-up 
of all ADA2-deficient patients is mandatory. Still, the findings in this work 
demonstrate that ADA2 deficiency should not be excluded based on the absence of 
overt inflammation and/or clinical vasculitis signs. 
Lymphoproliferation, i.e. hepatosplenomegaly and generalized lymphadenopathies, 
was a prominent feature in all three patients. Concerning the immune phenotype, both 
CID siblings presented with hypogammaglobulinemia, lymphopenia and a B cell 
differentiation defect, similar as to what was found by the group of Zhou et al. [69]. 
Although T cell proliferation tests in vitro were normal, an in vivo defect in T cell 
activation was observed as well which could account for the patients’ increased 
susceptibility to viral infections (e.g. severe and recurrent cutaneous HSV-1 infection) 
and their CID-like phenotype. The observed mild T cell defect could also account for 
the development of autoimmunity (auto-antibodies against erythrocytes and 
thrombocytes) in these patients, which is often associated with CID or CVID. Results 
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of extensive in vivo immunoprofiling have not been published by the other research 
groups, but in vitro tests of T cell activation were normal as well [69] and the presence 
and/or absence of autoantibodies is not mentioned [69, 70, 153]. In contrast with this 
CID-like phenotype, the patient with Castleman’s-like disease presented with 
polyclonal hypergammaglobulinemia, a feature consistent with hyperactivation of B 
cells. Additionally, in this patient all leucocyte subsets were within normal range 
compared to healthy age-matched controls. 
These clinical and immunophenotypical differences cannot be explained solely by the 
CECR1 genotype. The p.Arg169Gln mutation in the CID siblings was previously 
observed in hemizygous and homozygous form [69, 70] and the homozygous 
p.Gly47Arg mutation in the Castleman’s patient was found in several patients with 
polyarteritis nodosa [70]. It is possible that other genetic factors might play a role in 
the development of for example the immunological phenotype. The influence of 
(relatively rare) genetic polymorphisms on immune phenotype and for example T cell 
function have been described previously [111], and therefore differences in genetic 
background could be responsible for the observed immunophenotypic discrepancies. 
Three other paediatric patients with HHV8-negative Castleman’s-like disease and their 
unaffected parents were recruited through a collaboration with Professor Isabelle Kone 
Paut (France), however, sequencing of the coding regions of CECR1 in patients and 
parents did not reveal any recessively inherited mutations. The same result was 
obtained by the ‘National Institute of Health’ group that described the first cohort of 
ADA2-deficient patients and that also did not find CECR1 variants in their cohort of 
patients with HHV-8-negative Castleman’s disease [154]. This is not surprising since 
Castleman’s disease is reportedly associated with a variety of conditions such as 
underlying systemic inflammatory diseases, paraneoplastic syndrome mechanisms via 
ectopic cytokine secretion, and/or a non-HHV-8 virus [55].  
A striking difference seen in both the patient with Castleman’s-like disease and in the 
two siblings with CID, autoimmunity and lymphoproliferation; is the presence of an 
IL-6 signature. This is in stark contrast with the previously described ADA2-deficient 
cases in which no particular cytokine profile was found in serum [69, 70]. No increase 
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in TNFα was detected in serum of the three patients described here. In two other 
ADA2-deficient patients an upregulation of ISGs was found in peripheral blood, 
together with a marked overexpression of neutrophil-derived genes [155]. It is not clear 
whether type I IFN might play a role in disease pathogenesis, or whether this IFN 
signature is secondary to the general inflammation. Treatment with anti–interleukin-6 
receptor antibody (tocilizumab) resulted in a rapid, complete, and persistent 
suppression of all clinical features and laboratory abnormalities in the patient with 
Castleman’s-like disease, compatible with the major role of IL-6 in driving the 
inflammatory phenotype [48, 49]. However, this brings up the question why the high 
IL-6 levels are not having a similar effect in the two siblings with a CID-like phenotype. 
They did present with lymphoproliferation, but did not experience recurrent fevers nor 
increased acute-phase reactants or polyclonal hyperglobulinemia.  
2.2 ADA2 deficiency and IL-6? 
As mentioned above, an IL-6 signature was found in serum of all three patients, 
whereas IL-6 was undetectable in serum of other family members and healthy 
individuals. Immunohistochemical analysis of a specimen obtained on lymph-node 
biopsy from the Castleman’s-like disease patient confirmed strong expression of IL-6, 
mild expression of IL-1β and absent expression of TNFα, which together with the 
clinical presentation prompted his initial diagnosis. IL-6 is a cytokine that can be 
produced and secreted by many cells including monocytes, T cells, fibroblasts and 
endothelial cells. It can be a pro-inflammatory or protective/regenerative cytokine, 
depending on the signalling pathway used (IL-6 trans-signalling via the soluble IL-6R 
or classic IL-6 signalling via the membrane bound IL-6R respectively) [46]. Activation 
of the NF-κB pathway and IL-1β are strong stimuli for the production of IL-6 and its 
levels are increased in many if not all infectious and inflammatory diseases [46].  
It remains unclear at this moment how ADA2 deficiency could lead to IL-6 production 
in vivo. Answering this question may be difficult, since no ortholog for CECR1 exists in 
commonly used animal models such as mice and rat. However, findings in mice with 
ADA deficiency (the ortholog of human ADA1) suggest that there might be a link 
between loss-of-function of adenosine deaminase and IL-6: the accompanying increase 
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in adenosine levels have been reported to stimulate IL-6 induction through activation 
of the adenosine A2B receptor [156]. Furthermore, increasing evidence has shown that 
adenosine can drive monocyte differentiation toward pro-inflammatory 
monocytes/macrophages and increased IL-6 production through the adenosine A2B 
receptor in human and mice [157, 158]. Neither adenosine nor deoxyadenosine levels 
were increased in plasma of the patient with Castleman’s disease and of the 
untransplanted sibling with CID-like disease, which correlates with the normal ADA1 
activity found in all individuals and the dominant role of ADA1 in adenosine 
metabolism in physiological conditions and in the blood stream [159]. However, ADA2 
may be important for controlling adenosine levels in sites of inflammation or hypoxia 
where the adenosine concentration is significantly elevated and the extracellular pH is 
acidic, or locally in different tissues [159]. One hypothesis therefore is that locally 
increased adenosine levels due to absence of ADA2 could drive the pro-inflammatory 
macrophage polarization that was previously observed in vitro [69] and lead to local 
IL-6 production through the adenosine A2B receptor as mentioned above. IL-6 can 
enhance monocyte recruitment [160], rescue T cells from apoptosis [161], and boost 
proinflammatory T cell polarization [162], which could promote chronic inflammatory 
cell infiltrates. Through IL-6 trans signalling it could promote the release of additional 
IL-6 from T cells, fibroblasts and endothelial cells in a positive autocrine feedback 
system [46]. Finally, IL-6 could then have systemic effects when it enters the blood 
stream, whereas adenosine will be immediately metabolized by ADA1 when it does the 
same.  
It was hypothesized that ADA2 deficiency may compromise endothelial integrity in 
small blood vessels. Substantial endothelial damage as well as endothelial-cell 
activation has been shown in patient biopsy specimens from the brain and from skin 
lesions [69]. Furthermore, small hairpin RNA (shRNA) knockdown of ADA2 in 
myeloid U937 cells led to considerable disruption of cocultured monolayers of human 
primary dermal microvascular endothelial cells, as did monocytes from ADA2-
deficient patients [69]. The role of IL-6 has been demonstrated in endothelial 
activation and dysfunction, as well as its involvement in several types of vasculitis and 
in other disorders associated with compromised endothelial integrity such as arterial 
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aneurysms [162]. Therefore it seems reasonable to assume that the high IL-6 levels in 
both siblings with CID-like disease were contributing to their vascular disease.  
2.3 Treatment of ADA2 deficiency 
Despite severe early complications, allogeneic HSCT was successful both in rescuing 
the immunologic phenotype and in preventing further vascular disease in ADA2 
deficiency. During a seven year follow-up, consecutive clinical and biochemical 
investigations in the transplanted patient have shown no signs of immunologic 
disorder and no additional strokes. The course of the transplantation and the potential 
risks have been described in detail in the Journal of allergy and clinical immunology. 
Briefly, ADA2-deficient patients may be high-risk candidates for HSCT for several 
reasons. First, the inflammatory response associated with conditioning is 
superimposed on the inflammatory state intrinsic to ADA2 deficiency, which might 
negatively affect engraftment. Second, the compromised endothelial integrity observed 
in patients with ADA2 deficiency could predispose to development of veno-occlusive 
disease (VOD), a potentially fatal complication of HSCT. Third, this combination of 
inflammation and endothelial injury might further increase the risk of stroke in the 
pre-engraftment and early post-engraftment phases as observed in the transplanted 
patient. Suggested treatment for preventing these complications include VOD 
prophylaxis with defibrotide, pretreatment with anti–IL-6R mAbs to control IL-6 levels 
before the start of the HSCT and to damper the cytokine storm peri-HSCT, or  
treatment with anti–TNFα mAbs peri-HSCT given its usefulness in preventing and 
treating acute graft-vs-host disease (GvHD). However, given the underlying 
immunodeficiency, the risk of infection needs to be carefully balanced when using 
anti–IL-6R and anti–TNFα mAbs. 
ADA2 plasma activity was restored after allogeneic HSCT, which is consistent with 
bone marrow–derived monocytes and macrophages being the main sources of secreted 
ADA2. However, whether or not this translates into a restoration of ADA2 plasma 
activity in other tissues, remains unknown. Whether normal ADA2 plasma activity is 
sufficient to cure the disease, whether ADA2 plays a role in other tissues and what the 
effect of absent ADA2 tissue activity on long-term prognosis could be, remains unclear 
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as well. A report on HSCT in a patient with ADA2 deficiency with a 9-year follow-up is 
promising [163]. It is plausible that the benefit from HSCT to our patient is entirely due 
to restoration of normal plasma ADA2 levels. If true, future treatment with exogenous 
ADA2 might provide an alternative therapy for ADA2 deficiency in patients in whom 
allogeneic HSCT is contraindicated. 
In agreement with findings by other research groups [69, 70], treatment with a variety 
of immunosuppressive medications resulted in poor disease control in both siblings 
with CID-like disease. In contrast, treatment with tocilizumab resulted in complete 
and persistent suppression of all clinical features and laboratory abnormalities in the 
patient with Castleman’s-like disease. Four years after disease onset and three years 
after the start of the tocilizumab treatment the patient has not experienced any 
vasculitis or vasculopathy manifestations. While a possible explanation for the curative 
effect of allogeneic HSCT is available, the mechanisms behind achieving disease 
control through the use of anti-IL-6R mAbs remain unclear. This result suggests at 
least a partial contribution of IL-6 to disease pathogenesis in ADA2 deficiency in this 
patient. ADA2 plasma activity however remains absent in the patient. It is possible that 
controlling the inflammatory syndrome is sufficient to prevent vascular damage, 
however it has been hypothesized that ADA2 might also exert growth factor-like 
activity on endothelial cells [69]. What the effect of absent ADA2 plasma activity on 
long-term prognosis might be, and whether the patient might still be at risk for 
developing strokes/vasculopathy at a later age, remains unclear. A recent report on 
clinical manifestations and treatment of 15 patients with ADA2 deficiency mentions 
that one patient developed a stroke while under treatment with tocilizumab, and 
treatment was subsequently changed to the anti-TNFα mAb adalimumab [164]. At the 
moment, no clinical or biochemical signs suggesting persisting disease activity can be 
detected in the patient with Castleman’s-like disease, however, strict follow-up is 
necessary. Given the apparent complete control of the disease at this time, it does not 
seem necessary to change treatment from IL-6 blockade to TNFα blockade and it 
would be unethical and contraindicated to perform a (risky and potentially dangerous) 
allogeneic HSCT in this patient. However, if the patient were to develop strokes or 
other signs of vasculopathy, these therapeutic options would have to be reconsidered. 
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As more ADA2-deficient patients will be identified in the future and longer follow-up 
of other potential treatments such as TNFα blockade will become available, a more 
evidence-based decision can be made. 
Treatment with tocilizumab led to complete normalisation of the immunological 
disturbances (systemic inflammation and lymphoproliferation), but also had an 
important effect on other clinical disease manifestations. The patient also presented 
with significant growth retardation. In fact, after the development of disease, the 
patient’s growth ceased completely. However, after the start of the tocilizumab 
treatment an important catch-up growth was observed. His phenotype pre-tocilizumab 
resembled that of IL-6 transgenic mice, where overexpression of IL-6 during the 
prepubertal stage results in stunted growth, abnormalities of the insulin-like growth 
factor I system, defective growth plates, delayed development of ossification centres, 
uncoupling of osteoblast and osteoclast activity and defective ossification [165].  
Similar growth delays were observed in the two siblings with CID-like disease, and 
catch-up growth was observed in the older sibling post-HSCT. Additional factors such 
as glucocorticoid treatment may probably have played a role in the older sibling but 
cannot completely account for this, as the younger sibling only received treatment 
with IVIG for at least one year. These findings demonstrate the important effect of 
(systemic) inflammation on growth, and the necessity of treatments aiming at 
controlling this inflammation. 
3. Recessively inherited compound heterozygous STAT2 mutations in two siblings with 
severe viral illness  
3.1 The protective effect and potentially compensating role of IFN-γ during viral infections 
in STAT2-deficient patients 
IFN-γ rescues the viral phenotype of STAT2-deficient fibroblasts in the in vitro viral 
assay, whereas IFN-α does not. This finding however raises the question why STAT2-
deficient patients suffer from severe viral disease if IFN-γ can compensate for this 
cellular anomaly? Alternatively, it suggests that the outcome of the in vitro viral assay 
is not relevant for the clinical disease course in STAT2-deficient patients. 
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The in vitro viral assay is an artificial system, in which a monoculture of primary 
fibroblasts is infected with several (-) single-stranded (ss)RNA viruses 24 hours after 
addition of exogenous IFN-α or IFN-γ. Under these circumstances IFN-γ could 
(partially) protect patient fibroblasts from viral infection whereas IFN-α could not. 
This protection is pathogen-dependent and might not be complete, as infection with 
human parainfluenza virus type 3 (HPIV3) still led to considerable cell death in patient 
fibroblasts despite pretreatment with IFN-γ, in contrast with fibroblasts from other 
family members who were not susceptible to HPIV3-infection. This experimental set-
up obviously does not recapitulate what happens in vivo during a viral infection.   
After the start of an infection in vivo, type I IFN is produced by infected cells in 
response to the detection of the pathogen [141]. All cells can produce IFN-β with 
fibroblasts being one of the main producers, whereas IFN-α is mainly produced by 
hematopoietic cells, particularly pDCs. The first effect of type I IFN is the induction of 
a cell-intrinsic antiviral state in infected and neighbouring cells to limit further spread 
of the viral pathogen. Additionally, type I IFN modulates innate immune responses by 
promoting antigen presentation and NK cell functions, and activates the adaptive 
immune system, thus promoting the development of high-affinity antigen-specific T 
and B cell responses and immunological memory [141]. In contrast, type II IFN is 
produced by activated NK cells and T lymphocytes, in response to IL-12 and IL-18 
produced by antigen presenting cells (APCs) detecting viral infection [166]. There is an 
important overlap with the effect of type I IFN, although compared to type I IFN, IFN-γ 
has more pro-inflammatory effects given its role in macrophage activation [166]. 
However, IFN-γ also becomes important later in the antiviral response by coordinating 
the innate and adaptive immune response and establishing an antiviral state for longer 
term control [166].  
In the in vitro viral assay on fibroblast monocultures the response to both IFN-α and 
IFN-γ pretreatment is limited to the cell-intrinsic effects, and the assay clearly shows 
that primary fibroblasts of the patient have an increased viral susceptibility and fail to 
mount this initial cell-intrinsic antiviral response compared to fibroblasts of her family 
members in similar conditions. The observed protective effect of IFN-γ in vitro 
however is artificial, since high dose IFN-γ will not be present 24 hours before an in 
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vivo infection to induce a preventive antiviral state. In vivo the type I IFN response is 
one of the first lines of defence against viral infections. The absence of this first innate 
immune defence in the STAT2-deficient patient creates a window of opportunity for 
viral pathogens to replicate and spread faster and further, hence the increased 
frequency and severity of viral infections in STAT2-deficient patients. However, once 
type II IFN is produced, it can aid in controlling the infection. This could explain why 
the viral susceptibility phenotype of STAT2-deficient patients appears to be milder 
than that of STAT1-deficient patients, in whom both type I and type II IFN signalling 
are disturbed [134].  
Whether IFN-γ could be used in the treatment of STAT2-deficient patients is not clear 
at the moment. On the one hand, long term prophylactic treatment with IFN-γ has 
been used successfully and safely in patients with chronic granulomatous disease, a 
primary immunodeficiency disorder of phagocytes characterized by severe recurrent 
bacterial and fungal infections resulting from impaired killing of bacteria and fungi 
[167]. On the other hand, the life-threatening infectious episodes in the presented 
STAT2-deficient patients were accompanied by severe inflammation and immune 
dysregulation, even prompting investigations to exclude macrophage activation 
syndrome. Given the pro-inflammatory effects of IFN-γ and its role in macrophage 
activation [166], administration of IFN-γ during severe infectious episodes may 
improve antiviral immunity but may just as well lead to increased inflammation and 
clinical deterioration of the patient. Therefore, treatment with high dose IVIG together 
with supportive measures appear to be a safer option for life-threatening viral 
infections.  
3.2 Difference in susceptibility to various viral pathogens in STAT2 deficiency 
The susceptibility patterns observed in different PIDs demonstrate the interaction 
between different immune pathways and the virulence and immune evasion strategies 
of various viral pathogens. Just as in the first described kindred, the patients described 
in this work developed complicated disseminated measles following immunisation 
with the attenuated virus. This finding highlights the importance of type I IFN 
signalling and interferon-stimulated gene factor 3 (ISGF3)-complex formation in the 
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initial immune response against measles infections. However, while many of the 
common childhood viral illnesses had an unremarkable course in previously described 
STAT2-deficient individuals [75], the patients presented here also suffered from 
repeated and severe enterovirus infections ((+)ssRNA viruses), severe varicella 
infection and severe and prolonged Epstein-Barr virus (EBV) infection (both dsDNA 
viruses). Therefore, STAT2 deficiency in this second family appeared to be associated 
with increased susceptibility to a broader range of virus families than just (-)ssRNA 
viruses. It is not clear yet why some of the common childhood viral illnesses were more 
severe in the second kindred. Like in the patients from the first kindred with STAT2 
deficiency, it cannot be concluded irrefutably that the STAT2 defect is complete and 
that this could be the reason for the more severe phenotype. Whether other genetic 
factors could be contributing to this finding, remains to be elucidated. 
In contrast, the younger sibling of the second kindred experienced a relatively 
unremarkable RSV infection ((-)ssRNA virus) during the first year of life and did not 
require supportive therapy for this infection. This clinical observation correlates with 
the findings of the in vitro viral assay. While increased susceptibility of patient 
fibroblasts to in vitro infection with several (-)ssRNA viruses (measles virus (MeV), 
vesicular stomatitis virus (VSV), HPIV3) as well as a failure to signal through STAT2 in 
response to exogenous IFN-α was demonstrated, no increased susceptibility of patient 
fibroblast to RSV infection in vitro was detected compared to her mother and sibling. 
Additionally, pre-treatment with exogenous IFN-α partially reduced cell death in a 
similar manner during in vitro RSV infection in the patient, her mother and her sibling. 
Therefore, STAT2-deficient fibroblasts seemed to demonstrate similar behaviour 
during in vitro RSV infection as fibroblasts containing wild-type STAT2.  
One potential explication for this finding of similar susceptibility to RSV infection 
could be that RSV preferentially inhibits type I IFN signalling in humans by 
downregulating the expression of STAT2 [168]. Additionally, many viruses can directly 
activate IRFs and lead to induction of ISGs [169]. In mice it has been demonstrated 
that RSV infection leads to upregulation of IRF1 and subsequent ISG induction 
independent of type I IFN signalling, through detection of the virus by intracellular 
RIG-I and IFIH1 receptors and subsequent activation of MAVS [170]. These combined 
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effects could explain why the fibroblasts of the patient, her mother and her sibling 
demonstrate a similar susceptibility to RSV infection in vitro in the untreated 
condition. Similar mechanisms are probably also involved in in vivo RSV infections in 
humans: recently a vital role for a MAVS-mediated IRF1/IFN-λ pathway was 
demonstrated in the antiviral response in human lung epithelial cells during RSV 
infection [170]. All these findings together with the observation of unremarkable RSV 
infection in a STAT2-deficient individual suggests that type I IFN signalling through 
the ISGF3-complex is not critically important in antiviral immunity during RSV 
infection.  
It is not clear at the moment why patient fibroblasts experienced less cell death in vitro 
due to RSV infection after pretreatment with IFN-α, in a similar way as fibroblasts of 
her mother and sibling. Binding of IFN-α to IFNAR leads to phosphorylation of STAT1 
and STAT2, and therefore formation and activation of mainly the ISGF3-complex but 
also weak activation of the GAF-complex [141]. Seeing how RSV decreases STAT2 
expression in healthy individuals, one hypothesis could be that antiviral immunity 
against RSV is mostly GAF-dependent and ISGF3-independent, and that stimulation of 
IFNAR could sufficiently activate GAF to provide a similar protection in all family 
members. 
4. Contribution of variants in IFIH1, CECR1 and STAT2 to common disease 
In contrast with the possible monogenic nature of rare but severe early-onset 
disorders, diseases with later onset and higher prevalence in the population are 
thought to have a complex polygenic causation [5]. Less deleterious variants in genes 
associated with monogenic disorders could be contributing to these common forms of 
disease [5]. Less deleterious IFIH1 variants, together with other genetic and 
environmental factors, could be contributing to the development of for example adult-
onset SLE. Functional studies of the A946T IFIH1 risk allele (rs1990760), associated 
with increased risk of developing SLE [171], type I diabetes mellitus [172] but also 
sIgAD [39] in GWAS, support this hypothesis. It is not clear whether increased base-
line IFIH1 expression is present in individuals carrying the risk allele, but the risk allele 
does seem to lead to an increased IFN-β response during enteroviral infection and 
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increased IFIH1 expression following viral stimulation [173]. Therefore viral infection in 
individuals carrying the risk allele could lead to a higher and/or sustained IFN 
response capable of facilitating the onset of an inflammatory cascade that leads to 
autoimmune disease [173]. Several other common variants in or around the IFIH1 gene 
have been associated with increased risk for autoimmune disease [173]. In the future 
functional studies might further explain how these polymorphisms could contribute to 
disease development by for example altering the function of regulation of the IFIH1 
protein. 
It seems also plausible that less deleterious CECR1 variants could be contributing to for 
example development of vasculitis or strokes in early or late adulthood. No variants in 
or near CECR1 have been identified as risk alleles for vasculitis or vasculopathy in 
GWAS, but the identification of CECR1 mutations in Sneddon syndrome, an adult-
onset autoinflammatory disorder characterized by intermittent fevers, livedoid rash, 
leg ulcerations and strokes, indicates that ADA2 deficiency can also present at a later 
age. Additionally the finding of the disease-causing p.Tyr453Cys CECR1 mutation in 
heterozygous form in two brothers with late-onset lacunar strokes [69] suggests that 
variants in this gene leading to reduced plasma ADA2 activity could also contribute to 
more common vascular phenotypes in the general population. Likewise, while 
complete loss of STAT2 function causes increased and potentially fatal susceptibility to 
viral illness (especially to (-)ssRNA viruses such as measles), more common variants 
leading to reduced function of STAT2 could be involved in differences in viral 
susceptibility and disease severity within the general population.  
5. Relevance of screening for alterations in the peripheral immune system 
Advanced analysis of the peripheral immune system of patients and healthy 
individuals was performed, in order to identify alterations in the patient immune 
system compared to that of healthy age-matched individuals. Both cellular and 
humoral immune components were studied during the course of the project(s), and 
screening for immune cell alterations (i.e. changes in relative percentages of a limited 
set of immune cell subsets) in the examined patients compared to healthy age-
matched controls was performed prior to genetic analysis. The latter was done for two 
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reasons: 1) to gain insight in disease mechanisms and pathways involved in disease 
pathogenesis by observing alterations in the patient’s peripheral cellular immune 
system, and 2) to use the obtained information on immune cell alterations for the 
selection of candidate genetic variants.  
Screening for immune cell alterations revealed important changes in immune cell 
subsets of certain patients, e.g. an immune phenotype compatible with active SLE in 
the patient with the IFIH1 mutation or a defect in B cell differentiation and activation 
and a mild defect in T cell activation in the siblings with CID-like disease and ADA2 
deficiency. However, the impact of using the immune cell screening results for the 
selection of candidate genetic variants and for gaining insight in disease pathogenesis 
was limited. In three out of four examined cases the immune cell alteration obtained 
from the screening did not contribute to the selection of a candidate genetic variant, 
but instead the candidate variants were identified by using the genetic analysis 
strategy outlined in the introduction. Also, the observed immune cell alterations often 
did not provide new information on disease pathogenesis but more often confirmed 
what was already known and described in the literature, as was the case for the patient 
with IFIH1-associated SLE. Several aspects are contributing to the limited utility of the 
proposed immune phenotype screening. First, this screening method only assesses 
alterations in a limited number of immune cell subsets, mostly of the adaptive immune 
system. However, the disease could be caused by a genetic defect presenting itself in 
other subsets of the cellular immune system that are not assessed or by a defect in 
innate immunity, as is the case in STAT2 deficiency where all patient immune cell 
subsets assessed were within normal range. Next, another difficulty lies in interpreting 
results of this type of analysis due to the large variability and heterogeneity in the 
(healthy) human immune system. Only large differences with healthy age-matched 
individuals stand out, with absence of an immune cell subset being one of the results 
easiest to interpret. Finally, an important problem is due to the influence of (mostly) 
environmental factors such as immunomodulatory medication or intercurrent 
infection on the appearance of an immune phenotype, which may be even more 
important than the underlying genetic defect.  
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There might be a difference between patients with disorders associated with a hyper or 
hypo immune state. Patients with a hyper immune state are almost always treated with 
immunosuppressive medication, which greatly influences and distorts the immune 
phenotype. Additionally, based on observations obtained in this work, the alterations 
in immune cell subsets tend to be less specific in patients with hyper immune states, 
rendering them less useful in the selection of candidate genetic variants. In contrast, in 
patients with a disorder due to a hypo immune state (i.e. PID) who normally do not 
receive immunosuppressive treatment, important defects in specific immune cell 
subsets can often be observed as was the case in the siblings with CID-like disease and 
ADA2 deficiency. In this case, the information on the defect in B cell 
differentiation/activation and the mild defect in T cell activation, together with the 
information on in vitro growth factor-like activity of ADA2 on monocytes and T helper 
cells found in the literature, was used for withholding the CECR1 variant as a 
candidate.  
A precise clinical description combined with a broad assessment of the function of the 
peripheral immune system, by examining both humoral (e.g. serum antibodies, 
cytokines) and cellular components (e.g. the main subsets of innate and adaptive 
immune cells [174]), should be part of the initial work-up of each examined case. 
When a candidate genetic variant is available for a patient, detailed investigations of 
humoral components or immune cell subsets that are altered or that may play a role in 
disease pathogenesis is important for establishing a cellular phenotype linked to the 
immune disease. Functional tests, for example by stimulating cell types with a variety 
of ligands and measuring the cell response, might be more reliable than a momentary 
assessment of a phenotype that is subjected to various modifying factors (e.g. 
immunomodulatory medication or intermittent infection). For example, in a large 
family with autoinflammation and neutrophilic dermatosis due to an autosomal 
inherited MEFV variant, involvement of mutated pyrin but not the NLRP3 
inflammasome was demonstrated by an increased production of IL-1β by patient’s 
monocytes compared to healthy controls in response to lipopolysacharide (LPS) but 
not to adenosine triphosphate (ATP) [15]. 
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6. Clinical impact and contributions to patient care and well-being 
The identification of the underlying genetic defect is often very important for these 
patients. Finally patients and their caregivers receive an explanation for their (child’s) 
illness and for the substantial suffering they have endured over the course of their 
disease. Especially in families that have lost a child due to the illness, like the STAT2-
family, this can provide some kind of closure. The psychological impact of finally being 
able to label their disease should also not be underestimated. The identification of a 
similar genetic defect in other patients/families over the world can provide insight into 
the disease prognosis and guide further treatment. For example, in the previously 
published family with STAT2 deficiency the affected individuals experienced a 
decrease in infection frequency and severity with increasing age, compatible with the 
development of their adaptive immune system, and the ones that survived childhood 
continued to lead a normal life [75].  
Aside from the prognosis, the obtained insight in disease pathogenesis and the 
pathways involved can be used for the development of new treatments, and 
therapeutic experience of clinicians caring for other patients with similar genetic 
defects can be exchanged. For example, in ADA2 deficiency it became clear that the 
peri-HSCT stroke in the transplanted CID-sibling was in fact part of the phenotype, 
that allogeneic HSCT could be curative probably due to restoration of plasma ADA2 
activity and that it is therefore absolutely necessary to perform this procedure for the 
younger brother as well to prevent additional strokes. Before the genetic defect was 
known, the parents of these ADA2-deficient children refused permission to perform a 
HSCT in the second affected child, seeing how this procedure almost resulted in the 
death of his older brother. The observation in the older sibling of the important 
inflammatory state pre- and peri-HSCT, intrinsic to ADA2 deficiency and the probable 
reason for all the complications that this child experienced peri-HSCT, will allow for 
the preventive use of biologicals in his younger brother to control inflammation before 
the start of the HSCT and hopefully prevent further complications. Even when no new 
treatment is available (or necessary) in the near future, the identification of the genetic 
defect opens up the possibility of genetic counselling and pre-implantation genetic 
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diagnosis for patients or (in case of recessive disorders) their carrier siblings who want 
to have children of their own.  
  
133 
 
CONCLUSION 
The framework for genetic studies described in the introduction was successfully used 
to identify disease-causing variants in three different genes responsible for severe 
early-onset immune pathology in four unrelated families with very different clinical 
presentations. Together with numerous examples from the literature this demonstrates 
that genetic studies in single cases or families can be useful for implicating genes in 
severe early-onset immune pathology and for elucidating disease pathogenesis and 
pathways involved [14]. A precise clinical description combined with a broad 
assessment of the function of the peripheral immune system is essential for the genetic 
study of patients with disorders of immunity, and highlights the importance of 
collaborations between physicians and researchers with expertise in immune 
pathology. 
1. Phenotypic heterogeneity associated with mutations in IFIH1, CECR1 and 
STAT2 
One of the main contributions of this work is that it extends the phenotypic spectrum 
associated with IFIH1-associated type I interferonopathies and ADA2 deficiency, and 
strengthens the data on STAT2 deficiency as the cause for increased susceptibility to 
viral illness.  
Over the past 6-7 years the development and wide-spread use of NGS techniques have 
driven the discovery of genetic defects in a variety of human (immune) diseases, and 
the remarkable phenotypic heterogeneity associated with variants in a certain gene or 
even with the exact same genotype has become the rule rather than the exception. This 
phenotypic heterogeneity reflects the extreme diversity in human genetic variation 
that makes up a patient’s genetic background, as well as the influence of the 
environment in the development of a phenotype. Mutations in the same gene can lead 
to a spectrum of diseases with variable severity, as can be seen in CAPS, a 
heterogeneous group of autoinflammatory disorders caused by gain-of-function 
mutations in NLRP3 in which patients may present with three separate clinical 
conditions that form a disease-severity spectrum: familial cold autoinflammatory 
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syndrome (FCAS), Muckle-Wells syndrome (MWS) or neonatal-onset multisystem 
inflammatory disease (NOMID) [12]. Mutations in the same gene can also lead to 
disease manifestations in different organs. For example, gain-of-function mutations in 
NOD2 (nucleotide-binding oligomerization domain-containing protein 2) are 
associated with Blau syndrome, an early-onset autoinflammatory disease characterised 
by articular, cutaneous and ocular non-caseating granulomatous inflammation, but 
NOD2 mutations are also linked to susceptibility to Crohn's disease, a common 
polygenic inflammatory granulomatous bowel disease [175].  
Gain-of-function mutations in IFIH1 have been identified in a spectrum of disorders 
associated with elevated levels of type I IFN but with very different clinical 
presentations, such as SLE, AGS [135], HSP [42] and SMS [136]. STAT2 deficiency is 
responsible for increased susceptibility to viral infections, as demonstrated by the 
development of disseminated measles following the measles-mumps-rubella (MMR) 
vaccine in all described patients, but the severity of the phenotype can differ and in 
one family STAT2 deficiency was associated with mitochondrial dysfunction and 
subsequent neurological deterioration [133]. Finally, in ADA2 deficiency the entire 
spectrum of immunedysregulation is observed, ranging from an autoinflammatory 
syndrome (Castleman’s-like disease) without immunodeficiency, to an 
autoinflammatory vasculitis/vasculopathy associated with hypogamma-globulinemia, 
to a CID-like presentation with autoimmunity, lymphoproliferation and subclinical 
inflammation. The last result nicely demonstrates the clinical/phenotypical overlap 
between autoimmunity, autoinflammation, immunodeficiency and even 
lymphoproliferation that can occur when a (mono)genetic defect affects an essential 
component of the immune system. 
2. Treatment of ADA2 deficiency and STAT2 deficiency 
Another important contribution of this work is that it provides vital scientific and 
clinical information on successful treatments of ADA2 deficiency, where treatment 
with IL-6 blockade was successful in controlling the immunological manifestations of 
Castleman’s-like disease and allogeneic HSCT proved to be curative in one of the 
siblings with CID phenotype. Additionally, potential disease-related risks of HSCT in 
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ADA2 deficiency were described and several measures to prevent disease-related 
complications were suggested to guide future treatment of other patients. Several 
questions remain on the exact mechanisms through which disease control is achieved. 
ADA2 plasma activity was restored after allogeneic HSCT, and thus the restoration of 
normal plasma ADA2 levels could be responsible for the curative effect. Whether or 
not this translates into a restoration of ADA2 plasma activity in other tissues, whether 
this is even necessary and what the effect of absent ADA2 activity in other tissues on 
long-term prognosis might be, remains unclear. Disease control was also achieved 
through the use of anti-IL-6R mAbs (or TNFα blockade by other research groups [70, 
164]). It is possible that controlling the inflammatory syndrome is sufficient to prevent 
vascular damage, however ADA2 might also exert growth factor-like activity on 
endothelial cells [69]. What the effect of absent ADA2 plasma activity on long-term 
prognosis might be, and whether patients might still be at risk for developing 
strokes/vasculopathy at a later age, remains unclear.  
In STAT2 deficiency a good response to high dose IVIG was observed during (viral) 
infectious episodes associated with coagulopathy and severe immune dysregulation. 
The main hypothesis is that this response may in part be due to the known anti-
inflammatory effect of high doses of IVIG [176], however, it is possible that passive 
immunization may also be adding to the observed effect. Observations in the three 
families with STAT2 deficiency show a decrease in disease frequency and severity with 
increasing age, possibly corresponding to the development of the adaptive immune 
system. However, one sibling did succumb to an infection with a (probably viral) 
agent, indicating that patients may still be at risk for fatal viral disease beyond early 
childhood. Therefore, the question remains whether STAT2-deficient patients should 
be treated with Ig replacement therapy during childhood. A conservative treatment 
approach was taken in the three described families, with a low threshold for high dose 
IVIG treatment for the patient described in this work. This reflects the relatively mild 
nature of this PID, however more information on clinical course and prognosis of 
additional STAT2-deficient patients is necessary to guide future treatment. 
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FUTURE RESEARCH 
Disease-causing variants leading to a wide spectrum of clinical manifestations were 
identified in three genes: IFIH1, CECR1 and STAT2. Many questions remain on disease 
pathogenesis, modifying factors in disease development, the possible contributions of 
variants in IFIH1, CECR1 and STAT2 to common disease forms and potential 
treatments of the immunological diseases described in this work. 
Disease mechanisms through which variants in IFIH1 and STAT2 lead to respectively 
increased levels of type I IFN and loss of type I IFN signalling, have been identified and 
described by other research groups [75, 135]. It is still not clear though, how increased 
levels of IFN can give rise to such a wide spectrum of clinical manifestation in 
individuals with IFIH1 mutations, ranging from an autoinflammatory encephalopathy 
to a prototypic autoimmune disease to asymptomatic individuals. The identification of 
modifying genetic or environmental factors that drive disease towards a certain clinical 
presentation, will be a major challenge. As IFIH1 mutations are expected to be 
identified more frequently in other individuals, the study of this cohort of IFIH1 
mutation-positive individuals by for example GWAS to determine the burden of 
known autoimmune disease risk alleles, may provide insight into the interplay 
between this ‘Mendelian’ mutation and modifying genetic factors.  
Many questions on the disease pathogenesis of ADA2 deficiency remain unanswered as 
well. Potentially contributing mechanisms could be proinflammatory polarization of 
macrophages and disturbed endothelial integrity due to loss of ADA2 [69]. However, 
how ADA2 deficiency could lead to increased production of IL-6, what the role of IL-6 
might be in inflammation and vascular damage associated with ADA2 deficiency and 
whether IL-6 and its effects are present in all ADA2-deficient patients, remains 
unclear. The lack of a CECR1 ortholog in commonly used laboratory animals such as 
mouse or rat and therefore the absence of such animal models of ADA2 deficiency 
renders this questions all the more difficult to answer. Although the main feature of 
systemic inflammation has been found in all ADA2-deficient patients described so far, 
a spectrum of clinical manifestations can be found and no information is available yet 
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on possible modifying factors that could shape the clinical presentation of ADA2 
deficiency. 
The continued search for individuals with disease-causing variants in IFIH1, CECR1 and 
STAT2 can provide additional information on potential clinical disease manifestations 
and severity, response to different treatments and prognosis. For example, 
identification of additional patients with STAT2 deficiency can help clarify the 
question of long-term prognosis and the risk of contracting life-threatening viral 
disease at a later age. This can in turn guide further treatment of STAT2-deficient 
patients. Similarly, in ADA2 deficiency long-term follow-up of ADA2-deficient patients 
who received allogeneic HSCT or whose disease was controlled by biologicals (without 
restoration of ADA2 plasma activity), is necessary to gain insight into long-term effects 
of the different therapeutic options and to guide future treatment. Several treatments 
targeting the type I IFN signalling pathway such as the anti-IFNAR mAb anifrolumab, 
the JAK1/3-inhibitor tofacitinib or the JAK1/2-inhibitor baricitinib are being tested in 
clinical trials in patients with SLE or type I interferonopathies such as CANDLE and 
SAVI. Positive outcomes in these trials could open up the possibility of targeted 
therapies in (IFIH1-associated) type I interferonopathies.  
Similarly, (additional) common variants in or near IFIH1, CECR1 and STAT2 may be 
identified that could potentially contribute to more common forms of immune disease. 
In the future functional studies might further explain how these polymorphisms could 
contribute to disease development by for example altering the function or regulation 
of the respective proteins. Finally, many other genes may be responsible for or could be 
contributing to the development of certain immune phenotypes. For example, other 
underlying genetic defect(s) in iMCD, a genetically heterogeneous group of disorders, 
still need to be elucidated. Likewise, the underlying genetic defects in most of the 
different vasculitis forms have not been identified yet. Many patients with unique and 
potentially Mendelian phenotypes who need a genetic diagnosis and targeted 
treatment, are still available for study, and genetic studies on these patients can 
increase our understanding of the physiology and pathology of the human immune 
system. 
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